

NIRMISH SINGLA, M.D., M.S.C.S.

11122 Eugene Avenue

Fulton, MD 20759

248.761.2452

nirmish@gmail.com

EDUCATION

- 2018-2019 **University of Texas Southwestern Medical Center**, Dallas, TX
Master of Science in Clinical Science (M.S.C.S.), Center for Translational Medicine
- 2009-2013 **University of Michigan Medical School**, Ann Arbor, MI
M.D., *Dean's Award for Graduation with Distinctions in Research, Medical Education, Service*
- 2006-2009 **University of Michigan**, Ann Arbor, MI
B.S.E., Biomedical Engineering (Biochemical Concentration), *Summa Cum Laude*
Academic Minor, Biology

POSTGRADUATE TRAINING

- 2021 **Johns Hopkins University**, Baltimore, MD
Junior Faculty Leadership Program
- 2019-2020 **Memorial Sloan Kettering Cancer Center**, New York, NY
Society of Urologic Oncology (SUO) Clinical Fellow
- 2018-2019 **University of Texas Southwestern Medical Center**, Dallas, TX
Postdoctoral Research Fellow, Urologic Oncology
Physician Scientist Training Program (PSTP)
- 2018-2019 **University of Texas Southwestern Medical Center**, Dallas, TX
Physician Administrative Fellow, William P. Clements, Jr. University Hospital
- 2017-2018 **University of Texas Southwestern Medical Center**, Dallas, TX
Administrative Chief Resident, Urology
- 2014-2018 **University of Texas Southwestern Medical Center**, Dallas, TX
Resident, Urology
- 2013-2014 **University of Texas Southwestern Medical Center**, Dallas, TX
Intern, General Surgery

ACADEMIC APPOINTMENTS

- 2020-Present **The James Buchanan Brady Urological Institute, Johns Hopkins University**, Baltimore, MD
Associate Professor, Department of Urology (2022-Present)
Associate Professor, Department of Oncology (2022-Present)
Assistant Professor, Department of Urology (2020-2022)
Assistant Professor, Department of Oncology (2020-2022)
Director of Translational Research in GU Oncology (2020-Present)
Director, Kidney Cancer Program (2021-Present)
Director, Testicular Cancer Program (2021-Present)
Co-Director, Upper Tract Urothelial Carcinoma (UTUC) Multidisciplinary Clinic (2021-Present)
Vice Chair and Physician Advisor, Quality, Safety, & Service (2022-Present)
- 2019-2020 **Memorial Sloan Kettering Cancer Center**, New York, NY
Clinical Instructor, Urologic Oncology, Department of Surgery
- 2018-2019 **University of Texas Southwestern Medical Center**, Dallas, TX
Assistant Instructor, Urologic Oncology, Department of Urology

LICENSURE AND CERTIFICATION

Licensure

2020-Present	Maryland Board of Physicians (D0089693)
2018-2021	Texas Medical Board (R6905)
2021	New Hampshire Emergency License (EL05374)
2018-2020	The University of the State of New York Education Department (296314)

Board Certification

2022-Present	American Board of Urology (ABU ID 21007)
--------------	--

HONORS AND AWARDS

2023	Society of Urologic Oncology (SUO) – European Association of Urology (EAU) Exchange Program Scholarship: Medical University of Vienna
2023	American Urological Association (AUA) Urology Care Foundation Scholar Travel Fund
2022-2024	The Carolyn and Bill Stutt Scholar, Patrick C. Walsh Prostate Cancer Research Award, The Brady Urological Institute, Johns Hopkins University School of Medicine
2022-2024	Indian American Urological Association Anupam Ted Kedia Award, American Urological Association (AUA) Urology Care Foundation Research Scholar Award: “Tumor evolution of brain-specific tropism in metastatic renal cell carcinoma”
2022	Top Reviewers in 2022, <i>Journal of Urology</i>
2022	Top Reviewers in 2022, <i>Urology Practice</i>
2022	American Urological Association (AUA) Research Forum Early Career Investigator Showcase: “Tumor evolution of pancreas-specific tropism in metastatic renal cell carcinoma”
2021-2022	Kidney Cancer Association (KCA) Young Investigator Award (YIA): “Tumor evolution of brain-specific tropism in metastatic renal cell carcinoma”
2021	Maryland Magazine Top Doctors (Urology)
2021	Top Reviewers in 2020, <i>Urology</i> (Elsevier)
2020	Society of Urologic Oncology (SUO) Young Urologic Oncologists (YUO) Paper of the Year Award, First Runner-Up: “Pancreatic tropism of metastatic renal cell carcinoma”
2020	Best of Testicular Cancer and Penile Cancer, Society of Urologic Oncology (SUO) 21 st Annual Meeting: “Real-world application of pre-orchietomy miR-371a-3p test in testicular germ cell tumor management.” Co-author.
2020	Merit Award, Genitourinary Cancers Symposium, Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO): “Serum microRNA-371a-3p levels predict viable germ cell tumor in chemotherapy-naïve patients undergoing retroperitoneal lymph node dissection”
2020	American Association for the Advancement of Science (AAAS)/ <i>Science</i> Program for Excellence in Science
2019	American Association for Cancer Research (AACR) Scholar-in-Training Award: “Comprehensive molecular and genomic characterization of pancreatic tropism in metastatic renal cell carcinoma”
2019	AVENIO Oncology Research Grant for ctDNA Competition (Roche): “Evaluating the prognostic utility of circulating tumor DNA profiling in metastatic and clinically localized clear cell renal cell carcinoma”
2019	American Urological Association (AUA) Early-Career Investigators Workshop Travel Award: “Evaluating the prognostic utility of circulating tumor DNA profiling in metastatic and clinically localized clear cell renal cell carcinoma”
2019	Finalist, Resident Essay Competition. “Overcoming patient factors in the care of underserved testicular cancer patients.” Co-author, 98 th Annual Meeting of South Central Section (SCS) American Urological Association (AUA).
2018-2019	National Institutes of Health/National Cancer Institute (NIH/NCI) Ruth L. Kirschstein National Research Service Award (T32 Physician Scientist Oncology Training Program Research Grant)
2018, 2019	Star Reviewer for <i>Urologic Oncology</i>

2018	Rising Star in Oncology, Society for Translational Oncology Fellows' Forum (STOFF)
2018	John Quale Travel Fellowship Award, Bladder Cancer Advocacy Network (BCAN) Bladder Cancer Think Tank
2018	Best Reviewer in 2017 Award, Elsevier (<i>Journal of Urology</i>)
2018	Winner, 6 th Annual American Urological Association (AUA) National Chief Resident Debate
2017	Outstanding Contribution in Reviewing Award, Elsevier (<i>Clinical Genitourinary Cancer</i>)
2017	1 st Place, Resident Essay Competition. "Impact of insurance status on testicular cancer survival – implications of economic disparities in the United States." Co-author. 96 th Annual Meeting of South Central Section (SCS) American Urological Association (AUA).
2017	3 rd Place, Resident Essay Competition. "Preoperative predictors of non-organ-confined disease in upper tract urothelial carcinoma differ between China and the United States." Primary author. 96 th Annual Meeting of South Central Section (SCS) American Urological Association (AUA).
2017	Travel Grant, Vincent J. O'Connor, Jr. Visiting Professor Conference, Department of Urology, Northwestern University Feinberg School of Medicine
2017	Travel Grant, Boston Scientific Men's Health Resident Course
2016	1 st Place, Resident Essay Competition. "Management of urinary incontinence following sub-urethral sling removal." Primary author. 95 th Annual Meeting of South Central Section (SCS) American Urological Association (AUA)
2016	Finalist, Resident Essay Competition. "Formalin disinfection of prostate biopsy needles reduces post-biopsy infectious complications." Primary author. 95 th Annual Meeting of South Central Section (SCS) American Urological Association (AUA)
2016	Best poster in session: "Poster Session 01: Slings and things in female incontinence," European Association of Urology (EAU) 31 st Annual Congress. Munich, Germany
2016	Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) Research Foundation Resident Preceptorship Travel Grant
2015	1 st Place, Resident Quiz Bowl Competition, 94 th Annual Meeting of South Central Section (SCS) American Urological Association (AUA). National competitor, 5 th annual AUA Residents Bowl (2016).
2015-2020	Recognized Reviewer, Elsevier (<i>Clinical Genitourinary Cancer</i> (2015), <i>Urologic Oncology</i> (2018-2020), <i>European Urology</i> (2019), <i>European Urology Oncology</i> (2019), <i>Urology Case Reports</i> (2020))
2009-2013	Full-Tuition Dean's Merit Scholarship, University of Michigan Medical School
2013	Dean's Award for Graduation with Distinction in Research, University of Michigan Medical School
2013	Graduation with Distinction in Medical Education, University of Michigan Medical School
2013	Graduation with Distinction in Service, University of Michigan Medical School
2013	Association for Academic Surgery (AAS) Student Research Award. "White matter hyperintensities and atrophy on MRI as a predictor of short term cognitive change following deep brain stimulation surgery in patients with Parkinson's disease."
2009	International Internship Travel Award, Department of Biomedical Engineering, University of Michigan. Applied towards urology clinical and research rotations in Italy and Brazil
2009	Arlen R. Hellwarth Award, College of Engineering, University of Michigan
2008, 2009	Distinguished Leadership Award, College of Engineering, University of Michigan (twice awarded)
2008, 2009	Michigan Leadership Awards, University of Michigan
	Student Legacy Award (2009)
	Yeoman Service Award, Honorable Mention (2008, 2009)
	Outstanding Student Leader Award, Honorable Mention (2008, 2009)
	Outstanding New Member Award, Honorable Mention (2008, 2009)
2008	Suresh Ramnath Undergraduate Internship Award, Department of Neurosurgery, University of Michigan Health System (UMHS)
2008	College of Engineering Need and Merit Scholarship Award
2008	Cooley Writing Contest, Honorable Mention. "Victory at the NIH."
2007-2009	James B. Angell Scholar, six out of six consecutive terms

2007	Dunn, Morris Douglas and Jill Engineering Endowment Fund, University of Michigan College of Engineering Scholarship Award
2007	George M. Landes Prize for Technical Communication, Freshmen Division, Third Place. "A novel, non-invasive approach to diagnosing urinary tract obstruction using CFD."
2006-2009	Dean's List for Academic Excellence, University of Michigan College of Engineering, six out of six consecutive terms
2006-2009	University Honors, six out of six consecutive terms
2006	University of Michigan Regent Merits Scholarship
2006	Michigan Society of Professional Engineers (MSPE) \$2000 Scholarship Trust Grant
2006	Michigan Merit Award: Michigan Educational Assessment Program (MEAP) Scholarship
2006	National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS) Exceptional Summer Student Award. "Spectral sensitivity of glutamate ON-response components in the photopic ERG of <i>Danio rerio</i> retina."
2006	Intel International Science and Engineering Fair (ISEF) Finalist. "A Novel, Non-Invasive Approach to Diagnosing Obstructive Uropathy Using Computer Simulation."
2006	Science and Engineering Fair of Metro Detroit (SEFMD) Grand Award. "A Novel, Non-Invasive Approach to Diagnosing Obstructive Uropathy Using Computer Simulation." Mu Alpha Theta Award, SEFMD (2006) US Metric Association Award, SEFMD (2006)
2006	Michigan Science and Engineering Fair (MSEF) Second Place Award. "A Novel, Non-Invasive Approach to Diagnosing Obstructive Uropathy Using Computer Simulation." The Herbert Hoover Young Engineer Award, MSEF (2006)
2006	Southeastern Michigan Regional Junior Science and Humanities Symposium (JSJS) Third Place Award. "A Novel, Non-Invasive Approach to Diagnosing Urinary Tract Obstruction Using CFD and Computer Simulation."

GRANT SUPPORT AND RESEARCH FUNDING

9/2023-8/2028	Title: "TIGIT in acute kidney injury and repair" Institution: Johns Hopkins Medicine Principal Investigator: Sanjeev Noel, PhD Funding Award: NIH/NIDDK 1R01DK132278-01 Role: Collaborator
2/2023-2/2024	Title: "Prospective Phase II Trial of Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma" Institution: Johns Hopkins Medicine Principal Investigators: Curtiland Deville, MD; Sherif Shaaban, MD Funding Award: Robert L. Sloan Fund for Cancer Research Role: Co-Investigator
10/2022-9/2024	Title: "Rapid Visualization of Cavernous Nerves for Fluorescence-Guided, Nerve-Sparing, Robotic-Assisted Radical Prostatectomy" Institution: Brady Urological Institute, Johns Hopkins University School of Medicine Principal Investigators: Nirmish Singla, MD, MSCS (Lead PI); Nicholas Durr, PhD; Summer Gibbs, PhD Funding award: Patrick C. Walsh Prostate Cancer Research Award (\$200,000) Role: Lead PI
9/2022-8/2026	Title: "Circulating Biomarkers in Renal Cell Carcinoma" Institution: Dana-Farber Cancer Institute Principal Investigators: Rupal Bhatt, MD, PhD; Wenxin (Vincent) Xu, MD Funding award: Academy of Kidney Cancer Investigators – Early-Career Investigator Award [Department of Defense (DoD), Congressionally Directed Medical Research Program (CDMRP), FY21 Kidney Cancer Research Program (KCRP)] (\$1,290,500) Role: Collaborator

- 9/2022-8/2025 **Title:** “Characterizing the Prognostic and Predictive Role of Immune Cell Population Changes Induced by Neoadjuvant PD-1 Inhibition in Clear Cell Renal Cell Carcinoma”
Institution: Brady Urological Institute, Johns Hopkins University School of Medicine
Principal Investigators: Nirmish Singla, MD, MSCS (Lead PI); Jelani Zarif, PhD (Partnering PI)
Funding award: Translational Research Partnership Award – Correlative Studies Option [Department of Defense (DoD), Congressionally Directed Medical Research Program (CDMRP), FY21 Kidney Cancer Research Program (KCRP)] (\$1,228,123)
Role: Lead PI
- 7/2022-6/2025 **Title:** “Precision Therapy for Localized Urothelial Cancers”
Institution: Brady Urological Institute, Johns Hopkins University School of Medicine
Principal Investigator: David McConkey, PhD
Funding award: Commonwealth Program (\$600,000)
Role: Co-Investigator
- 7/2022-6/2024 **Title:** “Tumor evolution of brain-specific tropism in metastatic renal cell carcinoma”
Institution: Brady Urological Institute, Johns Hopkins University School of Medicine
Principal Investigators: Nirmish Singla, MD, MSCS; Chetan Bettegowda, MD, PhD
Funding award: American Urological Association (AUA) Urology Care Foundation Research Scholar Award [*Sponsor:* Indian American Urological Association Anupam Ted Kedia Award] (\$80,000)
- 7/2022-6/2023 **Title:** “Improving diagnostic and prognostic tools in upper tract urothelial carcinoma”
Institution: Brady Urological Institute, Johns Hopkins University School of Medicine; Paracelsus Medizinische Privatuniversität
Principal Investigators: Nirmish Singla, MD, MSCS (Mentor/Host); Maximilian Pallauf, MD (Post-Doctoral Research Fellow)
Funding award: Funding for Innovative Research Exchange (FIRE) Research & Innovation Fund (14,400€)
Role: Mentor/Host
- 1/2022-6/2024 **Title:** “Imagining a better future together: Improving and expanding upper tract urothelial cancer care”
Institution: Greenberg Bladder Cancer Institute, Brady Urological Institute, Johns Hopkins University School of Medicine
Principal Investigators: Nirmish Singla, MD, MSCS; Jeannie Hoffman-Censits, MD; David McConkey, PhD
Funding award: David and June Trone Family Foundation (\$975,000)
- 11/2021-6/2024 **Title:** “Characterizing bladder cancer in young patients and lymph node metastatic tropism in upper tract urothelial carcinoma”
Institution: Brady Urological Institute, Johns Hopkins University School of Medicine
Principal Investigator: Nirmish Singla, MD, MSCS
Funding award: Joseph Migliara Fund (\$450,000)
- 10/2021-9/2022 **Title:** “Tumor evolution of brain-specific tropism in metastatic renal cell carcinoma”
Institution: Brady Urological Institute, Johns Hopkins University School of Medicine
Principal Investigators: Nirmish Singla, MD, MSCS; Chetan Bettegowda, MD, PhD
Funding award: Kidney Cancer Association (KCA) Young Investigator Award (\$75,000)
- 8/2021-7/2022 **Title:** “Developing a novel organoid platform for germ cell tumors and investigating predominant microRNA isoforms for non-invasive biomarker detection”
Institution: Brady Urological Institute, Johns Hopkins University School of Medicine
Principal Investigator: Nirmish Singla, MD, MSCS
Funding award: Holliday Discovery Fund (\$45,000)
- 7/2021-6/2023 **Title:** Post-doctoral research fellow support for urologic oncology
Institution: Brady Urological Institute, Johns Hopkins University School of Medicine
Principal Investigator: Nirmish Singla, MD, MSCS
Funding award: Kuzak Fund (\$70,000)
- 2/2021-7/2021 **Title:** “Elucidating biological differences between African Americans and Caucasians with renal cell carcinoma”
Institution: Brady Urological Institute, Johns Hopkins University School of Medicine

- Principal Investigator:** Nirmish Singla, MD, MSCS
Funding award: Dan Hagaman Endowment (\$100,000)
- 1/2021-12/2026 **Title:** “A rollover study to follow the long-term outcomes for patients from study UT001 (formerly TC-UT-03) and study TC-BC-12 [BL007]”
Institution: Brady Urological Institute, Johns Hopkins University School of Medicine
Principal Investigator: Nirmish Singla, MD, MSCS
Funding award: UroGen Pharma, trial sponsor (\$107,478.27)
- 8/2020-7/2022 **Title:** “Establishing the Johns Hopkins Kidney Cancer Program: Improving diagnosis, prognosis, and early treatment of kidney cancer through multidisciplinary precision immuno-oncology”
Institution: Brady Urological Institute, Johns Hopkins University School of Medicine
Principal Investigator: Nirmish Singla, MD, MSCS
Funding award: Brady Urological Institute Research Start-Up Fund (\$60,000)
- 7/2018-6/2019 **Title:** “Comprehensive molecular characterization of tumor behavior, organotropism, and treatment response in metastatic clear cell renal cell carcinoma”
Institution: Kidney Cancer Program, Harold Simmons Cancer Center, University of Texas Southwestern Medical Center (UTSW) – designated NIH/NCI Specialized Programs of Research Excellence (SPORE) site for kidney cancer
Mentor: James Brugarolas, MD, PhD
Funding award: NIH/NCI T32 CA136515-09 Ruth L. Kirschstein National Research Service Award (\$56,000)
- 7/2018-6/2019 **Title:** “Leveraging a robust patient-derived xenograft (PDX) platform to characterize predictors for engraftment, oncologic outcomes, and treatment response in renal cell carcinoma”
Institution: Kidney Cancer Program, Harold Simmons Cancer Center, UTSW – designated NIH/NCI SPORE site for kidney cancer
Mentor: James Brugarolas, MD, PhD
Funding award: Physician Scientist Training Program (PSTP) grant, UTSW (\$50,000)
- 12/2009-12/2011 **Title:** “White matter hyperintensities on MRI as a predictor of short-term cognitive change following deep brain stimulation in patients with Parkinson’s disease”
Institution: Department of Neurosurgery, University of Michigan Health System (UMHS)
Mentor: Parag Patil, MD, PhD
Funding awards:
 1. American Parkinson Disease Association (APDA) Medical Student Summer Fellowship Award (2010)
 2. Parkinson’s Disease Foundation (PDF) Summer Fellowship Award (2010)
 3. Multidisciplinary Clinical Researchers in Training (MCRiT) Summer Practicum Award, Michigan Institute for Clinical and Health Research (2010)
 4. Student Biomedical Research Program (SBRP) Fellowship Award (2010)
- 6/2009-7/2009 **Title:** “Gene expression of extracellular matrix components in different Gleason scores: possible predictive factors in prostate cancer”
Institution: Urogenital Research Unit, Universidade do Estado do Rio de Janeiro (UERJ), Brazil
Mentor: Francisco Sampaio, MD, PhD
Funding award: International Internship Travel Award, Department of Biomedical Engineering, University of Michigan
- 1/2007-8/2008 **Title:** “Characterizing the TMPRSS2-ERG gene fusion in prostate cancer: assessing tumorigenicity and invasiveness of ERG and EZH2 *in vitro* and *in vivo*”
Institution: Michigan Center for Translational Pathology (MCTP), University of Michigan Health System (UMHS) – designated NIH/NCI Specialized Programs of Research Excellence (SPORE) site for prostate cancer
Mentor: Arul Chinnaiyan, MD, PhD
Funding award: Biomedical and Life Sciences Fellowship Award, Undergraduate Research Opportunity Program (2008)
- 6/2006-8/2006 **Title:** “Spectral sensitivity of glutamate ON-response components in the photopic ERG of zebrafish retina”
Institution: Neural Circuits Unit, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS)

Mentor: Ralph Nelson, PhD

Funding Award: NIH/NINDS Biomedical Research Internship Award, Summer Internship Program

CLINICAL TRIALS AND PROTOCOLS

- 2/2023-Present **Title:** Prospective Phase II Trial of Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma
Institution: Johns Hopkins Medicine
Study ID: N/A
Current Status: Not yet active
Role: Co-Investigator
- 6/2021-Present **Title:** The Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry
Institution: Johns Hopkins University School of Medicine
Study ID: NCT02346435
Current Status: Active
Role: Principal Investigator
- 6/2021-Present **Title:** Multicenter phase 3 pivotal study to evaluate the safety and efficacy of TOOKAD (padeliporfin) vascular targeted photodynamic therapy in the treatment of low grade upper tract urothelial cancer
Institution: Johns Hopkins University School of Medicine
Study ID: NCT04620239
Current Status: Active
Role: Site Principal Investigator
- 6/2021-Present **Title:** A rollover study to follow the long-term outcomes for patients from study UT001 (formerly TC-UT-03) and study TC-BC-12 [BL007]
Institution: Johns Hopkins University School of Medicine
Study ID: NCT02793128, IRB00272767
Current Status: Active
Role: Site Principal Investigator
- 6/2021-Present **Title:** Surgery in early metastatic seminoma (SEMS): Phase II trial of retroperitoneal lymph node dissection as first-line treatment for testicular seminoma with isolated retroperitoneal disease (1-3cm)
Institution: Johns Hopkins University School of Medicine
Study ID: NCT02537548, 4T-14-1, J15174
Current Status: Active
Role: Site Principal Investigator
- 5/2021-Present **Title:** Robot-assisted personalized prostate biopsy
Institution: Johns Hopkins University School of Medicine
Study ID: IRB00068488 (Award 1R01CA247959-01A1)
Current Status: Active
Role: Data and Safety Monitoring Board
- 4/2021-Present **Title:** A confirmatory, prospective, open-label, multi-centre phase 3 study to evaluate diagnostic performance of ⁸⁹Zirconium-labelled girentuximab (⁸⁹Zr-TLX250) to non-invasively detect clear cell renal cell carcinoma (ccRCC) by positron emission tomography/CT (PET/CT) imaging in patients with indeterminate renal masses (ZIRCON study)
Institution: Johns Hopkins University School of Medicine
Study ID: NCT03849118, IRB00190388, J2062
Current Status: Active (4/2021)
Role: Site Co-Investigator
- 8/2020-Present **Title:** Feasibility of ^{99m}Tc-tetrofosmin for differentiation of benign oncocytoma from renal cell carcinoma
Institution: Johns Hopkins University School of Medicine
Study ID: IRB00117851, J16133

- Current Status:** Active
Role: Co-Investigator
- 9/2018-Present **Title:** Phase II Trial of Stereotactic Ablative Body Radiation Therapy (SAbR) for Patients with Oligo-Progressive Renal Cell Cancer (RCC)
Institution: University of Texas Southwestern Medical Center (UTSW)
Study ID: NCT03696277, STU 052018-001
Current Status: Recruiting (10/2018)
Role: Co-Investigator
Principal Investigators: Raquibul Hannan, MD, PhD; James Brugarolas, MD, PhD
- 4/2016-Present **Title:** Phase II Trial of Stereotactic Ablative Body Radiation (SAbR) for Patients with Oligometastatic Renal Cell Carcinoma
Institution: University of Texas Southwestern Medical Center (UTSW)
Study ID: NCT02956798, STU 042016-046
Current Status: Recruiting (7/2018)
Role: Co-Investigator
Principal Investigators: Raquibul Hannan, MD, PhD; James Brugarolas, MD, PhD
- 6/2015-3/2021 **Title:** Safety Lead-in Phase II Trial of Neo-adjuvant Stereotactic Ablative Radiation Therapy (SAbR) for IVC Tumor Thrombus in Newly Diagnosed Renal Cell Carcinoma (RCC)
Institution: University of Texas Southwestern Medical Center (UTSW)
Study ID: NCT02473536, STU 022015-058
Current Status: Recruiting (1/2019)
Role: Collaborator/Coauthor
Principal Investigators: Raquibul Hannan, MD, PhD; Vitaly Margulis, MD
- 4/2015-11/2019 **Title:** A Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High Grade Upper Tract Urothelial Carcinoma
Institution: University of Texas Southwestern Medical Center (UTSW); ECOG-ACRIN Cancer Research Group
Study ID: NCT02412670, EA8141
Current Status: Active, not recruiting (7/2018)
Role: Collaborator/Coauthor
Principal Investigator: Vitaly Margulis, MD

ENGINEERING RESEARCH AND DEVELOPMENTS

- 10/2022-Present Rapid Visualization of Cavernous Nerves for Fluorescence-Guided, Nerve-Sparing, Robotic-Assisted Radical Prostatectomy
Brady Urological Institute, Johns Hopkins University School of Medicine
Principal Investigators: Nirmish Singla, MD, MSCS; Nicholas Durr, PhD; Summer Gibbs, PhD
- 1/2009-4/2009 A Device for the Identification of Pacemaker and Defibrillator Manufacturers
BiomedE 450: Biomedical Design, University of Michigan
Director: Rachael Schmedlen, PhD. Clients: Sanjaya Gupta, MD; Jerome Kalifa, MD, PhD
- 9/2008-12/2008 Captain Run-It: "With Our Circuits Combined!" Fitness Monitor Design Project
BiomedE 458: Biomedical Instrumentation and Design, University of Michigan
<http://umfitness.synthasite.com/>
- 9/2006-3/2007 Evaluation of shear stress on lipid packing in biological membranes: a model for atherosclerotic progression using fluorescence recovery after photobleaching (FRAP)
Department of Biomedical Engineering, University of Michigan
Principal Investigator: Michael Mayer, PhD
- 9/2006-12/2006 Combined genotypic and phenotypic lab-on-a-chip test for primary hypertension
Engineering 100: Biotechnology and Human Values, University of Michigan
Director: Rachael Schmedlen, PhD
- 1/2005-9/2005 Biomaterial modification of nerve guide conduits for optimal PC12 cell attachment and differentiation
Department of Biomedical Engineering, Wayne State University

1/2005-9/2005 Principal Investigator: Pamela VandeVord, PhD
A novel, non-invasive approach to diagnosing urinary tract obstruction using computational fluid dynamics (CFD) and computer simulation
Departments of Urology and Mechanical Engineering, Wayne State University
Principal Investigators: Joon Lee, PhD; Ajay Singla, MD

TEACHING AND MENTORING EXPERIENCE

2022-Present Faculty Lecturer, “Genes to Society” Pre-Clinical Medical Student Curriculum, The Johns Hopkins University School of Medicine
“Primer on Kidney Cancer” (2022)
“Fundamentals of Testicular Cancer: Origins and Management” (2022)

2022-Present Faculty Mentor, Medical Student Training in Aging Research (MSTAR) Program, Johns Hopkins Emelia Watts (2022)

2022-Present Faculty Mentor/Principal Investigator for Post-Doctoral Research Fellow: Maximilian Pallauf, MD

2022-Present Faculty Mentor, Johns Hopkins University School of Medicine Research Elective Jack Campbell (2022)

2021-Present Faculty Mentor, Johns Hopkins Surgery Center for Outcomes Research (JSCOR) Master of Public Health (MPH) Mentoring Program
Amir Khan (2021-2022) [role: Thesis Advisor]

2021-Present Faculty Mentor, Scholarly Concentrations Program, Johns Hopkins University School of Medicine
Terrence Tsou (2021-2022)
Shomari Sankara (2021-2022)

2021-Present Faculty Mentor/Principal Investigator for Research Specialist: Anirudh Yerrapragada, MPH

2021-Present Clinical Mentor: Gregory Howard, CRNP

2020-Present Faculty Mentor, Medical and Biological Illustration Graduate Program, Johns Hopkins University
Shirley Li (2021)
Susie Yun (2020)

2020-Present Society of Urologic Oncology (SUO) Fellows Trained (Graduated), The Brady Urological Institute, The Johns Hopkins University School of Medicine: 2

2020-Present Urology Residents Trained (Graduated), The Brady Urological Institute, The Johns Hopkins University School of Medicine: 6

2018-2019 Co-Leader, Education, Kidney Cancer Program, University of Texas Southwestern Medical Center (UTSW)
Co-Organizer, 2nd Annual Kidney Cancer Program Trainee Retreat

2008-2009 Instructional Aide, Department of Biomedical Engineering, University of Michigan
BiomedE 418: Quantitative Cell Biology (Jan. 2009-Apr. 2009)
BiomedE 221: Biophysical Chemistry (Sept. 2008-Dec. 2008)

2007-2008 Study Group Leader, University of Michigan Science Learning Center
Chemistry 215: Structure and Reactivity II (Organic Chemistry II) (Jan. 2008-Apr. 2008)
Physics 240: General Physics II (Electricity and Magnetism) (Sept. 2007-Dec. 2007)

2007-2008 Mentor, Staff, Co-Chief Logistics Officer: United InnoWorks Academy, Michigan Chapter

PROFESSIONAL AFFILIATIONS

2022-Present Associate Fellow member, American College of Surgeons (ACS)

2020-Present Eastern Cooperative Oncology Group – American College of Radiology Imaging Network (ECOG-ACRIN) Cancer Research Group

2019-Present American Association for the Advancement of Science (AAAS)

2018-Present Society of Urologic Oncology (SUO)
Young Urologic Oncologists Section (YUO)

	SUO-Clinical Trials Consortium (CTC)
2017-Present	American Society of Clinical Oncology (ASCO)
2017-Present	Kidney Cancer Association (KCA)
2017-Present	American Association for Cancer Research (AACR)
2015-2019	Texas Urological Society (TUS)
2014-Present	Société Internationale d'Urologie (SIU)
2014-Present	Indian American Urological Association (IAUA)
2014-Present	American Association of Clinical Urologists (AACU)
2013-Present	University of Michigan Department of Urology Reed Nesbit Society
2013-2015	Association for Academic Surgery (AAS)
2012-Present	American Urological Association (AUA)
2021-Present	Mid-Atlantic Section of AUA
2012-Present	International Young Urological Association (IYUA)
2009-2013	American Medical Association (AMA)
2009-2013	Michigan State Medical Society (MSMS)
2009-2013	Washtenaw County Medical Society
2009-2013	American Medical Student Association (AMSA)

ADMINISTRATIVE ACTIVITIES AND COMMITTEES

2022-Present	Vice Chair, Quality, Safety, & Service, Brady Urological Institute, Johns Hopkins University School of Medicine
2022-Present	Physician Advisor, Brady Urological Institute, Johns Hopkins University School of Medicine
2022-Present	Data Science Executive Committee, Brady Urological Institute, Johns Hopkins University School of Medicine
2022-Present	American Urological Association (AUA) Guideline Peer Reviewer AUA/SUO Guideline on Early Detection of Prostate Cancer (2022) AUA Upper Tract Urothelial Carcinoma Guideline (2023)
2022	IV Iodinated Contrast Shortage Committee, Johns Hopkins Office of Critical Event Preparedness and Response
2021-Present	Director and Co-Founder, Kidney Cancer Program, Johns Hopkins University
2021-Present	Director, Testicular Cancer Program, Johns Hopkins University
2021-Present	Co-Director and Co-Founder, Upper Tract Urothelial Carcinoma (UTUC) Multidisciplinary Clinic, Johns Hopkins University
2021-Present	National Comprehensive Cancer Network (NCCN) Testicular Cancer Guidelines Panel
2021-Present	Data and Safety Monitoring Board, "Robot-assisted personalized prostate biopsy" (IRB00068488; Award 1R01CA247959-01A1)
2021-Present	Kidney Cancer Association (KCA) Grant Review Panel
2021-Present	AUA Conflict of Interest (COI) Review Work Group
2021-Present	Multidisciplinary Genitourinary Oncology Tumor Board Conference Organizer
2020-Present	Director of Translational Research in GU Oncology, Johns Hopkins University
2020-Present	Department Representative (Urology), Faculty Senate, Johns Hopkins School of Medicine
2019-2020	Morbidity and Mortality Conference Administrative Fellow, Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center
2018-2019	Physician Administrative Fellow, William P. Clements, Jr. University Hospital, University of Texas Southwestern Medical Center (UTSW) Founder/Director, Physician Administrative Fellowship Program Product Evaluation Committee, Operating Room (OR) Value Analysis Team
2018-2019	Co-Leader, Education, Kidney Cancer Program, UTSW Co-Organizer, 2 nd Annual Kidney Cancer Program Trainee Retreat
2017-2018	Administrative Chief Resident, Department of Urology, UTSW
2017-2018	Graduate Medical Education Committee (GMEC), UTSW Policy Development and Review GMEC subcommittee, UTSW
2017-2018	Chief Resident Council, UTSW

2016-2018	Quality Improvement Committee, Department of Urology, UTSW
2015-2020	AUA Medical Student Education Committee (MSEC) (formerly National Medical Student Curriculum (NMSC) Committee), Education Council Hematuria module update. Accessible at: https://www.auanet.org/education/medical-student-core-content-and-other-resources.cfm (2016)
2015	Resident Interviewer, Department of Urology, UTSW
2014-Present	Membership Committee, IAUA
2013	Co-Founder, Advisor, Medical Innovation Student Group, University of Michigan
2012-2013	Curriculum Strategic Planning and Transformation, University of Michigan Medical School
2012-2013	Michigan Urological Surgery Improvement Collaborative (MUSIC): “Reducing fluoroquinolone-resistant <i>Escherichia coli</i> infectious complications following prostate biopsy” Development of patient checklist for risk stratification of fluoroquinolone resistance
2012	Michigan Quality System (MQS), University of Michigan Health System (UMHS): “Increasing the efficiency of operating room turnover for adult endourology cases using lean intervention”
2010-2011	National Delegate, AMA-Medical Student Section (MSS)
2009-2010	Region V Liaison, AMA-MSS
2009-2010	Vice Chair, Health Policy Committee, AMA-MSS, University of Michigan Chapter
2007-2009	Founder, Director, Physician Shadowing Initiative, University of Michigan

EDITORIAL ACTIVITIES

2022-Present	Editorial Advisory Board, <i>Kidney Cancer Journal</i> Reviewer (2021-Present)
2022-Present	Reviewer, <i>Journal of the National Comprehensive Cancer Network (JNCCN)</i>
2022-Present	Review Editor, <i>Frontiers in Urology</i>
2022-Present	Guest Editor, <i>Cancers</i> : “Advances in Locally Advanced and Metastatic Kidney Cancer”
2022-Present	Guest Editor, <i>Frontiers in Oncology</i> : “Prognostic Research and Precision Oncology in Upper Tract Urothelial Carcinoma – Volume II”
2021-Present	Guest Editor, <i>Frontiers in Oncology</i> : “New Insights in Upper Tract Urothelial Carcinoma: From Basic to Clinical”
2021-Present	Reviewer, <i>The Prostate</i>
2020-Present	Review Editor, <i>Frontiers in Surgery (Genitourinary Surgery)</i>
2020-Present	Associate Editor, <i>Urology Case Reports</i>
2020-Present	Editorial Board, <i>AME Medical Journal</i>
2020-Present	Reviewer, <i>JAMA Oncology</i>
2020-Present	Reviewer, <i>Bladder Cancer</i>
2018-Present	Reviewer, <i>European Urology</i>
2018-Present	Reviewer, <i>BJU International</i>
2018-Present	Reviewer, <i>Urologic Oncology: Seminars and Original Investigations</i>
2018-Present	Reviewer, <i>Urology Practice</i>
2018-Present	Reviewer, <i>BMC Urology</i>
2017-Present	Reviewer, <i>Advances in Urology</i>
2017-Present	Reviewer, <i>Translational Andrology and Urology</i>
2016-Present	Reviewer, <i>International Journal of Surgery</i>
2015-Present	Contributor/Blogger, <i>Urology Times</i> Member, Reader Reactor Panel, <i>Urology Times</i> (2017-Present)
2015-Present	Reviewer, <i>Journal of Urology</i> Statistical reviewer, <i>Journal of Urology</i> (2017-Present)
2015-Present	Reviewer, <i>Urology</i>
2015-Present	Reviewer, <i>Clinical Genitourinary Cancer</i>
2015-Present	Reviewer, <i>Canadian Journal of Urology (CJU)</i>
2015-Present	Reviewer, <i>Canadian Urological Association Journal (CUAJ)</i>
2015-Present	Editorial Board, <i>American Journal of Urology Research</i>
2008	Associate Editor, <i>Journal of Young Investigators (JYI)</i>

2007 Research Editor, *JYI*
2007-2009 Senior Copy Editor, *University of Michigan Undergraduate Research Forum (UMURF)*
2006-2008 Contributing Expert, Scholar Holler, LLC: <http://www.scholarholler.com>

BIBLIOGRAPHY

A. Peer-Reviewed Original Publications

1. **Singla N**, Nirschl TR, Obradovic AZ, Shenderov E, Lombardo K, Liu X, Pons A, Zarif JC, Rowe SP, Trock BJ, Hammers HJ, Bivalacqua TJ, Pierorazio PM, Deutsch JS, Lotan TL, Taube JM, Ged YMA, Gorin MA, Allaf ME, Drake CG. Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma. Submitted.
2. Agrawal P, Alam R, Cheaib JG, Young L, Agrawal G, Patel SH, Yerrapragada A, Pallauf M, Pierorazio PM, Allaf ME, Ged YMA, **Singla N**. Role of histology in influencing outcomes after cytoreductive nephrectomy for metastatic renal cell carcinoma. Submitted.
3. Agrawal P, Alam R, Orlando N, Cheaib JG, Young L, Agrawal G, Patel SH, Yerrapragada A, Pallauf M, Allaf ME, Ged YMA, **Singla N**. Cytoreductive nephrectomy with concomitant IVC tumor thrombectomy in metastatic renal cell carcinoma. Submitted.
4. Alam R, Rezaee ME, Pallauf M, Elias R, Yerrapragada A, Enikeev D, Fang D, Shariat SF, Woldu SL, Ged YMA, **Singla N**. Socioeconomic determinants of racial disparities in survival outcomes among patients with renal cell carcinoma. Submitted.
5. Gharaie S, Lee K, Noller K, Lo EK, Miller B, Jung HJ, Newman-Rivera AM, Kurzhagen JT, **Singla N**, Welling PA, Fan J, Cahan P, Noel S, Rabb H. Single cell and spatial transcriptomics analysis of murine kidney double negative T lymphocytes in normal and ischemic kidneys. Submitted.
6. Cheaib JG, Talwar R, Roberson DS, Patel HD, Alam R, Lee DJ, Canner JK, Gupta M, Patel SH, **Singla N**, Pavlovich CP, Allaf ME, Pierorazio PM. Urologist-level variation in the management of T1a renal cell carcinoma. Submitted.
7. Rezaee ME, Pallauf M, Fletcher SA, Pavlovich CP, Baraban E, Ged Y, **Singla N**. Prognostic significance of pT3a staging subclassifications in non-clear cell renal cell carcinoma: Not all pT3a are equal. Submitted.
8. Rezaee ME, Pallauf M, Fletcher SA, Han M, Pavlovich CP, Epstein JI, Allaf ME, Trock BJ, **Singla N**. Clinical significance of extraprostatic extension in grade group 1 prostate cancer. Submitted.
9. Xu W, Gaborieau V, Niman SM, Mukeriy A, Liu X, Maremanda KP, Takakura A, Zaridze D, Freedman ML, McDermott DF, Choueiri TK, Catalano PJ, Sabbisetti V, Bonventre J, Pierorazio PM, **Singla N**, Brennan P, Bhatt RS. Plasma KIM-1 for preoperative prediction of renal cell carcinoma versus benign renal masses, and association with clinical outcomes. Submitted.
10. Pallauf M, D'Andrea D, von Deimling M, Laukthina E, Kawada T, Matin SF, Boorjian SA, Potretzke AM, Daneshmand S, Djaladat H, Ghoreifi A, Soria F, Gontero P, Kikuchi E, Hayakawa N, Fujita K, Sfakianos JP, Ploussard G, Roumiguie M, Antonelli A, Roupert M, Khene ZE, Mari A, Campi R, Breda A, Heidenreich A, Boormans JL, Raman JD, Abdollah F, Grossmann NC, Rink M, Karakiewicz PI, Abufaraj M, Babjuk M, **Singla N**, Shariat SF, Pradere B. Comparison of neoadjuvant and adjuvant chemotherapy in upper tract urothelial cancer – Results from a propensity-score matched multi-center patient cohort. Submitted.
11. Antonelli L, Heidenreich A, Bagrodia A, Amini A, Baky F, Branger N, Cazzaniga W, Clinton TN, Djaladat H, Eggener S, Ghoreifi A, Hamilton RJ, Ho M, McFarland S, Nazzani S, Nicol D, Nicolai N, Olson K, Paffenholz P, Porter J, Qian Z, Rocco NR, Sexton WJ, Yerrapragada A, Stroup SP, Tachibana I, Terbuch A, **Singla N**, Cary C, Fankhauser CD. Outcomes after primary retroperitoneal lymph node dissection in men with stage II non-seminomatous germ cell tumor, a multicenter retrospective study. Submitted.
12. Johnson BA, Teply BA, Kagemann C, McGuire B, Lombardo K, Jing Y, Langbo W, Epstein JI, Netto GJ, Baras AS, Matoso A, McConkey DJ, Gupta A, Schoenberg MP, Ahuja N, Ross AE, Pierorazio PM, Comperat E, Hoffman-Censits J, **Singla N**, Patel SH, Kates M, Choi W, Bivalacqua TJ, Hahn NM. Neoadjuvant cisplatin, gemcitabine, and docetaxel in sarcomatoid bladder cancer – Clinical activity and whole transcriptome analysis. Submitted.

13. Bhanji Y, Baraban E, Antonucci B, Ged Y, **Singla N**. Robotic-assisted cytoreductive partial nephrectomy for metastatic sarcomatoid renal cell carcinoma following dramatic response to combination immunotherapy in a young female. Submitted.
14. Bhanji Y, **Singla N**. Bladder tumor on a stalk. Submitted.
15. Alkhatib KY, Cheaib JG, Pallauf M, **Singla N**, Chang P, Wagner AA, Pavlovich CP, McKiernan JM, Guzzo TJ, Allaf ME, Pierorazio PM. Active surveillance versus primary intervention for clinical T1a kidney tumors: Twelve-year experience of the DISSRM prospective comparative study. Submitted.
16. Yip W, Assel MJ, Wong NC, Tracey AT, Alvim RG, Nogueira L, Almassi N, **Singla N**, Clinton TN, Sjoberg DD, Al-Ahmadie H, Hakimi AA, Pietzak EJ, Cha EK, Donahue TF, Dalbagni G, Bochner BH, Bajorin DF, Coleman JA. Changes in the perioperative management and outcomes of patients with upper tract urothelial carcinoma undergoing radical nephroureterectomy at Memorial Sloan Kettering Cancer Center: Over 20 years of experience. Submitted.
17. Vovdenko S, Bazarkin A, Morozov A, Golan S, Babaevskaya D, Badaoff R, Gomez-Rivas J, **Singla N**, Fajkovic H, Enikeev D. The current state of circulating tumor cells in prostate cancer diagnostics. Submitted.
18. Belyaeva K, Rudenko V, Serova N, Morozov A, Taratkin M, Androsov A, **Singla N**, Shpunt I, Gomez-Rivas J, Fajkovic H, Enikeev D, Kapanadze L. Kidney computed tomography perfusion in patients with ureteral obstruction. Submitted.
19. Huang MM, Schwen ZR, Gupta M, Patel HD, Harris KT, Biles MJ, Liu J, **Singla N**, Allaf ME, Pierorazio PM. Clinicopathologic predictors of retroperitoneal teratoma and lymph node metastasis in nonseminomatous testicular cancer. Submitted.
20. Gold SA, **Singla N**, Bloom JB, Shakir N, Passoni N, Wong D, Hale GR, Merino M, Wood BJ, Turkbey B, Choyke PL, Costa D, Pinto PA, Roehrborn CG. Delineation of prostate cancer from BPH by excess PSA relative to predicted: A study in men undergoing MRI-targeted biopsy. Submitted.
21. Alam R, Patel HD, Cheaib JG, Winoker JS, de la Calle CM, Metcalf MR, **Singla N**, Bivalacqua TJ, Pierorazio PM, Kates MR, Patel SH. Survival outcomes in solitary kidney patients diagnosed with upper tract urothelial carcinoma treated with radical nephroureterectomy versus organ-sparing endoscopy. Submitted.
22. Srivastava A, Patel HV, Cheaib J, **Singla N**, Woldu S, Quek ML, Gupta GN, Kim IY, Singer EA, Jang TL, Pierorazio PM, Bagrodia A, Patel HD. Risk stratification in advanced non-seminomatous germ cell tumors (NSGCT): Validation of age and metastatic disease site to improve the traditional IGCCCG risk groups. Submitted.
23. Campbell JA, Cheaib JG, Patel SH, Metcalf MR, Rostom M, Matoso A, Epstein JI, **Singla N**, Ged Y, Pavlovich CP, Allaf ME, Pierorazio PM. Effect of rhabdoid and sarcomatoid differentiation on prognosis in patients with grade 4 renal cell carcinoma. Submitted.
24. von Deimling M, D'Andrea D, Pradere B, Laukhtina E, Yanagisawa T, Kawada T, Majdoub M, Rajwa P, Pallauf M, **Singla N**, Soria F, Margulis V, Chlosta P, Karakiewicz PI, Roupret M, Teoh JYC, Fisch M, Rink M, Moschini M, Lotan Y, Shariat SF. Clinical value of cholinesterase in patients treated with radical nephroureterectomy for upper urinary tract carcinoma. Accepted, *World Journal of Urology*.
25. Baraban E, Ged Y, **Singla N**, Allaf ME, Gorin MA, Markowski MC, Rowe SP, Argani P. Vascular expression of prostate specific membrane antigen (PSMA) in MiTF family translocation renal cell carcinoma and related neoplasms. Accepted, *Applied Immunohistochemistry & Molecular Morphology*.
26. Elias R, Tcheuyap VT, Kaushik AK, **Singla N**, Gao M, Torras OR, Christie A, Mulgaonkar A, Woolford L, Stevens C, Kettimuthu KP, Pavia-Jimenez A, Boroughs LK, Joyce A, Dakanali M, Notgrass H, Margulis V, Cadeddu J, Pedrosa I, Williams NS, Sun X, DeBerardinis RJ, Oz OK, Zhong H, Seshagiri S, Modrusan Z, Cantarel B, Kapur P, Brugarolas J. A renal cell carcinoma tumorgraft platform to advance precision medicine. In press, *Cell Reports*.
27. Duarte C, Hu J, Beuselinck B, Panian J, Weise N, Dizman N, Collier KA, Rathi N, Li H, Elias R, Martinez-Chanza N, Rose TL, Harshman LC, Gopalakrishnan D, Vaishampayan U, Zakharia Y, Narayan V, Carneiro BA, Mega A, **Singla N**, Meguid C, George S, Brugarolas J, Agarwal N, Mortazavi A, Pal S, McKay RR, Lam ET. Metastatic renal cell carcinoma to the pancreas and other sites—a multicenter retrospective study. In press, *eClinicalMedicine*.
28. Yip W, Ghoreifi A, Gerald T, Lee R, Howard J, Asghar A, Khanna A, Cai J, Aron M, Gill I, Thompson RH, Uzzo R, Margulis V, **Singla N**, Djaladat H. Perioperative complications and oncological outcomes of

- nephrectomy following immune checkpoint inhibitor therapy: A multicenter collaborative study. In press, *European Urology Oncology*.
29. Elgenidy A, Sonbol YT, Elmeirath AO, Afifi AM, **Singla N**. Revisiting treatment protocols for stage I testicular seminoma: A SEER-based analysis. In press, *Urologia Internationalis*.
 30. Deutsch JS, Lipson EJ, Ludmila D, Topalian SL, Ged Y, **Singla N**, Choueiri TK, Gupta S, Motzer RJ, McDermott D, Signoretti, Atkins M, Taube JM. Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma. In press, *Cell Reports Medicine*.
 31. Mulgaonkar A, Elias R, Woolford L, Nham K, Guan B, Kapur P, Christie A, Tcheuyap VT, **Singla N**, Bowman IA, Stevens C, Hao G, Brugarolas J, Sun X. ImmunoPET imaging with ⁸⁹Zr-labeled atezolizumab enables *in vivo* evaluation of PD-L1 in tumorgraft models of renal cell carcinoma. In press, *Clinical Cancer Research*.
 32. Alam R, Patel HD, Su ZT, Cheaib JG, Ged Y, **Singla N**, Allaf ME, Pierorazio PM. Self-reported quality of life as a predictor of mortality in renal cell carcinoma. In press, *Cancer*.
 33. Pallauf M, D'Andrea D, Konig F, Laukthina E, Yanagisawa T, Roupert M, Daneshmand S, Djaladat H, Ghoreifi A, Soria F, Fujita K, Boorjian SA, Potretzke AM, Mari A, Roumiguie M, Antonelli A, Bianchi A, Khene ZE, Sfakianos JP, Jamil M, Boormans JL, Raman JD, Grossmann NC, Breda A, Heidenreich A, Del Giudice F, **Singla N**, Shariat SF, Pradere B. Diagnostic accuracy of clinical lymph node staging for upper tract urothelial cancer patients – A multicenter retrospective patient cohort analysis. In press, *Journal of Urology*.
 34. Alam R, Yerrapragada A, Wlajnitz T, Watts E, Pallauf M, Enikeev D, Chang P, Wagner AA, McKiernan JM, Pierorazio PM, Allaf ME, **Singla N**. Evaluation of growth rates for small renal masses in elderly patients undergoing active surveillance. In press, *European Urology Open Science*.
 35. Taratkin M, **Singla N**, Babaevskaya D, Androsov A, Shariat SF, Fajkovic H, Baniel J, Enikeev D. A review of how lasers are used in UTUC surgery: Can the choice of laser affect outcomes? In press, *Cancers*.
 36. Morozov A, Taratkin M, Bazarkin A, Rivas JG, Puliatti S, Checcucci E, Belenchon IR, Kowalewski KF, Shpikina A, **Singla N**, Teoh JYC, Kozlov V, Cacciamani GE, Enikeev D. Artificial intelligence in prostate cancer identification and grading. In press, *Prostate Cancer and Prostatic Diseases*.
 37. Morozov A, Bazarkin A, Shpikina A, Allenov S, Enikeev M, Suvorov A, Taratkin M, **Singla N**, Teoh JYC, Barret E, Enikeev D. Thermal ablation vs. active surveillance for renal cell carcinoma. A systematic review and network meta-analysis. In press, *Minerva Urology and Nephrology*.
 38. Morozov A, Chuvalov L, Taratkin M, Enikeev M, Rapoport L, **Singla N**, Barret E, Poddubskaya E, Borodina M, Salomon G, Rivas JG, Enikeev D. A systematic review of cytoreductive prostatectomy outcomes and complications in patients with oligometastatic prostate cancer. In press, *Asian Journal of Urology*.
 39. Petov V, Azilgareeva C, Shpikina A, Morozov A, Krupinov GE, Kozlov V, **Singla N**, Rivas JG, Jesus MS, Puliatti S, Checcucci E, Rodler S, Belenchon IR, Kowalewski KF, Veccia A, Mcfarland J, Cacciamani GE, Taratkin M, Enikeev D. Robot-assisted magnetic resonance imaging-targeted versus systematic prostate biopsy: Systematic review and meta-analysis. In press, *Cancers (Basel)*.
 40. Schoenhals J, Mohamad O, Christie A, Zhang Y, **Singla N**, Bowman I, Hammers H, Courtney K, Cole S, Bagrodia A, Margulis V, Desai N, Garant A, Choy H, Timmerman R, Brugarolas J, Hannan R. Stereotactic ablative radiotherapy for oligoprogressive renal cell carcinoma. In press, *Advances in Radiation Oncology*.
 41. **Singla N**, Wong J, Singla S, Krailo M, Huang L, Shaikh F, Billmire D, Rescorla F, Ross J, Dicken B, Amatruda JF, Frazier AL, Bagrodia A. Clinicopathologic predictors of outcomes in children with stage I testicular germ cell tumors: A pooled *post hoc* analysis of trials from the Children's Oncology Group. In press, *Journal of Pediatric Urology*.
 42. Rabinowitz M, Esfandiary T, Cheaib J, Patel SH, Alam R, Metcalf M, Enikeev D, Pierorazio PM, Ged YMA, Allaf ME, **Singla N**. Characterizing tumor thrombus arising from non-clear cell renal cell carcinoma. In press, *European Urology Open Science*.
 43. Alam R, Patel SH, Kates MR, **Singla N**, Pavlovich CP, Allaf ME, Bivalacqua TJ, Pierorazio PM. Differential changes in self-reported quality of life in elderly populations after diagnosis of a genitourinary malignancy. In press, *Urologic Oncology: Seminars and Original Investigation*.
 44. Elgenidy A, Awad AK, Ahmad H, Shahid A, Kacimi SEO, Aly MG, **Singla N**, Afifi AM, Patel HD. Cause-specific mortality among patients with renal cell carcinoma in the United States from 2000 to 2018. In press, *Urologic Oncology: Seminars and Original Investigation*.

45. de la Calle C, Young E, **Singla N**. Hyperbilirubinemia following retroperitoneal mass resection in a patient with sickle cell anemia. In press, *Urology*.
46. Gilligan T, Lin DW, Aggarwal R, Bagrodia A, Cost N, Costa D, Davis NB, Derweesh IH, Drakaki A, Emamekhoo H, Evans C, Feldman DR, Geynisman DM, Hancock SL, Humphrey P, Levine EG, Longo T, Maughan B, McGregor B, Monk P, Picus J, Rais-Bahrami S, Saylor P, **Singla N**, Sircar K, Smith DC, Teply BA, Tzou K, VanderWeele D, Vaughn D, Yamoah K, Yamzon J, Berardi R, Pluchino LA. Testicular Cancer, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. In press, *Journal of the National Comprehensive Cancer Network*.
47. Pallauf M, Konig F, D'Andrea D, Laukhtina E, Mostafaei H, Motlagh RS, Quhal F, Aydh A, Yanagisawa T, Kawada T, Rajwa P, Lusuuardi L, Soria F, Karakiewicz PI, Roupret M, Rink M, Lotan Y, Margulis V, **Singla N**, Xylinas E, Shariat SF, Pradere B. A systematic review and meta-analysis of prognostic UTUC nomograms. In press, *Frontiers in Oncology*.
48. Reig Torras O, Mishra A, Christie A, McKenzie T, Onabolu O, **Singla N**, Plimack ER, Suarez C, Ornstein MC, Alpaugh RK, Elias R, Bowman IA, McKay RM, Przybycin C, Kapur P, Brugarolas J, Rini B. Molecular genetic determinants of shorter time on active surveillance in a prospective phase 2 clinical trial in metastatic renal cell carcinoma. In press, *European Urology*.
49. Silagy AW, Kotecha RR, Weng S, Holmes A, **Singla N**, Mano R, Attalla K, Weiss K, Dinatale RG, Patil S, Coleman JA, Motzer RJ, Russo P, Voss M, Hakimi AA. Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma. In press, *Cancer*.
50. Ray S, Cheaib JG, Biles MJ, Pineault KG, Johnson MH, Ged YMA, Markowski MC, **Singla N**, Allaf ME, Pierorazio PM. Local and regional recurrences of clinically localized renal cell carcinoma after nephrectomy: A 15 year institutional experience with prognostic features and oncologic outcomes. In press, *Urology*.
51. Mudalegundi S, Griggs-Demmin A, Haney N, **Singla N**. Rapidly growing adrenal ganglioneuroma in a young man. In press, *Urology Case Reports*.
52. Ghandour RA, Freifeld Y, Cheaib J, **Singla N**, Meng X, Kenigsberg A, Bagrodia A, Woldu SL, Hoffman-Censits J, Enikeev DV, Rapoport L, Petros FG, Raman JD, Pierorazio PM, Matin SF, Margulis V. Predictive model for systemic recurrence following cisplatin-based neoadjuvant chemotherapy and radical nephroureterectomy for high risk upper tract urothelial carcinoma. In press, *Urologic Oncology: Seminars and Original Investigation*.
53. Meng X, Vazquez L, Ames K, Howard JM, Kenigsberg AP, **Singla N**, Margulis V, Bagrodia A, Lotan Y, Xi Y, Woldu SL. The early impact of Medicaid expansion on urologic malignancies in the United States. In press, *Urologic Oncology: Seminars and Original Investigation*.
54. Badia RR, Chertack N, Meng X, Howard J, **Singla N**, Margulis V, Lotan Y, Woldu S, Bagrodia A. Prognostic factors of diagnostic delay and appropriate follow-up in testicular germ cell tumor patients. In press, *Urologic Oncology: Seminars and Original Investigation*.
55. Rodriguez K, Harris K, **Singla N**. Adrenal pheochromocytoma in a patient with Lynch Syndrome. In press, *Urology Case Reports*.
56. Morozov A, Babaevskaya D, Taratkin M, Inoyatov J, Laukhtina E, Moschini M, **Singla N**, Ribas JG, Teoh J, Glybochko P, Enikeev D. A systematic review on the learning curve for robot-assisted radical cystectomy: What do we know? In press, *Journal of Endourology*.
57. Kim K, Zhou Q, Christie A, Stevens C, Ma Y, Onabolu O, Chintalapati S, McKenzie T, Tcheuyap VT, Woolford L, Xie Z, Zhang H, **Singla N**, Palencia MM, Pedrosa I, Margulis V, Sagalowsky A, Wang T, Modrusan Z, Seshagiri S, Kapur P, Brugarolas J, Malladi S. Determinants of renal cell carcinoma invasion and metastatic competence. *Nature Communications* 12(1): 5760, 2021.
58. **Singla N**, Huang C, Benfante NE, Wong NC, Hakimi AA, Russo P. Open partial nephrectomy with kidney split: Effective surgical approach to resect completely endophytic tumors. *Urologic Oncology: Seminars and Original Investigation* 39(6): 371.e1-5, 2021.
59. Margulis V, Freifeld Y, Pop LM, Manna S, Kapur P, Pedrosa I, Christie A, Muhamad O, Veerla S, Mannala S, **Singla N**, Wait M, Bagrodia A, Gahan J, Brugarolas J, Timmerman R, Hannan R. Neoadjuvant SAbR for renal cell carcinoma inferior vena cava tumor thrombus – safety lead-in results of a phase II trial. *International Journal of Radiation Oncology, Biology, Physics* 110(4): 1135-1142, 2021.
60. Metcalf MR, Cheaib JG, Wainger J, Pena VN, Patel HD, **Singla N**, Pierorazio PM. Gender differences in the clinical management of cT1a renal cell carcinoma. *Urology* 151: 129-137, 2021.

61. Lafin JT, Kenigsberg A, Meng X, Abe D, Savelyeva A, **Singla N**, Woldu S, Lotan Y, Mauck R, Lewis C, Margulis V, Wong D, Jia L, Kapur P, Xu L, Speir R, Chesnut G, Frazier AL, Strand D, Coleman N, Murray MJ, Amatruda J, Bagrodia A. Serum small RNA sequencing and miR-375 assay do not identify the presence of pure teratoma at post-chemotherapy retroperitoneal lymph node dissection. *European Urology Open Science* 26: 83-87, 2021.
 62. Chien TM, Lee HY, **Singla N**, Margulis V, Lotan Y, Woldu SL, Huang CN, Li CC, Ke HL, Li WM, Li CY, Huang AM, Yang SF, Tu HP, Wu WJ, Yeh HC. Prognostic factors for contralateral recurrence of upper tract urothelial carcinoma after nephroureterectomy: A large multiregional study. *Cancers* 13(23): 5935, 2021.
 63. Taratkin M, Enikeev D, Laukhtina E, **Singla N**, Glybochko P. How lasers ablate stones: In-vitro study of laser lithotripsy (Ho:YAG and Tm-fiber lasers) in different environments. *Journal of Endourology* 35(6): 931-936, 2021.
 64. Wainger JJ, Cheaib JG, Patel HD, Huang MM, Biles MJ, Metcalf M, Canner JK, **Singla N**, Trock BJ, Allaf ME, Pierorazio P. Volume-outcome relationships for kidney cancer may be driven by disparities and patient risk. *Urologic Oncology: Seminars and Original Investigation* 39(7): 439.e1-8, 2021.
 65. Badia RR, Abe D, Wong D, **Singla N**, Savelyeva A, Chertack N, Woldu SL, Lotan Y, Mauck R, Ouyang D, Meng X, Lewis CM, Majmudar K, Jia L, Kapur P, Xu L, Frazier AL, Margulis V, Strand DW, Coleman N, Murray MJ, Amatruda JF, Lafin JT, Bagrodia A. Real-world application of pre-orchietomy miR-371a-3p test in testicular germ cell tumor management. *Journal of Urology* 205(1): 137-144, 2021.
 66. Huang MM, Cheaib JG, Su ZT, Biles MJ, Sharma R, Zhang A, **Singla N**, Bass EB, Pierorazio PM. Assessing quality of care in the diagnosis and treatment of early-stage testicular cancer: A critical review and summary. *Urologic Oncology: Seminars and Original Investigation* 39(7): 400-408, 2021.
 67. Badia R, Woldu S, Patel HD, **Singla N**, Srivastava A, Cheaib JG, Pierorazio PM, Bagrodia A. Clinical utility of the AJCC 8th edition pT1 subclassification and impact on practice patterns in stage I seminoma. *Urologic Oncology: Seminars and Original Investigation* 39(2): 136.e19-25, 2021.
 68. Yeh H, Li C, Li C, Cheng Y, Woldu SL, Robyak H, Huang C, Ke H, Li W, Lee H, Chien T, Yeh B, Yang S, Tu H, Sagalowsky AI, Raman JD, **Singla N**, Margulis V, Lotan Y, Hsieh J, Wu W. Interethnic differences in the impact of body mass index on upper tract urothelial carcinoma following radical nephroureterectomy. *World Journal of Urology* 39(2): 491-500, 2021.
 69. **Singla N**, Xie Z, Zhang Z, Gao M, Yousuf Q, Onabolu O, McKenzie T, Tcheuyap VT, Ma Y, Choi J, McKay R, Christie A, Torras OR, Bowman IA, Margulis V, Pedrosa I, Przybycin C, Wang T, Kapur P, Rini B, Brugarolas J. Pancreatic tropism in metastatic renal cell carcinoma. *JCI Insight* 5(7): e134564, 2020.
 70. **Singla N**, Hutchinson RC, Ghandour RA, Freifeld Y, Fang D, Sagalowsky AI, Lotan Y, Bagrodia A, Margulis V, Hammers HJ, Woldu SL. Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database. *Urologic Oncology: Seminars and Original Investigation* 38(6): 604.e9-17, 2020.
 71. **Singla N**, Christie A, Freifeld Y, Ghandour RA, Woldu SL, Clinton TN, Petros FG, Robyak H, Enikeev D, Yeh H, Fang D, Bagrodia A, Sagalowsky AI, Lotan Y, Raman JD, Matin SF, Margulis V. Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma. *Urologic Oncology: Seminars and Original Investigation* 38(12): 933.e7-12, 2020.
 72. Fang D*, **Singla N***, Bao Z, Jafri SM, Su X, Cao Z, Xiong G, Zhang L, Woldu S, Hutchinson R, Sagalowsky A, Lotan Y, Li X, Raman JD, Margulis V, Zhou L. The significance of preoperative serum sodium and hemoglobin in outcomes of upper tract urothelial carcinoma: Multi-center analysis between China and the United States. *Cancer Management and Research* 12: 9825-9836, 2020.
- *Co-first authors**
73. Chertack N, Ghandour RA, **Singla N**, Freifeld Y, Hutchinson R, Courtney K, Bowman IA, Arafat W, Meng X, Moore JA, Aydin AM, Margulis V, Lotan Y, Woldu S, Bagrodia A. Overcoming sociodemographic factors in the care of testicular cancer patients at a safety net hospital. *Cancer* 126(19): 4362-4370, 2020.
 74. Lu T, Wang S, Xu L, Zhou Q, **Singla N**, Gao J, Manna S, Pop L, Xie Z, Chen M, Lukes JJ, Brugarolas J, Hannan R, Wang T. Modeling neoantigen clonality and immunogenicity for predicting immunotherapy outcomes and prognosis. *Science Immunology* 5(44): eaaz3199, 2020.
 75. Cai Q, Christie A, Rajaram S, Zhou Q, Araj E, Chintalapati S, **Singla N**, Cadeddu J, Margulis V, Rakheja D, Pedrosa I, McKay R, Brugarolas J, Kapur P. Ontological analyses reveal clinically-significant clear cell

renal cell carcinoma subtypes with convergent evolutionary trajectories into an aggressive type. *EBioMedicine* 51: 102526, 2020 [Corrigendum 55: 102707, 2020].

76. Courtney KD, Ma Y, Diaz de Leon A, Christie A, Xie Z, Woolford L, **Singla N**, Joyce A, Hill H, Madhuranthakam AJ, Yuan Q, Xi Y, Zhang Y, Chang J, Fatunde O, Arriaga Y, Frankel AE, Kalva S, Zhang S, McKenzie T, Reig O, Figlin RA, Rini BI, McKay RM, Kapur P, Wang T, Pedrosa I, Brugarolas J. HIF-2 complex dissociation, target inhibition, and acquired resistance with PT2385, a first-in-class HIF-2 inhibitor in clear cell renal cell carcinoma patients. *Clinical Cancer Research* 26(4): 793-803, 2020.
77. Lafin JT*, **Singla N***, Woldu SL, Lotan Y, Lewis CM, Majmudar K, Savelyeva A, Kapur P, Margulis V, Strand DW, Murray MJ, Amatruda JF, Bagrodia A. Serum microRNA-371a-3p levels predict viable germ cell tumor in chemotherapy-naïve patients undergoing retroperitoneal lymph node dissection. *European Urology* 77(2): 290-292, 2020.

***Co-first authors**

78. Ghandour RA, Wong D, Kusin S, Meng X, **Singla N**, Freifeld Y, Bagrodia A, Margulis V, Sagalowsky A, Lotan Y, Woldu SL. Does grossly complete transurethral resection improve response to neoadjuvant chemotherapy? *Urologic Oncology: Seminars and Original Investigation* 38(9): 736.e11-18, 2020.
79. Ghandour R, Miranda AF, **Singla N**, Meng X, Enikeev D, Woldu S, Bagrodia A, Cadeddu J, Gahan J, Margulis V. Feasibility and safety of robotic excision of ipsilateral retroperitoneal recurrence after nephrectomy for renal cell carcinoma. *Urology* 145: 159-165, 2020.
80. Freifeld Y, Ghandour R, **Singla N**, Woldu S, Bagrodia A, Lotan Y, Rapoport L, Gazimiev M, Delafuente K, Kulangara R, Robyak H, Petros FG, Raman JD, Matin SF, Margulis V. Intraoperative prophylactic intravesical chemotherapy to reduce bladder recurrence following radical nephroureterectomy. *Urologic Oncology: Seminars and Original Investigation* 38(9): 737.e11-16, 2020.
81. Yeh H, Li C, **Singla N**, Woldu SL, Robyak H, Wen S, Huang C, Ke H, Li W, Lee H, Li C, Yeh B, Huang A, Yang S, Tu H, Shariat SF, Sagalowsky AI, Raman JD, Lotan Y, Hsieh J, Margulis V, Wu W. Validation of hyponatremia as a prognostic predictor in multiregional upper tract urothelial carcinoma. *Journal of Clinical Medicine* 9(4): 1218, 2020.
82. Enikeev D, Morozov A, Taratkin M, Barret E, Kozlov V, **Singla N**, Rivas JG, Podoinitsin A, Margulis V, Glybochko P. Active surveillance for intermediate risk prostate cancer: A systematic review and meta-analysis of current protocols and outcomes. *Clinical Genitourinary Cancer* 18(6): e739-e753, 2020.
83. Morozov A, Taratkin M, Barret E, **Singla N**, Bezrukov E, Chinenov D, Enikeev M, Gomez Rivas J, Shpikina A, Enikeev D. A systematic review of irreversible electroporation in localized prostate cancer treatment. *Andrologia* 52(10): e13789, 2020.
84. Enikeev D, Taratkin M, Morozov A, Shpikina A, **Singla N**, Rivas JG, Barret E, Glybochko P. Focal irreversible electroporation for localized prostate cancer management: Prospective assessment of efficacy and safety. *Minerva Urologica e Nefrologica* 72(5): 644-645, 2020.
85. Taratkin M, Laukhtina E, **Singla N**, Kozlov V, Potoldykova N, Kirill A, Tatyana A, Enikeev D. Temperature changes during laser lithotripsy with Ho:YAG laser and novel Tm-fiber lasers: A comparative in-vitro study. *World Journal of Urology* 38(12): 3261-3266, 2020.
86. Enikeev D, Taratkin MS, Morozov A, **Singla N**, Gabdulina S, Tarasov A, Sukhanov RB, Rivas JG, Laukhtina E, Arshiev M, Mikhailov V, Glybochko PV. Long-term outcomes of HoLEP: A 5-year single-centre experience. *Journal of Endourology* 34(10): 1055-1063, 2020.
87. **Singla N**, Elias R, Ghandour RA, Freifeld Y, Bowman IA, Rapoport L, Enikeev M, Lohrey J, Woldu SL, Gahan JC, Bagrodia A, Brugarolas J, Hammers HJ, Margulis V. Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma. *Urologic Oncology: Seminars and Original Investigation* 37(12): 924-931, 2019.
88. Patel HD*, **Singla N***, Ghandour RA, Freifeld Y, Woldu SL, Pierorazio PM, Bagrodia A. Site of extranodal metastasis impacts survival in patients with testicular germ cell tumors. *Cancer* 125(22): 3947-3952, 2019.

***Co-first authors**

89. Margulis V, Puligandla M, Trabulsi EJ, Plimack ER, Kessler ER, Matin SF, Godoy G, Alva A, Hahn NM, Carducci MA, Hoffman-Censits J; *Collaborating Coauthors*: **Singla N**, Ruggeri A, Howard L, McCann J, Delacroix S, Zibelman M, Oza Y, Wang J, Gartrell B, Hussain M, Matrana M, Benjamin S, Sonpavde G, Lam E, Bernard B, Zakharia Y, Taylor S, Milowsky M, Ghani S, Singh S, Kane K, Arriaga Y, Morgans A, Chism D. Phase II trial of neoadjuvant systemic chemotherapy followed by extirpative surgery for patients with high grade upper tract urothelial carcinoma. *Journal of Urology* 203(4): 690-698, 2020.

***Featured for CME credit**

90. Foerster B, Abufaraj M, Petros F, Azizi M, Gupta M, Schweitzer D, Margulis V, Iwata T, Kimura S, Shabsigh A, Briganti A, Ku JH, Mulwijk T, Kassouf W, Matin SF, Spiess PE, Pierorazio PM, Hendricksen K, Shariat SF, and *UTUC Collaboration Coauthors*: Clinton T, Broutian T, Bandini M, Monteiro LL, Liao R, Moschini M, Bivalacqua TJ, Krabbe L, Nasu Y, Egawa S, Joniau S, John H, van der Heijden MS, Glybochko PV, Fajkovic H, **Singla N**, Necchi A. Efficacy of preoperative chemotherapy in high-risk upper tract urothelial carcinoma (UTUC). *Journal of Urology* 203(6): 1101-1108, 2020.
91. Trivedi H, **Singla N**, Fetzer D, Kapur P, Bagrodia A. First do no harm: A cautious approach to early stage testicular cancer patients. *Reviews in Urology* 22(2): 85-89, 2020.
92. Yeh H, Margulis V, **Singla N**, Hernandez E, Panwar V, Woldu SL, Karam JA, Wood CG, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Li C, Ke H, Li W, Lee H, Rapoport LM, Lotan Y, Kapur P, Shariat SF, Hsieh J, Wu W. PTRF independently predicts progression and survival in multiracial upper tract urothelial carcinoma following radical nephroureterectomy. *Urologic Oncology: Seminars and Original Investigation* 38(5): 496-505, 2020.
93. Hatchette CV, Aoun SG, El Ahmadi TY, Smalley L, Patel AR, Zhao L, **Singla N**, Mauck R, Rickert KL, Whitworth T. Minimally-invasive endoscopic aspiration of a spinal epidural dermoid cyst extending from T10 to the sacrum: 2-dimensional operative video. *Operative Neurosurgery* 18(5): E172, 2020.
94. Ghandour RA, Ashbrook C, Freifeld Y, **Singla N**, El-Asmar JM, Lotan Y, Margulis V, Eggener S, Woldu SL, Bagrodia A. Nationwide patterns of care for stage II non-seminomatous germ cell tumor of the testicle. *European Urology Oncology* 3(2): 198-206, 2020.
95. Freifeld Y, Ghandour R, **Singla N**, Woldu S, Clinton T, Kulangara R, Bagrodia A, Matin SF, Petros FG, Raman JD, Robyak H, Yan J, Zhu H, Rapoport L, Lotan Y, Margulis V. Preoperative predictive model and nomogram for disease recurrence following radical nephroureterectomy for high grade upper tract urothelial carcinoma. *Urologic Oncology: Seminars and Original Investigation* 37(10): 758-764, 2019.
96. Freifeld Y, Woldu S, **Singla N**, Clinton T, Bagrodia A, Hutchinson R, Lotan Y, Margulis V. Impact of hospital case volume on outcomes following radical nephrectomy and inferior vena cava thrombectomy. *European Urology Oncology* 2(6): 691-698, 2019.
97. Shantharam G, Huang C, **Singla N**, Chen YB, Russo P. Primary renal well-differentiated neuroendocrine tumor extending into the inferior vena cava. *Urology* 135: e2-e4, 2020.
98. Wong D, **Singla N**, Bagrodia A. Massive intra-abdominal germ cell tumors: A case series and review of literature. *Reviews in Urology* 21(2-3): 136-140, 2019
99. Shakir NA, Wang C, **Singla N**, Alhalabi F, Christie A, Lemack GE, Zimmern PE. Multidimensional outcomes of suburethral synthetic midurethral sling removal. *World Journal of Urology* 38(8): 2005-2012, 2020.
100. Aydin AM*, **Singla N***, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Westerman ME, Sagalowsky AI, Shariat SF, Lotan Y, Bagrodia A, Kapur P, Margulis V, Krabbe L. Prognostic significance of BAP1 expression in patients with high-grade upper tract urothelial carcinoma: A multi-institutional study. *World Journal of Urology* 37(11): 2419-2427, 2019.

***Co-first authors**

101. Gold SA, Shih JH, Rais-Bahrami S, Bloom JB, Vourganti S, **Singla N**, Baroni RH, Coker MA, Failkoff J, Hale GR, Nix JW, Gordetsky JB, Porter KK, Thomas JV, Noschang J, Mehralivand S, Rayn KN, Shakir N, Passoni N, Costa D, Roehrborn CG, Wood BJ, Merino MJ, Choyke PL, Turkbey B, Pinto PA. When to target the seminal vesicles: A validated multiparametric magnetic resonance imaging and biopsy-driven model to detect seminal vesicle invasion in prostate cancer. *Journal of Urology* 201(5): 943-949, 2019.

***Cover article**

***Featured for CME credit**

102. **Singla N**, Walker JT, Woldu SL, de la Fuente K, Araj E, Swartz B, Kapur P, Roehrborn CG. Does proximity of positive prostate biopsy core to capsular margin help predict side-specific extracapsular extension at prostatectomy? *Canadian Journal of Urology* 26(1): 9634-9643, 2019.
103. Bagrodia A, Audenet F, Pietzak EJ, Kim K, Murray KS, Cha EK, Sfakianos JP, Iyer G, **Singla N**, Arcila ME, Bochner BH, Al-Ahmadie HA, Solit DB, Coleman JA. Genomic profile of urothelial carcinoma of the upper tract from ureteroscopy biopsy: feasibility and validation from matched radical nephroureterectomy specimens. *European Urology Focus* 5(3): 365-368, 2019.

104. Zhang Y, Schoenhals J, Christie A, Mohamad O, Wang C, Bowman I, **Singla N**, Hammers H, Courtney K, Bagrodia A, Margulis V, Desai N, Garant A, Choy H, Timmerman R, Brugarolas J, Hannan R. Stereotactic ablative radiotherapy (SABR) used to defer systemic therapy in oligometastatic renal cell cancer. *International Journal of Radiation Oncology, Biology, Physics* 105(2): 367-375, 2019.
105. Ghandour RA, Freifeld Y, **Singla N**, Lotan Y. Evaluation of hematuria in a large public health care system. *Bladder Cancer* 5(2): 119-129, 2019.
106. Petros FG, Qiao W, **Singla N**, Clinton TN, Robyak H, Raman JD, Margulis V, Matin SF. Preoperative multiplex nomogram for prediction of high-risk nonorgan-confined upper-tract urothelial carcinoma. *Urologic Oncology: Seminars and Original Investigations* 37(4): 292.e1-292.e9, 2019.
107. Woldu SL, Matulay JT, Clinton TN, **Singla N**, Freifeld Y, Sanli O, Krabbe L, Hutchinson RC, Lotan Y, Hammers H, Hannan R, Brugarolas J, Bagrodia A, Margulis V. Incidence and outcomes of delayed targeted therapy following cytoreductive nephrectomy for metastatic renal cell carcinoma: A nationwide cancer registry study. *Clinical Genitourinary Cancer* 16(6): e1221-e1235, 2018.
108. Woldu SL, Moore JA, Ci B, Freifeld Y, Clinton TN, Murat AA, **Singla N**, Krabbe L, Hutchinson RC, Amatruda JF, Sagalowsky A, Lotan Y, Arriaga Y, Margulis V, Xie Y, Bagrodia A. Practice patterns and impact of postchemotherapy retroperitoneal lymph node dissection on testicular cancer outcomes. *European Urology Oncology* 1(3): 242-251, 2018.
109. Hutchinson R, **Singla N**, Akhtar A, Haridas J, Bhat D, Roehrborn C, Lotan Y. Seniority of primary care physicians is associated with a decrease in PSA ordering habits in the years surrounding the United States Preventative Services Task Force recommendation against PSA screening. *Urologic Oncology: Seminars and Original Investigations* 36(11): 500.e21-500.e27, 2018.
110. Johnson B, Sorokin I, **Singla N**, Roehrborn C, Gahan J. Determining the learning curve for robotic-assisted simple prostatectomy for experienced robotic surgeons. *Journal of Endourology* 32(9): 865-870, 2018.
111. Fang D, Gong YQ, **Singla N**, Yang KL, Xiong GY, Zhang L, Li XS, Zhou LQ. The significance of the initial symptom in Chinese patients with upper tract urothelial carcinoma: Regular health examination is still underutilized. *Kaohsiung Journal of Medical Sciences* 34(9): 511-521, 2018.
112. **Singla N**, Krabbe L, Aydin AM, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Bagrodia A, Kapur P, Margulis V. Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma. *Urologic Oncology: Seminars and Original Investigations* 36(7): 343.e1-343.e8, 2018.
113. **Singla N**, Fang D, Su X, Bao Z, Cao Z, Robyak H, Xiong G, Zhang L, Woldu S, Hutchinson R, Sagalowsky A, Lotan Y, Li X, Zhou L, Raman J, Margulis V. Preoperative predictors of non-organ-confined disease in upper tract urothelial carcinoma differ between China and the United States. *Urologic Oncology: Seminars and Original Investigations* 36(3): 88.e11-88.e18, 2018.
114. Woldu SL, Ci B, Hutchinson RC, Krabbe LM, **Singla N**, Passoni NM, Clinton TN, Raj GV, Miller DS, Sagalowsky AI, Lotan Y, Xie Y, Margulis V, Bagrodia A. Usage and survival implications of surgical staging of inguinal lymph nodes in intermediate- to high-risk, clinical localized penile cancer: A propensity-score matched analysis. *Urologic Oncology: Seminars and Original Investigations* 36(4): 159.e7-159.e17, 2018.
115. Margolin EJ, Matulay JT, Li G, Meng X, Chao B, Vijay V, Silver H, Clinton TN, Krabbe LM, Woldu SL, **Singla N**, Bagrodia A, Margulis V, Huang WC, Bjurlin MA, Shah O, Anderson CB. Discordance between ureteroscopic biopsy and final pathology for upper tract urothelial carcinoma. *Journal of Urology* 199(6): 1440-1445, 2018.
116. Shakir NA, Wang C, **Singla N**, Alhalabi F, Christie A, Lemack GE, Zimmern PE. Challenges of multidimensional outcome reporting after suburethral midurethral sling removal. *Journal of Urology* 199(6): 1577-1583, 2018.
- *Featured for CME credit**
117. Hutchinson R, Rew C, Chen G, Woldu S, Krabbe L, Meissner M, Sheth K, **Singla N**, Shakir N, Master V, Karam J, Matin S, Borregales L, Wood C, Masterson T, Thompson RH, Leibovich B, Abel EJ, Bagrodia A, Margulis V. The adverse survival implications of bland thrombus in renal cell carcinoma with venous tumor thrombus. *Urology* 115: 119-124, 2018.
118. Woldu S, Aydin AM, Rao AV, Hutchinson RC, **Singla N**, Clinton TN, Krabbe L, Passoni NM, Raj GV, Miller DS, Amatruda JF, Sagalowsky AI, Lotan Y, Arriaga Y, Margulis V, Bagrodia A. Differences at

- presentation and treatment of testicular cancer in Hispanic men: Institutional and national hospital-based analysis. *Urology* 112: 103-111, 2018.
119. Fang D, He S, Xiong G, **Singla N**, Cao Z, Zhang L, Li X, Zhou L. Comparison of clinicopathologic features, epigenetic biomarkers and prognosis between renal pelvic and ureteral tumors in upper tract urothelial carcinoma. *BMC Urology* 18(1): 22-38, 2018.
 120. Woldu SL, Hutchinson RC, **Singla N**, Hornberger B, Roehrborn CG, Lotan Y. Prospective monitoring and adapting strategies for prevention of infection following transrectal prostate procedures. *Urology Practice* 5: 124-131, 2018.
 121. Woldu SL, Matulay JT, Clinton TN, **Singla N**, Krabbe L, Hutchinson RC, Sagalowsky A, Lotan Y, Margulis V, Bagrodia A. Impact of hospital case volume on testicular cancer outcomes and practice patterns. *Urologic Oncology: Seminars and Original Investigations* 36(1): 14.e7-14.e15, 2018.
 122. Arevalo MK, Sheth KR, Menon VS, Ostrov L, Hennes H, **Singla N**, Koral K, Schlomer BJ, Baker LA. Straight to the Operating Room: An emergent surgery track for acute testicular torsion transfers. *Journal of Pediatrics* 192: 178-183, 2018.
 123. Krabbe L, Heitzplatz B, Preuss S, Hutchinson RC, Woldu SL, **Singla N**, Boegemann M, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Rapoport LM, Glybochko PV, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Xylinas E, Margulis V. Prognostic value of PD-1 and PD-L1 expression in patients with high-grade urothelial carcinoma of the upper urinary tract. *Journal of Urology* 198(6): 1253-1262, 2017.
 124. Hutchinson RC, **Singla N**, Krabbe LM, Woldu SL, Chen G, Rew C, Tachibana I, Lotan Y, Cadeddu JA, Margulis V. Increased use of antihypertensive medications after partial nephrectomy versus radical nephrectomy. *Urologic Oncology: Seminars and Original Investigations* 35(11): 660.e17-660.e25, 2017.
 125. **Singla N**, Aggarwal H, Foster J, Alhalabi F, Lemack G, Zimmern P. Management of urinary incontinence following sub-urethral sling removal. *Journal of Urology* 198(3): 644-649, 2017.
- *Featured for CME credit**
126. Sorokin I, Sundaram V, **Singla N**, Walker J, Margulis V, Roehrborn C, Gahan JC. Robotic assisted versus open simple prostatectomy for benign prostatic hyperplasia in large glands: a propensity score matched comparison of peri-operative and short-term outcomes. *Journal of Endourology* 31(11): 1164-1169, 2017.
 127. Satyanarayan A, **Singla N**, Morey AF. Penile ossification: A reconstructive challenge. *Reviews in Urology* 19(1): 64-67, 2017.
 128. **Singla N**, Walker J, Woldu SL, Passoni NM, De La Fuente K, Roehrborn CG. Formalin disinfection of prostate biopsy needles may reduce post-biopsy infectious complications. *Prostate Cancer and Prostatic Diseases* 20(2): 216-220, 2017.
 129. **Singla N**, Fang D, Su X, Bao Z, Cao Z, Jafri S, Xiong G, Zhang L, Hutchinson R, Sagalowsky A, Lotan Y, Li X, Zhou L, Raman J, Margulis V. A multi-institutional evaluation of clinical and tumor characteristics in upper tract urothelial carcinoma from China and the United States. *Journal of Urology* 197(5): 1208-1213, 2017.
 130. Viers BR, Mathur S, Hofer MD, Dugi DD 3rd, Pagliara TJ, **Singla N**, Walker J, Scott JM, Morey AF. Clinical risk factors associated with urethral atrophy. *Urology* 103: 230-233, 2017.
 131. Morey AF, **Singla N**, Carmel M, Klein A, Tausch TJ, Siegel J, Tachibana I, Scott J. Standing cough test for evaluation of post-prostatectomy incontinence: A pilot study. *Canadian Journal of Urology* 24(1): 8664-8669, 2017.
- *Featured article**
132. **Singla N**, Haddad AQ, Passoni NM, Meissner M, Lotan Y. Anti-inflammatory use may not negatively impact oncologic outcomes following intravesical BCG for high-grade non-muscle-invasive bladder cancer. *World Journal of Urology* 35(1): 105-111, 2017.
 133. **Singla N**, Haddad AQ, Cefalu C, Margulis V. Gossypiboma manifesting as urachal mass. *Reviews in Urology* 18(4): 239-241, 2016.
 134. Fang D, Seisen T, Yang K, Liu P, Fan X, **Singla N**, Xiong G, Zhang L, Yu W, Zhang Z, Li X, Zhou L. A systematic review and meta-analysis of oncological and renal function outcomes obtained after segmental ureterectomy versus radical nephroureterectomy for upper tract urothelial carcinoma. *European Journal of Surgical Oncology* 42(11): 1625-1635, 2016.
 135. Su X, Tang Q, Fang D, Xiong G, **Singla N**, He Q, Zhang L, Liu P, Fan Y, Hao H, Li X, Zhou L. Comparisons of prognosis between urothelial carcinoma of the upper urinary tract and bladder with pT3-4 cancer. *International Journal of Clinical and Experimental Medicine* 9(9): 18308-18315, 2016.

136. **Singla N**, Hutchinson R, Menegaz C, Haddad AQ, Jiang L, Sagalowsky A, Cadeddu JA, Lotan Y, Margulis V. Comparing changes in renal function after radical surgery for upper tract urothelial carcinoma and renal cell carcinoma. *Urology* 96: 44-53, 2016.
137. **Singla N**, Lay A, Cadeddu J. Poor split renal function pre-operatively does not predict worse outcomes after pyeloplasty in adults. *Canadian Journal of Urology* 23(5): 8457-8464, 2016.
138. **Singla N**, Hutchinson R, Haddad A, Sagalowsky A, Lotan, Y, Margulis V. Preoperative hydronephrosis is associated with less decline in renal function after radical nephroureterectomy for upper tract urothelial carcinoma. *Canadian Journal of Urology* 23(4): 8334-8341, 2016.
139. Walker JT, **Singla N**, Roehrborn CG. Reducing infectious complications following transrectal ultrasound guided prostate biopsy: A systematic review. *Reviews in Urology* 18(2): 73-89, 2016.
140. Hofer MD, Aguilar-Cruz HJ, **Singla N**, Cordon BH, Scott JM, Morey AF. Expanding applications of renal mobilization and downward nephropexy in ureteral reconstruction. *Urology* 94: 232-236, 2016.
141. **Singla N**, Kunju LP, Jorns JM. Testicular size discrepancy in a man evaluated for vasectomy. *American Journal of Urology Research* 1(1): 8-10, 2015.
142. Morey AF, **Singla N**, Chung PH, Klein AK, Tausch TJ, Siegel JA, Tachibana I, Scott J, Carmel M. Male Stress Incontinence Grading Scale (MSIGS) for evaluation of men with post-prostatectomy incontinence: A pilot study. *Video Journal of Prosthetic Urology* 2: 064, 2016. Available at: <http://www.vjpu-issm.info/>
143. Fang D, Liu P, Li X, Xiong G, Zhang L, **Singla N**, Zhao G, He Q, He Z, Zhou L. Characteristics and treatment outcomes of pan-urothelial urothelial cell carcinoma: a descriptive analysis of 45 patients. *Scientific Reports* 5: 18014, 2015.
144. Starke N, **Singla N**, Haddad A, Lotan Y. Long-term outcomes of high risk bladder cancer screening cohort. *BJU International* 117(4):611-617, 2016.
145. **Singla N**, Gayed B, Bagrodia A, Krabbe LM, Palazzi KL, Mirheydar H, Harrow B, Jacobs C, Youssef R, Darwish O, Sagalowsky A, Lotan Y, Derweesh I, Margulis V. Multi-institutional analysis of renal function outcomes following radical nephroureterectomy and partial ureterectomy for upper tract urothelial carcinoma. *Urologic Oncology: Seminars and Original Investigations* 33(6): 268.e1-7, 2015.
146. **Singla N**, Siegel JA, Simhan J, Tausch TJ, Klein A, Thoreson GR, Morey AF. Does pressure regulating balloon location make a difference in functional outcomes of artificial urinary sphincter? *Journal of Urology* 194(1): 202-206, 2015.
147. Zhang L, Xiong G, Fang D, Li X, Liu J, Ci W, Zhao W, **Singla N**, He Z, Zhou L. Contralateral upper tract urothelial carcinoma after nephroureterectomy: the predictive role of DNA methylation. *Journal of Experimental & Clinical Cancer Research* 34(1): 5, 2015.
148. Fang D, Zhang L, Li X, Yu W, **Singla N**, Zhao G, Xiong G, Song Y, He Q, He Z, Zhou L. Presence of concomitant non-muscle invasive bladder cancer in Chinese patients with upper tract urothelial carcinoma: risk factors, characteristics and predictive value. *Annals of Surgical Oncology* 22(8): 2789-2798, 2015.
149. **Singla N**, Montie JE, Lee CT, Wolf JS, Faerber GJ. Experience in 45 consecutive patients with neobladders undergoing retrograde ureteroscopy for upper tract abnormalities. *Urology Practice* 2(5): 244-249, 2015.
150. **Singla N**, Sachdeva A, Little A. Urinary retention and episodic paresthesias. *JAMA Surgery* 150(5): 485-486, 2015.
151. Haddad A, **Singla N**, Gupta N, Raj G, Sagalowsky A, Margulis V, Lotan Y. Association of distance to treatment facility on quality and survival outcomes following radical cystectomy for bladder cancer. *Urology* 85(4): 876-882, 2015.
152. **Singla N**, Singla AK. Review of single surgeon 10-year experience with AUS with report of sterile cuff erosion managed non-surgically. *Urology* 85(1): 252-257, 2015.
153. Simhan J, Morey AF, **Singla N**, Tausch TJ, Scott JF, Lemack GE, Roehrborn CG. 3.5 cm artificial urinary sphincter cuff erosion occurs predominantly in irradiated patients. *Journal of Urology* 193(2): 593-597, 2015.
154. Haddad AQ, Kapur P, **Singla N**, Raman JD, Then MT, Nuhn P, Buchner A, Bastian P, Seitz C, Shariat SF, Bensalah K, Rioux-Leclercq N, Sagalowsky A, Lotan Y, Margulis V. Validation of mammalian target of rapamycin biomarker panel in patients with clear cell renal cell carcinoma. *Cancer* 121(1): 43-50, 2015.
155. Cary KC*, **Singla N***, Cowan JE, Carroll PR, Cooperberg MR. Impact of androgen deprivation on emotional and mental well-being in men with prostate cancer: Analysis from the CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) registry. *Journal of Urology* 191(4): 964-970, 2014.

*Co-first authors

156. Hervey-Jumper S, **Singla N**, Gebarski SS, Robertson P, Muraszko KM, Garton HJL, Maher CO. Diffuse pontine lesions in children with neurofibromatosis type I: making a case for UBO's. *Pediatric Neurosurgery* 49(1): 55-59, 2013.
157. Nelson R, **Singla N**. A spectral model for signal elements isolated from zebrafish photopic electroretinogram. *Visual Neuroscience* 26: 349-363, 2009.
- *Cover article**
158. **Singla N**, Singla AK, Lee JS. A novel, non-invasive approach to diagnosing urinary tract obstruction using CFD. *Journal of Young Investigators* 18(6): 2008.
159. Helgeson BE, Tomlins SA, Shah N, Laxman B, Cao Q, Prensner JR, Cao X, **Singla N**, Montie J, Varambally S, Mehra R, Chinnaiyan AM. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. *Cancer Research* 68(1): 73-80, 2008.
160. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, Cao Q, Prensner JR, Rubin MA, Shah RB, Mehra R, Chinnaiyan AM; *Acknowledged Collaborators*: Dhanasekaran S, Siddiqui J, LeBlanc M, **Singla N**, Pienta K, Craig R, Stoolman L. Role of the TMPRSS2-ERG gene fusion in prostate cancer. *Neoplasia* 10(2): 177-188, 2008.

B. Invited Reviews

1. Elias R, Ged Y, **Singla N**. Kidney cancer research highlights from ASCO 2023 meeting. Submitted, *Kidney Cancer Journal*.
2. Pallauf M, Ged Y, **Singla N**. Molecular differences in renal cell carcinoma between males and females. Accepted, *World Journal of Urology*.
3. Patel SH, **Singla N**, Pierorazio PM. Decision-making in active surveillance in kidney cancer: Current trends and future urine and tissue markers. In press, *World Journal of Urology*.
4. Ged Y, **Singla N**. Kidney cancer research highlights from ASCO 2022 meeting. *Kidney Cancer Journal* 20(2): 61-64, 2022.
5. Ged Y, **Singla N**. Kidney cancer research highlights from ASCO GU 2022 meeting. *Kidney Cancer Journal* 20(1): 30-32, 2022.
6. **Singla N**, Freifeld Y, Ghandour RA, Hammers HJ. Rational approaches to treatment duration with immunotherapy in metastatic renal cell carcinoma. *European Urology Focus* 6(1): 31-33, 2020.
7. Elias R, Sharma A, **Singla N**, Brugarolas J. Next generation sequencing in renal cell carcinoma: Towards precision medicine. *Kidney Cancer Journal* 17(4): 94-104, 2019.
- *Cover article**
8. **Singla N**, Lafin JT, Ghandour RA, Kaffenberger S, Amatruda JF, Bagrodia A. Genetics of testicular germ cell tumors. *Current Opinion in Urology* 29(4): 344-349, 2019.
9. **Singla N**, Ghandour RA, Margulis V. Is cytoreductive nephrectomy relevant in the immunotherapy era? *Current Opinion in Urology* 29(5): 526-530, 2019.
10. **Singla N**, Ghandour RA, Margulis V. Sex differences in upper tract urothelial carcinomas. *Current Opinion in Urology* 29(3): 256-260, 2019.
11. **Singla N**, Ghandour RA, Raj GV. Investigational luteinizing hormone releasing hormone (LHRH) agonists and other hormonal agents in early stage clinical trials for prostate cancer. *Expert Opinion on Investigational Drugs* 28(3): 249-259, 2019.
12. Ghandour RA*, **Singla N***, Margulis V. The use of cytoreductive nephrectomy in patients with renal cell carcinoma. *Expert Review of Anticancer Therapy* 19(5): 405-411, 2019.
- *Co-first authors**
13. Ghandour RA*, **Singla N***, Bagrodia A. Management of stage II germ cell tumors. *Urologic Clinics of North America* 46(3): 363-376, 2019.
- *Co-first authors**
14. Ghandour RA, **Singla N**, Lotan Y. Treatment options and outcomes in non-metastatic muscle invasive bladder cancer. *Trends in Cancer* 5(7): 426-439, 2019.
15. Tse J, Ghandour RA, **Singla N**, Lotan Y, Margulis V. Current advances in BCG-unresponsive non-muscle invasive bladder cancer. *Expert Opinion on Investigational Drugs* 28(9): 757-770, 2019.
16. Tse J, Ghandour R, **Singla N**, Lotan Y. Molecular predictors of complete response following neoadjuvant chemotherapy in urothelial carcinoma of the bladder and upper tracts. *International Journal of Molecular Sciences* 20(4): 793-808, 2019.

17. Cordon BH, **Singla N**, Singla AK. Artificial urinary sphincters for male stress urinary incontinence: Current perspectives. *Medical Devices: Evidence and Research* 9: 175-183, 2016.
18. **Singla N**, Singla AK. Evaluation and management of lower urinary tract symptoms after outlet surgery for benign prostatic hyperplasia. *Current Bladder Dysfunction Reports* 11(3): 242-247, 2016.
19. **Singla N**, Gahan J. New technologies in tumor ablation. *Current Opinion in Urology* 26(3): 248-253, 2016.
20. **Singla N**, Morey AF. Rectourethral fistula reconstruction in elderly patients. *Current Opinion in Urology* 26(2): 171-176, 2016.
21. Satyanarayan A, Mooney R, **Singla N**. Surgical management of post-prostatectomy incontinence. *European Medical Journal (EMJ) Urology* 4(1): 75-80, 2016.
22. **Singla N**, Singla AK. Evolution of robotic technology in urologic surgery. *Urologické Listy* 12(3): 13-16, 2014.
23. **Singla N**, Singla AK. Post-prostatectomy incontinence: Etiology, evaluation, and management. *Turkish Journal of Urology* 40(1): 1-8, 2014.
24. **Singla N**, Singla AK. Robotic-Assisted Surgery: Urological Applications and Outcomes. *Journal of Robotic Surgery* 1: 33-37, 2014.

C. Editorials and Replies

1. Fletcher SA, **Singla N**. Editorial comment: "Outcomes of hematuria evaluation by advanced practice providers and urologists." The role of advanced practice providers in hematuria evaluation: Looking under the microscope. Accepted, *Urology*.
2. **Singla N**. Editorial comment: "Characterization of patients with metastatic renal cell carcinoma experiencing complete response to first-line therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)." Accepted, *Journal of Urology*.
3. Ged Y, Markowski MC, **Singla N**, Rowe SP. The shifting treatment paradigm of metastatic renal cell carcinoma. Accepted, *Nature Reviews Urology*.
4. Pallauf M, Ged Y, **Singla N**. A swinging pendulum: Bringing back cytoreductive nephrectomy in the era of immune checkpoint inhibition. In press, *European Urology Oncology*.
5. Pallauf M, **Singla N**. Editorial comment: "Persistent asymptomatic isolated microscopic hematuria in adolescents is not associated with an increased risk for early onset urinary tract cancer." A tale of asymptomatic microscopic hematuria. In press, *Urology*.
6. **Singla N**, Wong J, Singla S, Krailo M, Huang L, Shaikh F, Billmire D, Rescorla F, Ross J, Dicken B, Amatruda JF, Frazier AL, Bagrodia A. Response to Commentary re Clinicopathologic predictors of outcomes in children with stage I testicular germ cell tumors: A pooled *post hoc* analysis of trials from the Children's Oncology Group. In press, *Journal of Pediatric Urology*.
7. Sheu ZL, **Singla N**, Chen CH, Hsieh JT, Yeh HC. Editorial: Prognostic research and precision oncology in upper tract urothelial carcinoma. In press, *Frontiers in Oncology*.
8. de la Calle C, **Singla N**. Editorial Commentary: "Positive Impact of Implementing a Comprehensive Genetic Testing Protocol for Prostate Cancer Patients in a Multi-disciplinary Uro-oncology Practice." In press, *Urology Practice*.
9. de la Calle C, **Singla N**. Editorial Commentary: "A Novel Metric for Hospital-Quality in Kidney Cancer Surgery: A Veteran's Affairs National Health System Validation of Concept." In press, *Urology Practice*.
10. **Singla N**, Margulis V. Locally advanced kidney cancer: A new space for immunotherapy? In press, *European Urology Oncology*.
11. **Singla N**. A commentary on: "A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomy." *PracticeUpdate*. Published online, Nov. 2022: <https://www.practiceupdate.com/content/survival-outcomes-in-patients-with-mrcc-receiving-immune-checkpoint-inhibitor-therapy-with-or-without-cytoreductive-nephrectomy/144156/65/3/1>
12. **Singla N**. How can we predict pT3a kidney cancer and what does it mean? *Kidney Cancer Journal* 19(4): 103, 2021.
13. McConkey DJ, **Singla N**, Pierorazio P, Lombardo K, Matoso A, Hoffman-Censits J. Molecular subtypes of upper tract urothelial cancer: Setting the stage for precision therapy. *Cancer Cell* 39(6): 745-747, 2021.
14. **Singla N**. Rational therapeutic sequencing in metastatic renal cell carcinoma: Insights gained from IMmotion150. *European Urology* 79(5): 674-675, 2021.

15. **Singla N**, Pierorazio P, Allaf M, Ged Y. PROTECTing patients with locally advanced kidney cancer. “Re: Robert J. Motzer, Paul Russo, Naomi Haas, et al. Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. *Eur Urol* 2021;79:334-8.” *European Urology* 80(1): e33-34, 2021.
16. **Singla N**. Novel strategies in locally advanced kidney cancer – Highlights from KEYNOTE-564. *Kidney Cancer Journal* 19(S2): s74, 2021.
17. Meyer AR, Rowe SP, **Singla N**. Integrating ^{99m}Tc-sestamibi and ONEX to optimize renal mass risk stratification. “Re: Patrick D. McGillivray, Diaki Ueno, Aydin Pooli, et al. Distinguishing Benign Renal Tumors with an Oncocytic Gene Expression (ONEX) Classifier. *Eur Urol* 2021;79:107-11.” *European Urology* 80(1): e20-21, 2021.
18. **Singla N**, Margulis V, on behalf of ECOG-ACRIN 8141 Investigators. A new standard for a rare disease? Optimizing the timing of chemotherapy for upper tract urothelial carcinoma. “Re: Alison Birtle, Mark Johnson, John Chester, et al. Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial. *Lancet* 2020;395:1268-77.” *European Urology* 79(1): e28, 2021.
19. Patel SH, **Singla N**, Pierorazio PM. Contemporary prognostic model for renal cell carcinoma: Is it time for biomarkers? *European Urology* 80(1): 32-33, 2021.
20. **Singla N**, Margulis V. Differences between upper tract urothelial carcinoma and bladder cancer. *AUA News* 26(7): 15-16, 2021.
21. **Singla N**. A commentary on: “Survival benefit of chemotherapy in a contemporary cohort of metastatic urachal carcinoma.” *Practice Update*. Published online, Dec. 2021: <https://www.practiceupdate.com/content/survival-benefit-of-chemotherapy-in-metastatic-urachal-carcinoma/126509/65/3/1>
22. **Singla N**. Progress toward precision medicine in frontline treatment of metastatic renal cell carcinoma. *JAMA Oncology* 6(1): 25-26, 2020.
23. **Singla N**. A new therapeutic era for metastatic renal cell carcinoma: Call for a new prognostic model. *JAMA Oncology* 6(5): 633-634, 2020.
24. **Singla N**, Singla S. Harnessing big data with machine learning in precision oncology. *Kidney Cancer Journal* 18(3): 83-84, 2020.
25. **Singla N**. Putting IMmotion into motion: Personalizing frontline treatment for metastatic renal cell carcinoma. “Re: Brian I. Rini, Thomas Powles, Michael B. Atkins, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): A multicentre, open-label, phase 3, randomised controlled trial. *Lancet* 2019;393:2404-15.” *European Urology* 77(6): e168-e169, 2020.
26. **Singla N**. Unraveling the obesity paradox in immunogenic malignancies: A step towards precision oncology? “Re: Alejandro Sanchez, Helena Furberg, Fengshen Kuo, et al. Transcriptomic Signatures Related to the Obesity Paradox in Patients with Clear Cell Renal Cell Carcinoma: A Cohort Study. *Lancet Oncol* 2020;21:283-93.” *European Urology* 78(2): e87-e88, 2020.
27. **Singla N**, Margulis V. The next surgical frontier in kidney cancer: Nephrectomy after immune checkpoint inhibition. “Re: Geraldine Pignot, Antoine Thiery-Vuillemin, Jochen Walz, et al. Nephrectomy after complete response to immune checkpoint inhibitors for metastatic renal cell carcinoma: A new surgical challenge? *Eur Urol*. In press. <https://doi.org/10.1016/j.eururo.2019.12.018>.” *European Urology* 78(2): e79-e80, 2020.
28. **Singla N**. Uveal melanoma and kidney cancer: More similar than meets the eye. *Kidney Cancer Journal* 18(2): 61, 2020.
29. **Singla N**. Academic mentorship: Choosing the right research mentor(s). *Kidney Cancer Journal* 18(4): 114, 2020.
30. **Singla N**. Editorial comment: “Perioperative Outcome of Suprarenal Resection of Vena Cava without Reconstruction in Urologic Malignancies: A Case Series and Review of the Literature.” *Urology* 142: 153-154, 2020.
31. **Singla N**. Improving continence outcomes after prostatectomy: Integrating MRI with the Retzius-sparing approach. *Translational Andrology and Urology* 9(2): 151-152, 2020.
32. Enikeev D, Taratkin M, Lavrinenko N, Panferov A, **Singla N**. Re: Welk, et al., an opioid prescription for men undergoing minor urologic surgery is associated with an increased risk of new persistent opioid use. *Translational Andrology and Urology* 9(5): 2299-2301, 2020.

33. Margulis V, Puligandla M, Trabulsi EJ, Plimack ER, Kessler ER, Matin SF, Godoy G, Alva A, Hahn NM, Carducci MA, Hoffman-Censits J; *Collaborating Coauthors: Singla N, Ruggeri A, Howard L, McCann J, Delacroix S, Zibelman M, Oza Y, Wang J, Gartrell B, Hussain M, Matrana M, Benjamin S, Sonpavde G, Lam E, Bernard B, Zakharia Y, Taylor S, Milowsky M, Ghani S, Singh S, Kane K, Arriaga Y, Morgans A, Chism D*. Reply by Authors: "Phase II trial of neoadjuvant systemic chemotherapy followed by extirpative surgery for patients with high grade upper tract urothelial carcinoma." *Journal of Urology* 203(4): 690-698.
34. Bagrodia A, Pierorazio P, **Singla N**, Albers P. The complex and nuanced care of early stage testicular cancer: Lessons from the EAU and AUA testis cancer guidelines. *European Urology* 77(2): 139-141, 2020.
35. **Singla N**, Lafin JT, Bagrodia A. MicroRNAs: Turning the tide in testicular cancer. *European Urology* 76(5): 541-542, 2019.
36. **Singla N**, Yeh H. Interethnic differences in the impact of body mass index on upper tract urothelial carcinoma following radical nephroureterectomy: Beyond the abstract. *UroToday*. Published online, May 2020: <https://www.urotoday.com/recent-abstracts/urologic-oncology/upper-tract-tumors/121592-interethnic-differences-in-the-impact-of-body-mass-index-on-upper-tract-urothelial-carcinoma-following-radical-nephroureterectomy-beyond-the-abstract.html>
37. **Singla N**, Bagrodia A. The complex and nuanced care of early stage testicular cancer: Lessons from the EAU and AUA testis cancer guidelines: Beyond the abstract. *UroToday*. Published online, May 2020: <https://www.urotoday.com/recent-abstracts/urologic-oncology/testicular-cancer/120721-the-complex-and-nuanced-care-for-early-stage-testicular-cancer-lessons-from-the-european-association-of-urology-and-american-urological-association-testis-cancer-guidelines-beyond-the-abstract.html>
38. Ghandour RA, **Singla N**, Bagrodia A. Management of stage II germ cell tumors: Beyond the abstract. *UroToday*. Published online, Nov. 2019: <https://www.urotoday.com/recent-abstracts/urologic-oncology/testicular-cancer/116301-management-of-stage-ii-germ-cell-tumors-beyond-the-abstract.html>
39. **Singla N**. Editorial comment: "American Urological Association Non-muscle Invasive Bladder Cancer Risk Model Validation: Should patient age be added to the risk model?." *Journal of Urology* 202(4): 688, 2019.
40. **Singla N**, Hakimi AA, Margulis V. The evolving role of cytoreductive nephrectomy. *Current Opinion in Urology* 29(5): 505-506, 2019.
41. **Singla N**. The value of protecting research time during training. *European Urology* 76(3): 411-412, 2019.
42. **Singla N**. ETS rearrangements, neuroendocrine modulators, and androgen resistance: What can the microenvironment reveal in prostate cancer? *European Urology Oncology* 2(4): 413-414, 2019.
43. **Singla N**, Margulis V. Editorial comment: "Risk factors for complications and non-diagnostic results following 1155 consecutive percutaneous core renal mass biopsies." *Journal of Urology* 201(6): 1086, 2019.
44. **Singla N**, Ghandour RA, Raj GV. Biomarkers for platinum sensitivity in bladder cancer: Are we there yet? *Translational Andrology and Urology* 8(Suppl 3): S236-S239, 2019.
45. Kenigsberg AP, **Singla N**, Cadeddu JA. Challenging cases in urology: Hematuria in a man with a history of prostate cancer. *Urology Times*. Published online, Sept. 2019: <https://www.urologytimes.com/article/challenging-case-hematuria-man-history-prostate-ca>
46. **Singla N**. Practicing integrity in the lab and in the clinic. *Oncology Fellows* 11(3): 18-19. Published online, Aug. 2019: <https://www.onclive.com/publications/oncology-fellows/2019/september-2019/oncology-fellow-stresses-integrity-in-the-lab-and-clinic>
47. **Singla N**, Margulis V. Is there a role for radiation for primary kidney tumors? *AUANews* 24(6): 4, 2019. Published online, June 2019: <https://epub.auanet.org/publication/?i=592420>
48. **Singla N**. Comment on "Unraveling the molecular profile underpinning pancreatic tropisms in metastatic clear cell renal cell carcinoma." European Association of Urology (EAU) Edu Platform. Published online, May 2019: <https://kidney.uroonco.uroweb.org/publication/unraveling-the-molecular-profile-underpinning-pancreatic-tropisms-in-metastatic-clear-cell-renal-cell-carcinoma/>
49. **Singla N**, Margulis V. Editorial comment: "Contemporary management of incident prostate cancer in large community urology practices in the United States." *Urology* 129: 85, 2019.
50. **Singla N**, Hannan R, Margulis V. Editorial comment: "Role of stereotactic body radiation therapy in the management of oligometastatic renal cell carcinoma." *Journal of Urology* 201(1): 76, 2019 [Erratum 201(4): 821, 2019].
51. **Singla N**. Editorial comment: "Association of androgen deprivation therapy and thromboembolic events: A systematic review and meta-analysis." *Urology* 114: 162, 2018.

52. **Singla N.** Lessons of residency extend beyond the technical. *Urology Times* 46(4): 40, 2018. Published online, April 2018: <http://urologytimes.com/modern-medicine-feature-articles/lessons-residency-extend-beyond-technical>
53. Krabbe L, Heitzplatz B, Preuss S, Hutchinson RC, Woldu SL, **Singla N**, Boegemann M, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Rapoport LM, Glybochko PV, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Xylinas E, Margulis V. Reply by Authors: "Prognostic value of PD-1 and PD-L1 expression in patients with high-grade urothelial carcinoma of the upper urinary tract." *Journal of Urology* 199(5): 1353-1354, 2018.
54. Woldu SL, Hutchinson RC, **Singla N**, Hornberger B, Roehrborn CG, Lotan Y. Reply by Authors: "Prospective monitoring and adapting strategies for prevention of infection following transrectal prostate procedures." *Urology Practice* 5: 131, 2018.
55. **Singla N**, Lotan Y. Challenging cases in urology: Hematuria in a man with prune belly syndrome. *Urology Times: Urologists in Cancer Care* 8(5): 9-10, 2019. Published online, March 2018: <http://urologytimes.modernmedicine.com/urology-times/news/challenging-cases-urology-hematuria-man-prune-belly-syndrome>
56. **Singla N.** Life after residency: Is a fellowship in your future? *Urology Times*. Published online, August 2017: <http://urologytimes.modernmedicine.com/urology-times/news/life-after-residency-fellowship-your-future>
57. **Singla N.** Visiting professorships offer unique benefit to residents. *Urology Times* 45(6): 4, 2017. Published online, May 2017: <http://urologytimes.modernmedicine.com/urology-times/news/visiting-professorships-offer-unique-benefit-residents>
58. **Singla N.** How to command patient trust while building experience. *Urology Times* 45(4): 27, 2017. Published online, Feb. 2017: <http://urologytimes.modernmedicine.com/urology-times/news/how-command-patient-trust-while-building-experience>
59. **Singla N**, Margulis V. A multi-institutional evaluation of clinical and tumor characteristics in upper tract urothelial carcinoma from China and the United States: Beyond the abstract. *UroToday*. Published online, Feb. 2017: <https://www.urotoday.com/recent-abstracts/urologic-oncology/bladder-cancer/93868-a-multi-institutional-comparison-of-clinicopathologic-characteristics-and-oncologic-outcomes-of-upper-tract-urothelial-carcinoma-in-china-and-the-united-states-beyond-the-abstract.html>
60. **Singla N.** A systematic review and meta-analysis of oncological and renal function outcomes obtained after segmental ureterectomy versus radical nephroureterectomy for upper tract urothelial carcinoma: Beyond the abstract. *UroToday*. Published online, Jan. 2017: <https://www.urotoday.com/recent-abstracts/urologic-oncology/renal-cancer/93864-renal-function-outcomes-after-surgical-management-of-upper-tract-urothelial-carcinoma-beyond-the-abstract.html>
61. **Singla N.** Preoperative hydronephrosis is associated with less decline in renal function after radical nephroureterectomy for upper tract urothelial carcinoma: Beyond the abstract. *UroToday*. Published online, Jan. 2017: <https://www.urotoday.com/recent-abstracts/urologic-oncology/renal-cancer/93865-renal-function-outcomes-after-surgical-management-of-upper-tract-urothelial-carcinoma-beyond-the-abstract-2.html>
62. **Singla N.** Consider choice E: Effective learning during residency. *Urology Times* 45(1): 4, 2017. Published online, Jan. 2017: <http://urologytimes.modernmedicine.com/urology-times/news/consider-choice-e-effective-learning-during-residency>
63. **Singla N.** Quality improvement: Why residents should get involved. *Urology Times* 44(10): 4, 2016. Published online, Aug. 2016: <http://urologytimes.modernmedicine.com/urology-times/news/quality-improvement-why-residents-should-get-involved>
64. **Singla N.** The urology match: Shaping the future of our field. *Urology Times* 44(5): 16, 2016. Published online, Mar. 2016: <http://urologytimes.modernmedicine.com/urology-times/news/urology-match-shaping-future-our-field>
65. **Singla N.** Urology mentors: For many, the quest begins at home. *Urology Times* 44(3): 4, 2016. Published online, Jan. 2016: <http://urologytimes.modernmedicine.com/urology-times/news/urology-mentors-many-quest-begins-home>
66. **Singla N**, Singla AK. Reply: To PMID 25530393 "Review of single-surgeon 10-year experience with artificial urinary sphincter with report of sterile cuff erosion managed nonsurgically." *Urology* 85(1): 256-257, 2015.

67. **Singla N.** Dr. Arul Chinnaiyan: The Michigan Research Experience, *University of Michigan Undergraduate Research Forum* 5: 5-6, 2008.
68. **Singla N.** Editorial: Design and Development of Resonance Frequency Tracking Software Using LabVIEW, *Journal of Young Investigators* 18(5): 2008.

D. Book Chapters

1. Nirschl TR, Liu JL, **Singla N.** "Overview of Preclinical Research," *Translational Urology: Handbook for Designing and Conducting Clinical and Translational Research*, Eds. Eltorai AEM, Arab A, Atala AJ, Siddiqui M. Elsevier. In press.
2. Alam R, **Singla N.** "Correlation," *Translational Urology: Handbook for Designing and Conducting Clinical and Translational Research*, Eds. Eltorai AEM, Arab A, Atala AJ, Siddiqui M. Elsevier. In press.
3. Su ZT, **Singla N**, Patel HD. "Cost-Effectiveness Analysis: Design, Measures, and Classic Example," *Translational Urology: Handbook for Designing and Conducting Clinical and Translational Research*, Eds. Eltorai AEM, Arab A, Atala AJ, Siddiqui M. Elsevier. In press.
4. de la Calle CM, **Singla N.** "Urogenital Malignancies," *Comprehensive Textbook of Surgery* (2nd ed), Eds. Vyas D and Mittal V. In press.
5. **Singla N**, Singla AK. "Bladder Dysfunction," *Comprehensive Textbook of Surgery* (2nd ed), Eds. Vyas D and Mittal V. In press.
6. **Singla N**, Singla AK. "Prostate," *Comprehensive Textbook of Surgery* (2nd ed), Eds. Vyas D and Mittal V. In press.
7. **Singla N**, Singla AK. "Urinary Tract Infections (UTIs)," *Comprehensive Textbook of Surgery* (2nd ed), Eds. Vyas D and Mittal V. In press.
8. **Singla N**, Margulis V. "Chapter 4: Nephroureterectomy; Critical Element 4: Perioperative Intravesical Chemotherapy," *Operative Standards for Cancer Surgery, Volume III*, American College of Surgeons (ACS) Clinical Research Program, Alliance for Clinical Trials in Oncology. Lippincott, Williams, and Wilkins. In press.
9. Margulis V, Ghandour RA, **Singla N.** "Nephroureterectomy for Upper Tract Urothelial Carcinoma: Indications and Techniques," *Bladder Cancer Intervention: A Practical Guide*, Eds. Kamat A and Black P. Springer Nature, 2021. 439-446. Print.
10. Ghandour RA, **Singla N**, Lotan Y. "Using Urinary Biomarkers in Urothelial Carcinoma of the Bladder and Upper Tracts," *Bladder Cancer Intervention: A Practical Guide*, Eds. Kamat A and Black P. Springer Nature, 2021. 21-31. Print.
11. Ghandour RA, **Singla N**, Bagrodia A. "Management of Stage II Germ Cell Tumors," *Modern Management of Testicular Cancer*, Ed. Daneshmand S. Elsevier Health Sciences, 2019. 363-376. Print.
12. Singla AK, **Singla N.** "Chapter 165: Male Slings for Treatment of Post-Prostatectomy Incontinence," *Smith's Textbook of Endourology* (4th ed), Eds. Smith AD, Preminger GM, Kavoussi LR, Badlani GH, Rastinehad AR. John Wiley & Sons, Ltd., 2019. 1890-1901. Print.
13. **Singla N**, Singla AK. "Penoscrotal Implantation of Artificial Urinary Sphincter (AUS)," *Genito-Üriner Sistem Protezleri Atlası*, Eds. Kadioglu A, Çayan S, Onur R, Demirtas A. Nobel Tıp Kitabevi, 2019. 199-202. Print.
14. **Singla N**, Singla AK. "Use of Tandem Cuffs in Artificial Urinary Sphincter (AUS) Implantation," *Genito-Üriner Sistem Protezleri Atlası*, Eds. Kadioglu A, Çayan S, Onur R, Demirtas A. Nobel Tıp Kitabevi, 2019. 213-216. Print.
15. **Singla N**, Morey AF. "Post-Prostatectomy Incontinence: Introduction and Prevalence," *Post-Prostatectomy Incontinence*, Eds. Singla AK and Comiter C. Springer International Publishing, 2017. 1-9. Print.
16. Singla AK, **Singla N.** "Burch Colposuspension," *Native Tissue Repair for Incontinence and Prolapse*, Eds. De E and Zimmern PE. Springer International Publishing, 2017. 69-75. Print.
17. Kreshover J, Ramasamy R, **Singla N.** "Medical Student Curriculum: Hematuria." American Urological Association *AUAUniversity*. Published online, July 2016:
<https://www.auanet.org/education/auauniversity/for-medical-students/medical-students-curriculum/medical-student-curriculum/hematuria>

PANELS, PRESENTATIONS, AND COURSES

A. Poster Presentations

1. **Singla N**, Nirschl TR, Obradovic AZ, Shenderov E, Lombardo K, Liu X, Pons A, Zarif JC, Rowe SP, Trock BJ, Hammers HJ, Bivalacqua TJ, Pierorazio PM, Deutsch JS, Lotan TL, Taube JM, Ged YMA, Gorin MA, Allaf ME, Drake CG. “Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma.” 2023 Genitourinary Cancers Symposium, American Society of Clinical Oncology (ASCO). San Francisco, CA (Feb. 2023)
J Clin Oncol 41(6S):708, 2023.
2. Fletcher SA, Pallauf M, Watts EK, Lombardo KA, Campbell JA, Mari A, Roupret M, Boorjian SA, Djaladat H, Kikuchi E, Soria F, Rink M, Raman JD, Abdollah F, Ploussard G, Hoffman-Censits JH, McConkey DJ, Shariat SF, Pradere B, **Singla N**. “Oncologic outcomes in patients with residual invasive upper tract urothelial carcinoma following neoadjuvant chemotherapy.” 2023 Genitourinary Cancers Symposium, American Society of Clinical Oncology (ASCO). San Francisco, CA (Feb. 2023)
J Clin Oncol 41(6S):475, 2023.
3. Patel SH, Gabrielson A, Collins C, **Singla N**, Bivalacqua T, Hahn NM, Kates MR. “Intravesical gemcitabine and docetaxel in the treatment of BCG-naïve non-muscle invasive urothelial carcinoma of the bladder: Updates from a phase 2 trial.” 2023 Genitourinary Cancers Symposium, American Society of Clinical Oncology (ASCO). San Francisco, CA (Feb. 2023)
J Clin Oncol 41(6S):507, 2023.
4. Ged Y, Feinaj A, Markowski MC, Yerrapragada A, Elias R, Bettgowda C, **Singla N**, Kamson D. “Mapping distribution of brain metastases in renal cell carcinoma (RCC) and association with clinical features.” 2023 Genitourinary Cancers Symposium, American Society of Clinical Oncology (ASCO). San Francisco, CA (Feb. 2023)
J Clin Oncol 41(6S):727, 2023.
5. Hoffman-Censits JH, Johnson BA, Hahn NM, Choi W, Smith A, **Singla N**, McConkey DJ, Kates MR. “Atezolizumab with platinum and etoposide chemotherapy followed by cystectomy for patients with localized small cell neuroendocrine bladder cancer.” 2023 Genitourinary Cancers Symposium, American Society of Clinical Oncology (ASCO). San Francisco, CA (Feb. 2023)
J Clin Oncol 41(6S):TPS599, 2023.
6. Watts E, Pallauf M, Fletcher S, Lombardo K, McConkey D, Hoffman-Censits J, **Singla N**. “The Impact of Frailty on Post-Operative Survival in Patients Undergoing Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma.” Society of Women in Urology 12th Annual Clinical Mentoring Conference. Scottsdale, AZ (Jan. 2023)
7. Fletcher SA, Watts EK, Pallauf M, Lombardo KA, Campbell JA, Hoffman-Censits J, McConkey DJ, **Singla N**. “Long-term oncologic outcomes in patients with invasive upper tract urothelial carcinoma unresponsive to neoadjuvant chemotherapy in the primary tumor.” 23rd Annual Meeting of the Society of Urologic Oncology (SUO). San Diego, CA (Dec. 2022)
8. Agrawal P, Alam R, Cheaib JG, Young L, Agrawal G, Patel SH, Yerrapragada A, Pallauf M, Pierorazio PM, Allaf ME, Ged Y, **Singla N**. “Role of histology in influencing outcomes after cytoreductive nephrectomy for metastatic renal cell carcinoma.” 23rd Annual Meeting of the Society of Urologic Oncology (SUO). San Diego, CA (Dec. 2022)
9. Agrawal P, Alam R, Cheaib JG, Young L, Agrawal G, Patel SH, Yerrapragada A, Pallauf M, Pierorazio PM, Allaf ME, Ged Y, **Singla N**. “Cytoreductive nephrectomy with concomitant IVC tumor thrombectomy in metastatic renal cell carcinoma.” 23rd Annual Meeting of the Society of Urologic Oncology (SUO). San Diego, CA (Dec. 2022)
10. Alam R, Watts E, Alam A, Patel SH, Allaf ME, Pierorazio PM, **Singla N**. “Characterization of small renal mass growth rates in elderly patients undergoing active surveillance.” 23rd Annual Meeting of the Society of Urologic Oncology (SUO). San Diego, CA (Dec. 2022)
11. Pierorazio PM, Kleinmann N, Shabsigh A, Hu B, Raman JD, Scherr D, Kaimakliotis H, Pak R, Erlich Y, Nielsen M, Sankin A, **Singla N**, Meads A, Lahiri S, Seltzer E, Schoenberg M. “Long-term outcomes of treatment with UGN-101, a mitomycin-containing reverse thermal gel, for primary chemoablation of low-grade upper tract urothelial carcinoma (LG UTUC).” 23rd Annual Meeting of the Society of Urologic Oncology (SUO). San Diego, CA (Dec. 2022)

12. Chevli KK, Shore ND, Trainer A, Saltzstein D, Ehrlich Y, Raman JD, Friedman B, Hu B, Sankin A, Scherr D, Nielsen M, **Singla N**, Meads A, Lahiri S, Schoenberg M, Seltzer E, Huang WC. "Long-term outcomes of treatment with UGN-102 for primary chemoablation of low-grade intermediate risk non-muscle invasive bladder cancer (LG IR NMIBC)." 23rd Annual Meeting of the Society of Urologic Oncology (SUO). San Diego, CA (Dec. 2022)
13. Sawhney V, DeMarco MM, **Singla N**, Kates M. "Renal transplantation, waitlisting, and survival among patients with renal cancer as the cause of end stage renal disease." 23rd Annual Meeting of the Society of Urologic Oncology (SUO). San Diego, CA (Dec. 2022)
14. Pallauf M, D'Andrea D, Konig F, Laukthina E, Yanagisawa T, Roupret M, Daneshmand S, Djaladat H, Ghoreifi A, Soria F, Fujita K, Boorjian SA, Potretzke AM, Mari A, Campi R, Roumiguie M, Kikuchi E, Antonelli A, Bianchi A, Khene ZE, Sfakianos JP, Jamil M, Boormans JL, Raman JD, Grossmann NC, Breda A, Heidenreich A, Del Giudice F, **Singla N**, Karakiewicz PI, Shariat SF, Pradere B. "Diagnostic accuracy of clinical lymph node staging for upper tract urothelial cancer patients – A multicenter, retrospective, observational study." 23rd Annual Meeting of the Society of Urologic Oncology (SUO). San Diego, CA (Dec. 2022)
15. Pallauf M, von Deimling M, Laukthina E, Kawada T, Matin SF, Boorjian SA, Potretzke AM, Daneshmand S, Djaladat H, Ghoreifi A, Soria F, Gontero P, Kikuchi E, Hayakawa N, Fujita K, Sfakianos JP, Ploussard G, Roumiguie M, Antonelli A, Roupret M, Khene ZE, Mari A, Campi R, Breda A, Heidenreich A, Boormans JL, Raman JD, Abdollah F, Grossmann NC, Rink M, Karakiewicz PI, Abufaraj M, Babjuk M, **Singla N**, Shariat SF, Pradere B. "Comparison of neoadjuvant and adjuvant chemotherapy in upper tract urothelial cancer – Results from a propensity-score matched multi-center patient cohort." 23rd Annual Meeting of the Society of Urologic Oncology (SUO). San Diego, CA (Dec. 2022)
16. Rezaee ME, Pallauf M, Fletcher SA, Han M, Pavlovich CP, Epstein JI, Allaf ME, Trock BJ, **Singla N**. "Clinical significance of extraprostatic extension in grade group 1 prostate cancer." 17th Annual Donald S. Coffey Prostate Cancer Research Day. Johns Hopkins University. Baltimore, MD (Nov. 2022)
17. Gharaie S, Lee K, Noller K, Lo EK, Jung HJ, Kurzhagen JT, **Singla N**, Welling PA, Cahan P, Noel S, Rabb H. "Strengths and Limitations of Integrating Single Cell and Spatial Transcriptomics to Study T Cells in Normal and AKI Kidneys." Kidney Week 2022. American Society of Nephrology. Orlando, FL (Nov. 2022)
FR-PO147 *J Am Soc Nephrol* 33:364, 2022.
18. Agrawal P, Alam R, Cheaib J, Young L, Agrawal G, Patel S, Yerrapragada A, Pallauf M, Pierorazio P, Allaf M, Ged Y, **Singla N**. "Role of histology in influencing outcomes after cytoreductive nephrectomy for metastatic renal cell carcinoma." KCRS22 Kidney Cancer Research Summit. Philadelphia, PA (Oct. 2022)
19. Agrawal P, Alam R, Cheaib J, Young L, Agrawal G, Patel S, Yerrapragada A, Pallauf M, Pierorazio P, Allaf M, Ged Y, **Singla N**. "Cytoreductive nephrectomy with concomitant IVC tumor thrombectomy in metastatic renal cell carcinoma." KCRS22 Kidney Cancer Research Summit. Philadelphia, PA (Oct. 2022)
20. Alam R, Watts E, Alam A, Patel S, Allaf M, Pierorazio P, **Singla N**. "Evaluation of growth rates for small renal masses in elderly patients undergoing active surveillance." KCRS22 Kidney Cancer Research Summit. Philadelphia, PA (Oct. 2022)
21. Agrawal P, Cheaib JG, Alam R, Patel SH, Yerrapragada A, Pierorazio PM, Allaf ME, Ged Y, **Singla N**. "Role of histology in influencing outcomes after cytoreductive nephrectomy for metastatic renal cell carcinoma." Mid-Atlantic American Urological Association (MA-AUA) Annual Meeting. New Orleans, LA (Oct. 2022)
MP4-04 *Can J Urol* 29:30, 2022.
22. Agrawal P, Cheaib JG, Alam R, Patel SH, Yerrapragada A, Pierorazio PM, Allaf ME, Ged Y, **Singla N**. "Role of histology in influencing outcomes after cytoreductive nephrectomy for metastatic renal cell carcinoma with caval tumor thrombus." Mid-Atlantic American Urological Association (MA-AUA) Annual Meeting. New Orleans, LA (Oct. 2022)
MP2-14 *Can J Urol* 29:18, 2022.
23. Alam R, Cheaib J, Biles M, Winoker J, **Singla N**, Bivalacqua T, Pierorazio P, Kates M, Patel S. "Survival outcomes comparing radical nephroureterectomy versus endoscopic treatment in solitary kidney patients diagnosed with high-grade upper tract urothelial carcinoma." 39th World Congress of Endourology and Uro-Technology. San Diego, CA (Oct. 2022)

- MP2-05 *J Endourol* 36(S1):A41-A42, 2022.
24. Xu W, Gaborieau V, Niman SM, Maremanda KP, Mukeriy A, Zaridze D, **Singla N**, Freedman ML, McDermott DF, Choueiri TK, Catalano PJ, Sabbisetti V, Brennan P, Bhatt RS. "Plasma KIM-1 for preoperative identification and risk stratification of renal cell carcinoma." European Society for Medical Oncology (ESMO) Congress 2022. Paris, France (Sept. 2022)
1471P *Ann Oncol* 33(S7):S1219, 2022.
 25. **Singla N**. "Tumor evolution of pancreas-specific tropism in metastatic renal cell carcinoma." Early Career Investigator Showcase, American Urological Association (AUA) Annual Meeting. New Orleans, LA (May 2022)
 26. Ghoreifi A, Gerald T, Lee R, Howard J, Asghar A, Khanna A, Quinn D, Gill I, Thompson RH, Uzzo R, Margulis V, **Singla N**, Djaladat H. "Outcomes of nephrectomy for renal cell carcinoma with venous thrombus following immune checkpoint inhibitor therapy: A multicenter collaborative study." American Urological Association (AUA) Annual Meeting. New Orleans, LA (May 2022)
MP12-08 *J Urol* 207(5 Suppl):e169, 2022.
 27. Patel S, Collins C, **Singla N**, Gabrielson A, Bivalacqua TJ, Hahn N, Kates M. "Intravesical gemcitabine and docetaxel (GemDoce) in the treatment of BCG naïve non-muscle invasive urothelial carcinoma of the bladder: Updates from a phase 2 trial." American Urological Association (AUA) Annual Meeting. New Orleans, LA (May 2022)
MP59-15 *J Urol* 207(5 Suppl):e1008, 2022.
 28. Morozov A, Babaevskaya D, Taratkin M, Inoyatov J, Laukhtina E, Moschini M, **Singla N**, Rivas JG, Teoh J, Glybochko P, Enikeev D. "The learning curve for robot-assisted radical cystectomy: A systematic review." American Urological Association (AUA) Annual Meeting. New Orleans, LA (May 2022)
MP19-12 *J Urol* 207(5 Suppl):e311-e312, 2022.
 29. Mulgaonkar A, Woolford L, Elias R, Nham K, Guan B, Hao G, Stevens C, Tcheuyap VT, Haldeman S, Miyata J, Carrillo D, Qin Q, **Singla N**, Bowman I, Cadeddu J, Margulis V, Christie A, Kapur P, Pedrosa I, Dakanali M, Oz O, Sun X, Brugarolas J. "PD-L1 PET: A potential biomarker of checkpoint inhibitor sensitivity in renal cancer." American Association for Cancer Research (AACR) Annual Meeting. New Orleans, LA (Apr. 2022)
Cancer Res 82(12 Suppl):1234, 2022.
 30. Drescher M, Patel SH, Alam R, de la Calle C, Yerrapragada A, Bettgowda C, Matoso A, Ged Y, **Singla N**. "Characteristics and outcomes of patients managed with surgical resection of brain metastasis from renal cell carcinoma." 2022 Genitourinary Cancers Symposium, American Society of Clinical Oncology (ASCO). San Francisco, CA (Feb. 2022)
J Clin Oncol 40(6S):392, 2022.
 31. Cheaib JG, Patel SH, Alam R, Metcalf M, Trock B, Jing Y, Ged ME, Pierorazio P, **Singla N**. "Racial differences in the natural history of small renal masses: A prospective registry study." 2022 Genitourinary Cancers Symposium, American Society of Clinical Oncology (ASCO). San Francisco, CA (Feb. 2022)
J Clin Oncol 40(6S):295, 2022.
 32. Wang S, Cheaib JG, Patel SH, Alam R, Metcalf M, Jing Y, Trock B, Allaf ME, Ged Y, Pierorazio P, **Singla N**. "Clinicopathologic and survival differences between African Americans and Caucasians with renal cell carcinoma." 2022 Genitourinary Cancers Symposium, American Society of Clinical Oncology (ASCO). San Francisco, CA (Feb. 2022)
J Clin Oncol 40(6S):296, 2022.
 33. Alam R, Cheaib JG, Biles MJ, Winoker JS, **Singla N**, Bivalacqua T, Pierorazio PM, Kates MR, Patel SH. "Survival outcomes comparing radical nephroureterectomy versus endoscopic treatment in solitary kidney patients diagnosed with upper tract urothelial carcinoma." 2022 Genitourinary Cancers Symposium, American Society of Clinical Oncology (ASCO). San Francisco, CA (Feb. 2022)
J Clin Oncol 40(6S):477, 2022.
 34. Cheaib JG, Patel SH, Alam R, Metcalf MR, de la Calle C, Jing Y, Trock BJ, Ged Y, Allaf ME, Pierorazio PM, **Singla N**. "Racial differences in the natural history of small renal masses: A prospective registry study." 21st Annual Meeting of the Society of Urologic Oncology (SUO). Orlando, FL (Dec. 2021)
 35. Srivastava A, Patel H, Cheaib J, **Singla N**, Woldu S, Quek M, Gupta G, Kim I, Singer E, Jang T, Pierorazio P, Bagrodia A, Patel H. "Risk stratification in advanced non-seminomatous germ cell tumors (NSGCT): Validation of age and metastatic disease site to improve the traditional IGCCCG risk groups." 21st Annual Meeting of the Society of Urologic Oncology (SUO). Orlando, FL (Dec. 2021)

36. Kim K, Zhou Q, Christie A, Stevens C, Ma Y, Onabolu O, Chintalapati S, McKenzie T, Tcheuyap V, Woolford L, Xie Z, Zhang H, **Singla N**, Parida P, Marquez-Palencia M, Pedrosa I, Margulis V, Sagalowsky A, Wang T, Modrusan Z, Seshagiri S, Kapur P, Brugarolas J, Malladi S. "Determinants of renal cell carcinoma invasion and metastatic competence." Kidney Cancer Research Summit (KCRS21). Philadelphia, PA (Oct. 2021)
37. Rabinowitz M, Esfandiary T, Cheaib J, Patel S, Alam R, Metcalf M, Enikeev D, Allaf M, Ged Y, Pierorazio P, **Singla N**. "Characterizing tumor thrombus arising from non clear cell renal cell carcinoma." Mid-Atlantic American Urological Association (MA-AUA) Annual Meeting. National Harbor, MD (Oct. 2021)
MP4-13 *Can J Urol* 28(3):30, 2021.
38. Rostom M, Cheaib J, Campbell J, Patel S, Allaf M, Ged Y, **Singla N**, Pierorazio P. "Survival outcomes in late, intermediate and early recurrence renal cell carcinoma." Mid-Atlantic American Urological Association (MA-AUA) Annual Meeting. National Harbor, MD (Oct. 2021)
MP4-10 *Can J Urol* 28(3):29, 2021.
39. Alam R, Patel S, Kates M, **Singla N**, Bivalacqua T, Pierorazio P. "Self-reported quality of life as a predictor of mortality in bladder and upper tract malignancies." American Urological Association (AUA) Annual Meeting. Las Vegas, NV (Sept. 2021)
MP38-18 *J Urol* 206(3 Suppl):e701-e702, 2021.
40. Alam R, Patel S, Kates M, **Singla N**, Allaf M, Bivalacqua T, Pierorazio P. "Quality of life after a urologic cancer diagnosis." American Urological Association (AUA) Annual Meeting. Las Vegas, NV (Sept. 2021)
MP19-04 *J Urol* 206(3 Suppl):e328, 2021.
41. Cheaib J, Patel S, Alam R, Tsou T, Metcalf M, Han M, Pavlovich C, **Singla N**, Allaf M, Pierorazio P. "Surgeon-specific variation in operative outcomes for patients with clinical T1 renal masses." American Urological Association (AUA) Annual Meeting. Las Vegas, NV (Sept. 2021)
MP42-04 *J Urol* 206(3 Suppl):e771-e772, 2021.
42. Badia R, Woldu SL, Patel HD, **Singla N**, Srivastava A, Cheaib JG, Pierorazio PM, Bagrodia A. "Clinical utility of the AJCC eighth edition pT1 subclassification and impact on practice patterns in stage I seminoma." 2021 Genitourinary Cancers Symposium, American Society of Clinical Oncology (ASCO). (Feb. 2021) [On-site meeting canceled due to COVID-19]
J Clin Oncol 39(6S):377, 2021.
43. Badia R, Ghandour R, Howard J, Cheaib JG, Soud R, Eggener SE, **Singla N**, Pierorazio PM, Bagrodia A. "Pre-orchietomy serum tumor markers as a predictor of recurrence in stage I germ cell tumors." 2021 Genitourinary Cancers Symposium, American Society of Clinical Oncology (ASCO). (Feb. 2021) [On-site meeting canceled due to COVID-19]
J Clin Oncol 39(6S):389, 2021.
44. Badia R, Abe D, Wong D, **Singla N**, Savelyeva A, Chertack N, Jia L, Kapur P, Murray M, Amatruda JF, Lafin JT, Bagrodia A. "Real-world application of pre-orchietomy miR-371a-3p test in testicular germ cell tumor (GCT) management." 2021 Genitourinary Cancers Symposium, American Society of Clinical Oncology (ASCO). (Feb. 2021) [On-site meeting canceled due to COVID-19]
J Clin Oncol 39(6S):387, 2021.
45. Badia RR, Abe D, Wong D, **Singla N**, Savelyeva A, Chertack N, Jia L, Kapur P, Murray MJ, Amatruda JF, Lafin JT, Bagrodia A. "Real-world application of pre-orchietomy miR-371a-3p test in testicular germ cell tumor management." 21st Annual Meeting of the Society of Urologic Oncology (SUO). (Dec. 2020) [On-site meeting canceled due to COVID-19]
Best of Testicular Cancer and Penile Cancer
46. Metcalf MR, Cheaib JG, Wainger J, Pena VN, Patel HD, **Singla N**, Pierorazio P. "Gender and racial differences in the clinical management of advanced renal cell carcinoma." 21st Annual Meeting of the Society of Urologic Oncology (SUO). (Dec. 2020) [On-site meeting canceled due to COVID-19]
47. Metcalf MR, Cheaib JG, Wainger J, Pena VN, Patel HD, **Singla N**, Pierorazio P. "Gender and racial differences in the clinical management of clinical T1a renal cell carcinoma." 21st Annual Meeting of the Society of Urologic Oncology (SUO). (Dec. 2020) [On-site meeting canceled due to COVID-19]
48. Fang D, Zhengqing B, **Singla N**, Lotan Y, Li X, Raman JD, Margulis V, Zhou L. "The significance of preoperative serum sodium and hemoglobin in upper tract urothelial carcinoma outcomes: Multi-center validation between China and the United States." 35th Annual Congress of the European Association of Urology (EAU). Amsterdam, Netherlands (July 2020) [On-site meeting canceled due to COVID-19]

- Eur Urol Open Sci* 19(Suppl 2):e2210, 2020.
49. Taratkin M, Laukhtina E, **Singla N**, Rapoport L, Enikeev D. "Temperature changes during laser lithotripsy with Ho:YAG laser and novel Tm-fiber lasers: A comparative in-vitro study." 35th Annual Congress of the European Association of Urology (EAU). Amsterdam, Netherlands (July 2020) [On-site meeting canceled due to COVID-19]
Eur Urol Open Sci 19(Suppl 2):e347, 2020.
 50. Wong NC, Assel M, Tracey A, Alvim R, Almassi N, **Singla N**, Chesnut G, Clinton TN, Sjoberg D, Bochner BH, Dalbagni G, Donat SM, Herr HW, Cha E, Donahue T, Pietzak E, Al-Ahmadie H, Iyer G, Teo MY, Rosenberg JE, Bajorin DF, Coleman JA. "Trends in perioperative management and outcomes in patients with upper tract urothelial carcinoma following radical nephroureterectomy at Memorial Sloan Kettering Cancer Center." American Urological Association (AUA) Annual Meeting. (May 2020) [On-site meeting canceled due to COVID-19]
MP82-07 *J Urol* 203(4 Suppl):e1248, 2020.
 51. Singla S, Wong J, **Singla N**, Krailo MD, Huang L, Shaikh F, Billmire DF, Rescorla FJ, Ross JH, Dicken BJ, Amatruda JF, Frazier AL, Bagrodia A. "Clinicopathologic predictors of outcomes in children with stage I germ cell tumors: A pooled *post hoc* analysis of trials from the Children's Oncology Group." American Urological Association (AUA) Annual Meeting. (May 2020) [On-site meeting canceled due to COVID-19]
MP11-02 *J Urol* 203(4 Suppl):e135, 2020.
 52. Ghandour R, Freifeld Y, Cheaib J, **Singla N**, Meng X, Kenigsberg A, Bagrodia A, Woldu S, Petros F, Raman J, Pierorazio P, Matin S, Margulis V. "Predictive model for systemic recurrence following cisplatin-based neoadjuvant chemotherapy and radical nephroureterectomy for upper tract urothelial carcinoma." American Urological Association (AUA) Annual Meeting. (May 2020) [On-site meeting canceled due to COVID-19]
MP82-10 *J Urol* 203(4 Suppl):e1249-e1250, 2020.
 53. **Singla N**, Lafin JT, Woldu SL, Lotan Y, Lewis CM, Majmudar K, Savelyeva A, Kapur P, Margulis V, Strand DW, Murray MJ, Amatruda JF, Bagrodia A. "Serum microRNA-371a-3p levels predict viable germ cell tumor in chemotherapy-naïve patients undergoing retroperitoneal lymph node dissection." 2020 Genitourinary Cancers Symposium, American Society of Clinical Oncology (ASCO). San Francisco, CA (Feb. 2020)
J Clin Oncol 38(6S):417, 2020.
Selected for Poster Walk
 54. Singla S, Wong J, **Singla N**, Krailo MD, Huang L, Shaikh F, Billmire DF, Rescorla FJ, Ross JH, Dicken BJ, Amatruda JF, Frazier AL, Bagrodia A. "Clinicopathologic predictors of outcomes in children with stage I germ cell tumors: A pooled *post hoc* analysis of trials from the Children's Oncology Group." 2020 Genitourinary Cancers Symposium, American Society of Clinical Oncology (ASCO). San Francisco, CA (Feb. 2020)
J Clin Oncol 38(6S):418, 2020.
 55. Kenigsberg AP, Lafin JT, Meng X, Abe D, Savelyeva A, **Singla N**, Woldu SL, Lotan Y, Kapur P, Margulis V, Amatruda JF, Bagrodia A. "Predictive capacity of miRNA-375 in identifying teratoma in post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND)." 2020 Genitourinary Cancers Symposium, American Society of Clinical Oncology (ASCO). San Francisco, CA (Feb. 2020)
J Clin Oncol 38(6S):416, 2020.
 56. Wong NC, Assel M, Tracey A, Alvim R, Almassi N, **Singla N**, Clinton TN, Chesnut GT, Sjoberg DD, Bajorin DF, Coleman J. "Trends in management and outcomes in patients with upper tract urothelial carcinoma following radical nephroureterectomy at Memorial Sloan Kettering Cancer Center." 2020 Genitourinary Cancers Symposium, American Society of Clinical Oncology (ASCO). San Francisco, CA (Feb. 2020)
J Clin Oncol 38(6S):469, 2020.
 57. Chertack N, Ghandour R, **Singla N**, Freifeld YN, Hutchinson RC, Courtney KD, Moore JA, Aydin A, Margulis V, Lotan Y, Woldu SL, Bagrodia A. "Overcoming sociodemographic factors in the care of testicular cancer patients at a safety net hospital." 2020 Genitourinary Cancers Symposium, American Society of Clinical Oncology (ASCO). San Francisco, CA (Feb. 2020)
J Clin Oncol 38(6S):398, 2020.

58. Taratkin M, Laukhtina E, **Singla N**, Enikeev D. "How lasers ablate stones: *In-vitro* study of laser lithotripsy (Ho:YAG and Tm-fiber lasers) in different environments." 7th Meeting of the European Association of Urology (EAU) Section of Uro-Technology (ESUT). Leipzig, Germany (Jan. 2020)
Eur Urol Open Sci 19(Suppl 1): e12, 2020.
59. **Singla N**, Hutchinson RC, Ghandour RA, Freifeld Y, Sagalowsky AI, Lotan Y, Bagrodia A, Margulis V, Hammers HJ, Woldu SL. "Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: A national population-based analysis." 20th Annual Meeting of the Society of Urologic Oncology (SUO). Washington, D.C. (Dec. 2019)
60. Singla S, Wong J, **Singla N**, Krailo M, Huang L, Shaikh F, Billmire D, Rescorla F, Ross J, Dicken B, Amatruda JF, Frazier AL, Bagrodia A. "Clinicopathologic predictors of outcomes in children with stage I germ cell tumors: A pooled *post hoc* analysis of trials from the Children's Oncology Group." 20th Annual Meeting of the Society of Urologic Oncology (SUO). Washington, D.C. (Dec. 2019)
61. Kenigsberg A, Lafin J, Meng X, Abe D, Savalyeva A, **Singla N**, Woldu S, Lotan Y, Kapur P, Margulis V, Amatruda J, Bagrodia A. "Predictive capacity of miRNA-375 in identifying teratoma on post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND)." 20th Annual Meeting of the Society of Urologic Oncology (SUO). Washington, D.C. (Dec. 2019)
62. Ghandour R, Freifeld Y, **Singla N**, Meng X, Bagrodia A, Woldu S, Petros F, Raman J, Matin S, Margulis V. "Predictive model for systemic recurrence following cisplatin-based neoadjuvant chemotherapy and radical nephroureterectomy for upper tract urothelial carcinoma." 20th Annual Meeting of the Society of Urologic Oncology (SUO). Washington, D.C. (Dec. 2019)
63. Ghandour R, Wong D, Cusin S, **Singla N**, Freifeld Y, Hutchinson R, Bagrodia A, Sagalowsky A, Margulis V, Lotan Y, Woldu S. "Does grossly complete transurethral resection improve complete response after neoadjuvant chemotherapy?" 20th Annual Meeting of the Society of Urologic Oncology (SUO). Washington, D.C. (Dec. 2019)
64. Ghandour R, Cheaib J, Wong D, Andolfi C, **Singla N**, Chertack N, Freifeld Y, Barashi N, Margulis V, Woldu S, Pierorazio P, Eggener S, Bagrodia A. "Do mixed nonseminomatous germ cell tumors behave the same with or without a seminomatous component?" 98th Annual Meeting of South Central Section (SCS) American Urological Association (AUA). Colorado Springs, CO (Sept. 2019)
65. Ghandour R, Wong D, Kusin S, **Singla N**, Freifeld Y, Bhanvadia R, Hutchinson R, Bagrodia A, Margulis V, Sagalowsky A, Lotan Y, Woldu S. "Does grossly complete transurethral resection improve complete response after neoadjuvant chemotherapy?" 98th Annual Meeting of South Central Section (SCS) American Urological Association (AUA). Colorado Springs, CO (Sept. 2019)
66. **Singla N**, Onabolu O, Woolford L, Stevens C, Tcheuyap V, McKenzie T, Yousuf Q, Ma Y, Choi J, Zhang Z, Xie Z, Wang T, McKay R, Christie A, Pedrosa I, Przybycin C, Kapur P, Rini B, Brugarolas J. "Unraveling the molecular profile underpinning pancreatic tropisms in metastatic clear cell renal cell carcinoma." [Online publication only] American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, IL (June 2019)
J Clin Oncol 37(suppl):e16096, 2019.
67. **Singla N**, Woolford L, Stevens C, Tcheuyap V, Onabolu O, Xie Z, McKay R, Wang T, Christie A, Gahan J, Bagrodia A, Raj G, Sagalowsky A, Lotan Y, Cadeddu J, Margulis V, Kapur P, Brugarolas J. "Leveraging a robust patient-derived xenograft platform to characterize predictors for engraftment and oncologic outcomes in renal cell carcinoma patients." [Online publication only] American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, IL (June 2019)
J Clin Oncol 37(suppl):e16100, 2019.
68. Margulis V, **Singla N**, Elias R, Ghandour R, Freifeld YN, Bowman IA, Woldu SL, Gahan J, Bagrodia A, Brugarolas J, Hammers HJ. "Pathologic response and surgical outcomes in patients undergoing nephrectomy after receipt of immune checkpoint inhibitors for renal cell carcinoma." [Online publication only] American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, IL (June 2019)
J Clin Oncol 37(suppl):e16102, 2019.
69. Yeh HC, **Singla N**, Hernandez E, Panwar V, Margulis V, Kapur P, Shariat SF, Wu WJ, Hsieh JT. "PTRF promotes cell survival and predicts disease progression in upper tract urothelial carcinoma." American Association for Cancer Research (AACR) Special Conference on Bladder Cancer: Transforming the Field. Denver, CO (May 2019)
Clin Cancer Res 26(15 Suppl):B21, 2020.

70. **Singla N**, Woolford L, Stevens C, Tcheuyap V, Onabolu O, Xie Z, McKay R, Wang T, Christie A, Gahan J, Bagrodia A, Raj G, Sagalowsky A, Lotan Y, Cadeddu J, Margulis V, Kapur P, Brugarolas J. “Leveraging a robust patient-derived xenograft platform to characterize predictors for engraftment and oncologic outcomes in renal cell carcinoma patients.” American Urological Association (AUA) Annual Meeting. Chicago, IL (May 2019)
MP21-07 J Urol 201(4 Suppl):e294, 2019.
71. Ghandour R, Ashbrook C, Freifeld Y, **Singla N**, Lotan Y, Margulis V, Woldu S, Bagrodia A. “Nationwide patterns of care for stage II non-seminomatous germ cell tumor: RPLND and chemotherapy utilization.” American Urological Association (AUA) Annual Meeting. Chicago, IL (May 2019)
MP49-06 J Urol 201(4 Suppl):e707-e708, 2019.
72. **Singla N**, Choi J, Onabolu O, Woolford L, Stevens C, Tcheuyap V, McKenzie T, Xie Z, Wang T, McKay R, Christie A, Kapur P, Rini B, Brugarolas J. “Comprehensive molecular and genomic characterization of pancreatic tropism in metastatic renal cell carcinoma.” American Association for Cancer Research (AACR) Annual Meeting. Atlanta, GA (Apr. 2019)
Cancer Res 79(13 Suppl):2505, 2019.
73. Elias R, **Singla N**, Christie A, Kapur P, Bowman IA, Hammers HJ, Hannan R, Brugarolas J. “Outcomes of combined ipilimumab and nivolumab therapy following progression on nivolumab monotherapy in renal cell carcinoma: A retrospective cohort study.” American Association for Cancer Research (AACR) Annual Meeting. Atlanta, GA (Apr. 2019)
Cancer Res 79(13 Suppl):4106, 2019.
74. **Singla N**, Woolford L, Stevens C, Tcheuyap V, Onabolu O, Xie Z, McKay R, Wang T, Christie A, Gahan J, Bagrodia A, Raj G, Sagalowsky A, Lotan Y, Cadeddu J, Margulis V, Kapur P, Brugarolas J. “Leveraging a robust patient-derived xenograft platform to characterize predictors for engraftment and oncologic outcomes in renal cell carcinoma patients.” 34th Annual Congress of the European Association of Urology (EAU). Barcelona, Spain (Mar. 2019)
European Urology Supplements 18(1):e81-e82, 2019.
75. **Singla N**, Choi J, Onabolu O, Woolford L, Stevens C, Tcheuyap V, McKenzie T, Xie Z, Wang T, McKay R, Christie A, Kapur P, Rini B, Brugarolas J. “Comprehensive molecular and genomic characterization of pancreatic tropism in metastatic renal cell carcinoma.” 34th Annual Congress of the European Association of Urology (EAU). Barcelona, Spain (Mar. 2019)
European Urology Supplements 18(1):e76-e77, 2019.
Selected for extended presentation
76. Shakir N, Wang C, **Singla N**, Alhalabi F, Christie A, Lemack G, Zimmern P. “Sustained benefit of suburethral synthetic midurethral sling removal at long-term follow-up” Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) 2019 Winter Meeting. Miami, FL (Feb. 2019)
Neurourology and Urodynamics 38 Suppl 1:S179-S180, 2019.
77. **Singla N**, Woolford L, Stevens C, Tcheuyap V, Onabolu O, Xie Z, McKay R, Wang T, Christie A, Gahan J, Bagrodia A, Raj G, Sagalowsky A, Lotan Y, Cadeddu J, Margulis V, Kapur P, Brugarolas J. “Leveraging a robust patient-derived xenograft platform to characterize predictors for engraftment and oncologic outcomes in renal cell carcinoma patients.” 2019 Genitourinary Cancers Symposium, American Society of Clinical Oncology (ASCO). San Francisco, CA (Feb. 2019)
J Clin Oncol 37(7S):651, 2019.
78. **Singla N**, Choi J, Onabolu O, Woolford L, Stevens C, Tcheuyap V, McKenzie T, Xie Z, Wang T, McKay R, Christie A, Kapur P, Rini B, Brugarolas J. “Comprehensive molecular and genomic characterization of pancreatic tropism in metastatic renal cell carcinoma.” 2019 Genitourinary Cancers Symposium, American Society of Clinical Oncology (ASCO). San Francisco, CA (Feb. 2019)
J Clin Oncol 37(7S):633, 2019.
79. **Singla N**, Elias R, Ghandour R, Freifeld Y, Bowman I, Woldu S, Gahan J, Bagrodia A, Brugarolas J, Hammers H, Margulis V. “Safety and feasibility of nephrectomy after receipt of immune checkpoint inhibitors for renal cell carcinoma.” 2019 Genitourinary Cancers Symposium, American Society of Clinical Oncology (ASCO). San Francisco, CA (Feb. 2019)
J Clin Oncol 37(7S):619, 2019.
80. Cai Q, Christie A, Kim M, Zhou Q, Araj E, Cadeddu J, Margulis V, **Singla N**, Rajaram S, Pedrosa I, Rakheja D, McKay R, Brugarolas J, Kapur P. “The role of architectural patterns and cytologic features in

- the prognosis of clear cell renal cell carcinoma.” 2019 Genitourinary Cancers Symposium, American Society of Clinical Oncology (ASCO). San Francisco, CA (Feb. 2019)
J Clin Oncol 37(7S):632, 2019.
81. Elias R, Yan F, Formella J, Levonyak N, **Singla N**, Christie A, Bowman I, Hammers H, Kapur P, Hannan R, Brugarolas J. “Immune-related adverse events are associated with improved outcomes in ICI-treated renal cell carcinoma patients.” 2019 Genitourinary Cancers Symposium, American Society of Clinical Oncology (ASCO). San Francisco, CA (Feb. 2019)
J Clin Oncol 37(7S):645, 2019.
 82. Zhang Y, Schoenhals J, Christie A, Wang C, Mohamad O, **Singla N**, Desai N, Choy H, Courtney K, Bagrodia A, Margulis V, Bowman I, Timmerman R, Brugarolas J, Hannan R. “Outcomes of stereotactic ablative radiotherapy for extra-cranial oligo-metastatic renal cell cancer.” 2019 Genitourinary Cancers Symposium, American Society of Clinical Oncology (ASCO). San Francisco, CA (Feb. 2019)
J Clin Oncol 37(7S):599, 2019.
 83. Freifeld Y, Woldu S, **Singla N**, Ghandour R, Clinton T, Kulangara R, Bagrodia A, Raman JD, Matin SF, Petros FG, Zhu H, Yan J, Lotan Y, Margulis V. “Preoperative predictive model for systemic disease recurrence following radical nephroureterectomy for high grade upper tract urothelial carcinoma.” 19th Annual Meeting of the Society of Urologic Oncology (SUO). Phoenix, AZ (Nov. 2018)
 84. Clinton T, Krabbe L, Ryan S, Hamilton Z, Matulay J, **Singla N**, Woldu S, Freifeld Y, Bagrodia A, Derweesh I, Raman J, Karam J, Matin S, Wood C, Margulis V. “Grade obtained on ureteroscopic biopsy for upper tract urothelial carcinoma – can we rely on it for final treatment decisions?” 19th Annual Meeting of the Society of Urologic Oncology (SUO). Phoenix, AZ (Nov. 2018)
 85. Ghandour R, Ashbrook C, Freifeld Y, **Singla N**, Lotan Y, Margulis V, Woldu S, Bagrodia A. “Nationwide patterns of care for stage II non-seminomatous germ cell tumor: RPLND and chemotherapy utilization.” 19th Annual Meeting of the Society of Urologic Oncology (SUO). Phoenix, AZ (Nov. 2018)
 86. Woldu SL, Moore JA, Ci B, Freifeld Y, Clinton TN, Murat AA, **Singla N**, Krabbe L, Hutchinson RC, Amatruda JF, Sagalowsky A, Lotan Y, Arriaga Y, Margulis V, Xie Y, Bagrodia A. “Utilization and impact of post-chemotherapy retroperitoneal lymph node dissection in advanced non-seminomatous germ cell tumor.” American Urological Association (AUA) Annual Meeting. San Francisco, CA (May 2018)
MP37-01 *J Urol* 199(4 Suppl):e491-e492, 2018.
 87. Woldu SL, Matulay JT, Clinton TN, **Singla N**, Freifeld YN, Sanli ON, Krabbe L, Hutchinson RC, Lotan Y, Hammers HJ, Hannan R, Brugarolas J, Bagrodia A, Margulis V. “Utilization and survival implications of a delayed approach to targeted therapy for metastatic renal cell carcinoma: A nationwide cancer registry study.” 2018 Genitourinary Cancers Symposium, American Society of Clinical Oncology (ASCO). San Francisco, CA (Feb. 2018)
J Clin Oncol 36(6S):586, 2018.
 88. **Singla N**, Krabbe L, Aydin A, Panwar V, Hutchinson R, Woldu S, Wood C, Karam J, Weizer A, Raman J, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky A, Shariat S, Lotan Y, Bagrodia A, Kapur P, Margulis V. “Prognostic significance of EZH2 expression in upper tract urothelial carcinoma.” 18th Annual Meeting of the Society of Urologic Oncology (SUO). Washington, D.C. (Nov. 2017)
 89. Petros F, Qiao W, **Singla N**, Robyak H, Margulis V, Raman J, Matin S. “Preoperative multiplex nomogram for prediction of high-risk non-organ confined upper-tract urothelial carcinoma.” 18th Annual Meeting of the Society of Urologic Oncology (SUO). Washington, D.C. (Nov. 2017)
 90. Krabbe L, **Singla N**, Aydin A, Panwar V, Hutchinson R, Woldu S, Wood C, Karam J, Weizer A, Raman J, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky A, Shariat S, Lotan Y, Bagrodia A, Kapur P, Margulis V. “Prognostic significance of BAP1 expression in upper tract urothelial carcinoma.” 18th Annual Meeting of the Society of Urologic Oncology (SUO). Washington, D.C. (Nov. 2017)
 91. **Singla N**, Woldu S, Walker J, de la Fuente K, Roehrborn C. “Predictors and implications for Gleason score up-grading at prostatectomy for clinically localized prostate cancer: A risk-stratified approach.” 96th Annual Meeting of South Central Section (SCS) American Urological Association (AUA). Naples, FL (Nov. 2017)
 92. Rao A, Woldu S, Aydin A, Hutchinson R, **Singla N**, Clinton T, Krabbe L, Passoni N, Raj G, Lotan Y, Sagalowsky A, Miller S, Margulis V, Bagrodia A. “Differences between Hispanic and non-Hispanic white

- men with testicular germ cell tumors in the United States.” 96th Annual Meeting of South Central Section (SCS) American Urological Association (AUA). Naples, FL (Nov. 2017)
93. Sorokin I, Johnson B, **Singla N**, Roehrborn C, Gahan J. “Evaluating the learning curve for robotic assisted simple prostatectomy.” 35th World Congress Endourology and SWL. Vancouver, Canada (Sept. 2017)
MP30-4 *J Endourol* 31(S2):A357, 2017.
 94. Sorokin I, Johnson B, Sundaram V, **Singla N**, Margulis V, Roehrborn C, Gahan J. “Robotic assisted versus open simple prostatectomy for benign prostatic hyperplasia in large glands: a propensity score matched comparison.” 35th World Congress Endourology and SWL. Vancouver, Canada (Sept. 2017)
MP30-17 *J Endourol* 31(S2):A362-A363, 2017.
 95. **Singla N**, Aydin A, Panwar V, Hutchinson R, Woldu S, Wood C, Karam J, Weizer A, Raman J, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky A, Shariat S, Lotan Y, Bagrodia A, Kapur P, Margulis V, Krabbe L. “Prognostic significance of BAP1 expression in upper tract urothelial carcinoma.” American Urological Association (AUA) Annual Meeting. Boston, MA (May 2017)
MP71-05 *J Urol* 197(4 Suppl):e946, 2017.
 96. Aydin A, **Singla N**, Panwar V, Hutchinson R, Woldu S, Wood C, Karam J, Weizer A, Raman J, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky A, Shariat S, Lotan Y, Bagrodia A, Kapur P, Margulis V, Krabbe L. “Prognostic significance of EZH2 expression in upper tract urothelial carcinoma.” American Urological Association (AUA) Annual Meeting. Boston, MA (May 2017)
MP71-06 *J Urol* 197(4 Suppl):e947, 2017.
 97. Krabbe L, Heitzplatz B, Hutchinson R, Woldu S, **Singla N**, Preuss S, Boegemann M, Wood C, Karam J, Weizer A, Raman J, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky A, Shariat S, Lotan Y, Xylinas E, Margulis V. “Prognostic value of PD-1 and PD-L1 expression in patients with high-grade urothelial carcinoma of the upper urinary tract.” American Urological Association (AUA) Annual Meeting. Boston, MA (May 2017)
MP71-03 *J Urol* 197(4 Suppl):e945, 2017.
 98. Woldu S, Hutchinson R, **Singla N**, Krabbe L, Sagalowsky A, Lotan Y, Bagrodia A, Margulis V. “Factors associated with stage at presentation and survival in penile cancer.” American Urological Association (AUA) Annual Meeting. Boston, MA (May 2017)
MP92-14 *J Urol* 197(4 Suppl):e1232-e1233, 2017.
 99. Hutchinson R, **Singla N**, Krabbe L, Woldu S, Chen G, Rew C, Tachibana I, Lotan Y, Cadeddu JA, Margulis V. “Differential hemodynamic and antihypertensive changes after partial nephrectomy versus radical nephrectomy.” American Urological Association (AUA) Annual Meeting. Boston, MA (May 2017)
MP72-20 *J Urol* 197(4 Suppl):e962-e963, 2017.
 100. Aydin A, Woldu S, Hutchinson R, Krabbe L, **Singla N**, Amatruda J, Sagalowsky A, Margulis V, Bagrodia A. “Neutrophil-to-lymphocyte ratio – a simple biomarker in testicular cancer.” American Urological Association (AUA) Annual Meeting. Boston, MA (May 2017)
MP80-16 *J Urol* 197(4 Suppl):e1087, 2017.
 101. **Singla N**, Walker J, Passoni N, De La Fuente K, Roehrborn C. “Proximity of positive prostate biopsy core to capsular margin may help predict extracapsular extension and positive margin at prostatectomy.” 17th Annual Meeting of the Society of Urologic Oncology (SUO). San Antonio, TX (Nov. 2016)
 102. Hutchinson R, Woldu S, **Singla N**, Akhtar A, Haridas J, Bhat D, Roehrborn C, Lotan Y. “Impact of primary care physician experience on adherence to United States Preventative Services Task Force recommendation against PSA screening.” 17th Annual Meeting of the Society of Urologic Oncology (SUO). San Antonio, TX (Nov. 2016)
 103. Woldu S, Hutchinson R, **Singla N**, Hornberger B, Roehrborn C, Lotan Y. “Adapting strategies for prevention of infection following transrectal prostate biopsy and fiducial marker placement.” 17th Annual Meeting of the Society of Urologic Oncology (SUO). San Antonio, TX (Nov. 2016)
 104. Sundaram V, **Singla N**, Roehrborn C, Margulis V, Gahan J. “Perioperative outcomes of robotic assisted simple prostatectomy for benign prostatic hyperplasia.” 34th World Congress Endourology and SWL. Cape Town, South Africa (Nov. 2016)
J Endourol 30(S2):A235, 2016.
 105. Sundaram V, **Singla N**, Roehrborn C, Margulis V, Gahan J. “Perioperative outcomes of robotic assisted simple prostatectomy for benign prostatic hyperplasia.” 95th Annual Meeting of South Central Section (SCS) American Urological Association (AUA). Colorado Springs, CO (Sept. 2016)

106. Mathur S, Hofer MD, **Singla N**, Cordon BH, Scott J, Morey AF. "Analysis of clinical and morphometric risk factors associated with urethral atrophy." 95th Annual Meeting of South Central Section (SCS) American Urological Association (AUA). Colorado Springs, CO (Sept. 2016)
107. Hutchinson R, Krabbe L, **Singla N**, Lotan Y. "PSA screening in the era of the United States Preventative Services Task Force recommendation: Does provider opinion drive screening practice?" 95th Annual Meeting of South Central Section (SCS) American Urological Association (AUA). Colorado Springs, CO (Sept. 2016)
108. **Singla N**, Aggarwal H, Foster J, Alhalabi F, Lemack G, Zimmern P. "Management of urinary incontinence following sub-urethral sling removal." International Continence Society (ICS) Annual Meeting. Tokyo, Japan (Sept. 2016)
109. Aggarwal H, Foster J, **Singla N**, Alhalabi F, Lemack G, Zimmern P. "Is there a difference in outcome between early versus delayed removal of suburethral mid-urethral sling?" International Continence Society (ICS) Annual Meeting. Tokyo, Japan (Sept. 2016)
110. Fang D, Xiong G, Zhu Y, **Singla N**, Zhang L, Li X, Zhou L. "Homogeneous or heterogeneous biological behaviors between ureteral and renal pelvic tumors? A comparison of clinical features, pathological outcomes, epigenetic biomarkers and oncologic prognosis." 14th Urological Association of Asia (UAA) Congress 2016. Suntec City, Singapore (July 2016)
111. **Singla N**, Passoni N, Walker J, De La Fuente K, Roehrborn C. "Proximity of positive prostate biopsy core to capsular margin may help predict extracapsular extension and positive margin at prostatectomy." American Urological Association (AUA) Annual Meeting. San Diego, CA (May 2016)
MP57-09 *J Urol* 195(4 Suppl):e756, 2016.
112. **Singla N**, Hutchinson R, Haddad A, Sagalowsky A, Lotan Y, Margulis V. "Comparing changes in renal function after radical surgery for upper tract urothelial carcinoma and renal cell carcinoma." American Urological Association (AUA) Annual Meeting. San Diego, CA (May 2016)
MP41-02 *J Urol* 195(4 Suppl):e560, 2016.
113. Haddad A, Hutchinson R, **Singla N**, Wood E, Miranda G, Gershman B, Margulis V, Sagalowsky A, Raj G, Svatek R, Black P, Boorjian S, Shah J, Daneshmand S, Lotan Y. "Association of distance to treatment facility with survival and quality outcomes following radical cystectomy: A multi-institutional study." American Urological Association (AUA) Annual Meeting. San Diego, CA (May 2016)
MP01-17 *J Urol* 195(4 Suppl):e7-e8, 2016.
114. Aggarwal H, Foster J, **Singla N**, Alhalabi F, Lemack G, Zimmern P. "Is there a difference in outcome between early versus delayed removal of suburethral mid-urethral sling?" American Urological Association (AUA) Annual Meeting. San Diego, CA (May 2016)
S&T-41 *J Urol* 195(4 Suppl):e325, 2016.
115. Hofer MD, **Singla N**, Cordon BH, Scott JM, Morey AF. "Analysis of clinical and morphometric risk factors associated with urethral atrophy." American Urological Association (AUA) Annual Meeting. San Diego, CA (May 2016)
MP87-01 *J Urol* 195(4 Suppl):e1114, 2016.
116. Fang D, Xiong G, Zhu Y, **Singla N**, Zhang L, Li X, Zhou L. "Homogeneous or heterogeneous biological behaviors between ureteral and renal pelvic tumors? A comparison of clinical features, pathological outcomes, epigenetic biomarkers and oncologic prognosis." American Urological Association (AUA) Annual Meeting. San Diego, CA (May 2016)
MP27-04 *J Urol* 195(4 Suppl):e363, 2016.
117. Su X, Tang Q, Fang D, Xiong G, He Q, Zhang L, Liu P, Fan Y, Hao H, Li X, Zhou L, **Singla N**. "Comparisons of prognosis between urothelial carcinoma of the upper urinary tract and bladder with pT3-4 diseases." The 2016 Huaxia Medical Forum-Genitourinary Tumor & The 2016 Greatwall International Translational Andrology and Urology Forum (GUT-HMF2016 & GITA2016). Tianjin, China (Apr. 2016)
Translational Andrology and Urology 5(S1):AB063, 2016.
118. Foster J, **Singla N**, Aggarwal H, Alhalabi F, Lemack G, Zimmern P. "Mid-term outcomes following sub-urethral synthetic sling removal in women." European Association of Urology (EAU) 31st Annual Congress. Munich, Germany (Mar. 2016)
European Urology Supplements 15(3):e3, 2016.
Best poster in session ("Poster Session 01: Slings and things in female incontinence")

119. Aggarwal H, Foster J, **Singla N**, Alhalabi F, Lemack G, Zimmern P. "Is there a difference between early versus delayed removal of suburethral mid-urethral sling?" European Association of Urology (EAU) 31st Annual Congress. Munich, Germany (Mar. 2016)
European Urology Supplements 15(3):e902, 2016.
120. Aggarwal H, Foster J, **Singla N**, Alhalabi F, Lemack G, Zimmern P. "Is there a difference between early versus delayed removal of suburethral mid-urethral sling?" Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) 2016 Winter Meeting. New Orleans, LA (Feb. 2016)
Poster #M14 *Neurourology and Urodynamics* 35 Suppl 1:S26-S27, 2016.
121. Hutchinson R, **Singla N**, Haddad A, Margulis V. "Characteristics of isolated low grade upper tract urothelial carcinoma: Sessile tumor architecture is associated with adverse oncologic outcomes." 16th Annual Meeting of the Society of Urologic Oncology (SUO). Washington, DC (Dec. 2015)
122. **Singla N**, Lay A, Cadeddu J. "Poor split renal function pre-operatively does not predict worse outcomes after pyeloplasty in adults." 94th Annual Meeting of South Central Section (SCS) American Urological Association (AUA). Scottsdale, AZ (Oct. 2015)
123. **Singla N**, Siegel JA, Simhan J, Tausch TJ, Klein A, Thoreson GR, Morey AF. "Location of AUS pressure regulating balloon: functional outcomes of high submuscular position are equivalent to space of retzius." American Urological Association (AUA) Annual Meeting. New Orleans, LA (May 2015)
MP88-15 *J Urol* 193(4 Suppl):e1097-e1098, 2015.
124. Zhang L, Xiong G, Fang D, Li X, Liu J, Ci W, Zhao W, **Singla N**, He Z, Zhou L. "Contralateral upper tract urothelial carcinoma after nephroureterectomy: the predictive role of methylation status." American Urological Association (AUA) Annual Meeting. New Orleans, LA (May 2015)
MP2-01 *J Urol* 193(4 Suppl):e9-e10, 2015.
125. Wimberly J, **Singla N**, Rosenfeld E, Christie A, Zimmern P. "Do Patients Want to Know About Surgeon Experience?" 11th International Congress on Clinical Ethics Consultation (ICCEC). New York City, NY (May 2015)
126. Haddad A, **Singla N**, Gupta N, Raj G, Sagalowsky A, Margulis V, Lotan Y. "Distance to treatment facility and survival outcomes following radical cystectomy for bladder cancer." 15th Annual Meeting of the Society of Urologic Oncology (SUO). Bethesda, MD (Dec. 2014)
127. Haddad A, Kapur P, **Singla N**, Raman J, Then M, Nuhn P, Buchner A, Bastian P, Seitz C, Shariat S, Bensalah K, Rioux-Leclercq N, Sagalowsky A, Lotan Y, Margulis V. "Validation of mammalian target of rapamycin biomarker panel in patients with clear cell renal cell carcinoma." 15th Annual Meeting of the Society of Urologic Oncology (SUO). Bethesda, MD (Dec. 2014)
128. Starke N, Haddad A, **Singla N**, Lotan Y. "Long-term outcomes of high risk bladder cancer screening cohort." 15th Annual Meeting of the Society of Urologic Oncology (SUO). Bethesda, MD (Dec. 2014)
129. **Singla N**, Simhan J, Siegel J, Tausch T, Morey AF. "Location of AUS pressure regulating balloon: Functional outcomes of high submuscular position are equivalent to space of retzius." 20th Annual Fall Scientific Meeting of Sexual Medicine Society of North America, Inc. (SMSNA). Miami, FL (Nov. 2014)
130. Wimberly J, **Singla N**, Rosenfeld E, Christie A, Zimmern P. "Do Patients Want to Know About Surgeon Experience?" 93rd Annual Meeting of South Central Section (SCS) American Urological Association (AUA). Rancho Mirage, CA (Oct. 2014)
131. **Singla N**, Bagrodia A, Gayed B, Krabbe LM, Palazzi KL, Mirheydar H, Harrow B, Jacobs C, Youssef R, Darwish O, Sagalowsky A, Lotan Y, Derweesh I, Margulis V. "Multi-institutional analysis of renal function outcomes following radical nephroureterectomy and partial ureterectomy for upper tract urothelial carcinoma." American Urological Association (AUA) Annual Meeting. Orlando, FL (May 2014)
MP30-08 *J Urol* 191(4 Suppl):e316, 2014.
132. **Singla N**, Singla AK. "Fate of Eroded Artificial Urinary Sphincter (AUS)," 92nd Annual Meeting of South Central Section (SCS) American Urological Association (AUA). Chicago, IL (Sept. 2013)
133. **Singla N**, Wan J, Bloom DA, Park JM. "Natural history of detrusor leak point pressure evolution in myelomeningocele patients," 92nd Annual Meeting of South Central Section (SCS) American Urological Association (AUA). Chicago, IL (Sept. 2013)
134. Cary KC, Cowan JE, **Singla N**, Carroll PR, Cooperberg MR. "Impact of Androgen Deprivation Therapy (ADT) on Mental and Emotional Well-Being in Men with Prostate Cancer: Analysis from the CaPSURE Registry," American Urological Association (AUA) Annual Meeting. San Diego, CA (May 2013)
J Urol 189(4 Suppl):e616, 2013.

135. **Singla N**, Wan J, Bloom DA, Park JM. "Natural history of detrusor leak point pressure evolution in myelomeningocele patients," 2013 Research and Scientific Sessions (CME), Michigan Association of Physicians of Indian Origin (MAPI). Troy, MI (Mar. 2013)
136. **Singla N**, Mehta M, Wolf JS, Kin J, Billi J. "Increasing the efficiency of operating room turnover for adult endourology cases," 2013 Research and Scientific Sessions (CME), Michigan Association of Physicians of Indian Origin (MAPI). Troy, MI (Mar. 2013)
137. **Singla N**, Singla AK. "Fate of Eroded Artificial Urinary Sphincter (AUS)," 2013 Research and Scientific Sessions (CME), Michigan Association of Physicians of Indian Origin (MAPI). Troy, MI (Mar. 2013)
138. Cary KC, Cowan JE, **Singla N**, Carroll PR, Cooperberg MR. "Impact of Androgen Deprivation Therapy (ADT) on Mental and Emotional Well-Being in Men with Prostate Cancer: Analysis from the CaPSURE Registry," Society of Urologic Oncology (SUO) 13th Annual Meeting. Bethesda, MD (Nov. 2012)
139. **Singla N**, Laxman B, Tomlins SA, Chinnaiyan AM. "Assessing the role of ERG overexpression in prostate cancer," American Medical Association (AMA) Joint Research Symposium. Honolulu, HI (Nov. 2012)
AMA-MSS and AMA-RFS Joint Research Symposium Guide: 75-76, 2012.
140. **Singla N**, Wan J, Bloom DA, Park JM. "Natural history of leak point pressure evolution in patients with myelomeningocele," 3rd Annual Michigan State Medical Society (MSMS) Foundation Annual Scientific Meeting. Troy, MI (Oct. 2012)
141. **Singla N**, Montie JE, Lee CT, Wolf JS, Faerber GJ. "Retrograde Ureterscopy in Patients with Orthotopic Neobladder," 5th Annual A. Alfred Taubman Medical Research Institute Symposium. Ann Arbor, MI (Oct. 2012)
142. **Singla N**, Laxman B, Tomlins SA, Chinnaiyan AM. "Assessment of tumorigenicity and invasiveness by overexpression of ERG in normal cells *in vitro* and *in vivo*," 5th Annual A. Alfred Taubman Medical Research Institute Symposium. Ann Arbor, MI (Oct. 2012)
143. **Singla N**, Persad CC, Patil PG. "White matter hyperintensities and atrophy on MRI as a predictor of short-term cognitive change following deep brain stimulation in patients with Parkinson's Disease," 5th Annual A. Alfred Taubman Medical Research Institute Symposium. Ann Arbor, MI (Oct. 2012)
144. **Singla N**, Montie JE, Lee CT, Wolf JS, Faerber GJ. "Retrograde Ureterscopy in Patients with Orthotopic Neobladder," 30th World Congress Endourology and SWL. Istanbul, Turkey (Sept. 2012)
J Endourol 26(S1):A95, 2012.
145. **Singla N**, Persad CC, Patil PG. "White Matter Hyperintensities and Atrophy on MRI as a Predictor of Short-Term Cognitive Change Following Deep Brain Stimulation in Patients with Parkinson's Disease," American Medical Association (AMA) Joint Research Symposium. San Diego, CA (Nov. 2010)
AMA-MSS and AMA-RFS Joint Research Symposium Guide: 208-209, 2010.
146. **Singla N**, Persad CC, Patil PG. "White Matter Hyperintensities and Atrophy on MRI as a Predictor of Short-Term Cognitive Change Following Deep Brain Stimulation in Patients with Parkinson's Disease," Student Biomedical Research Fall Forum. Ann Arbor, MI (Nov. 2010)
56th Annual Student Biomedical Research Fall Forum, Official Program and Abstracts. 56: 2010.
147. **Singla N**, Persad CC, Patil PG. "White Matter Hyperintensities and Atrophy on MRI as a Predictor of Short-Term Cognitive Change Following Deep Brain Stimulation in Patients with Parkinson's Disease," Annual Symposium 2010, A. Alfred Taubman Research Institute and Michigan Institute for Clinical & Health Research (MICHR). Ann Arbor, MI (Oct. 2010)
Translational Research: The Bridge from Discovery to Medical Practice: 9, 2010.
148. **Singla N**, Hewes P, Hill D, Kim D, Kochanski R, Sweet J. "A Device for the Identification of Pacemaker and Defibrillator Manufacturers," Spring 2009 University of Michigan College of Engineering Design Exposition. Ann Arbor, MI (Apr. 2009)
149. Adamson MD, Majd S, **Singla N**, Mayer M. "The Effect of Shear Stress on the Fluidity of Supported Lipid Bilayers," Biophysical Society 53rd Annual Meeting. Boston, MA (Mar. 2009)
Biophysical Journal 96(3): 348a, 2009.
150. Helgeson BE, Tomlins SA, Shah N, Laxman B, Cao Q, Prensner JR, Cao X, **Singla N**, Montie JE, Varambally S, Mehra R, Chinnaiyan AM. "Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 Gene Fusions in Prostate Cancer," 2007 Cancer Research Symposium. Ann Arbor, MI (Nov. 2007)
151. **Singla N**, Laxman B, Tomlins SA, Chinnaiyan AM. "Assessment of tumorigenicity and invasiveness by overexpression of ERG in normal cells *in vitro* and *in vivo*," Student Biomedical Research Fall Forum. Ann Arbor, MI (Nov. 2007)

53rd Annual Student Biomedical Research Fall Forum, Official Program and Abstracts. 53: 2007.

152. **Singla N**, Laxman B, Tomlins SA, Chinnaiyan AM. "Assessment of tumorigenicity and invasiveness by overexpression of ERG in normal cells *in vitro* and *in vivo*," INTEL and Engineering & Physical Science Fall Forum. Ann Arbor, MI (Sept. 2007)
153. Nelson R, **Singla N**. "Spectral Composition of Cone-Photoreceptor and On-Bipolar Signals in the Zebrafish Electroretinogram," Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. Fort Lauderdale, FL (May 2007)
Investigative Ophthalmology & Visual Science 48: E-Abstract 1283, 2007.
154. **Singla N**, Nelson R. "Spectral sensitivity of glutamate ON-response components in the photopic ERG of *Danio rerio* retina," National Institutes of Health (NIH) Summer Research Poster Day Program. Bethesda, MD (Aug. 2006)
NIH/NINDS Exceptional Summer Student Award
155. **Singla N**. "A Novel, Non-Invasive Approach to Diagnosing Obstructive Uropathy Using Computer Simulation," Intel International Science and Engineering Fair (ISEF). Indianapolis, IN (May 2006)
156. **Singla N**. "A Novel, Non-Invasive Approach to Diagnosing Obstructive Uropathy Using Computer Simulation," Michigan Science and Engineering Fair (MSEF), Flint, MI (Apr. 2006)
Second Place Award
157. **Singla N**. "A Novel, Non-Invasive Approach to Diagnosing Obstructive Uropathy Using Computer Simulation," Science and Engineering Fair of Metro Detroit (SEFMD), Detroit, MI (Mar. 2006)
Grand Award

B. Podium and Plenary Presentations

1. **Singla N**. "Multimodal Management in Locally Advanced and Metastatic Kidney Cancer." Komplexni Novinky V Onkourologii (KNOU) 2023. Prague, Czech Republic (May 2023)
Plenary Session
2. **Singla N**. "Biomarkers in Localized RCC and Plans for PROSPER." Kidney Cancer Course. 23rd Annual Meeting of the Society of Urologic Oncology (SUO). San Diego, CA (Nov. 2022)
3. Alam R, Rostom M, Patel S, Woldu S, Ged Y, **Singla N**. "Investigation of race and associated socioeconomic factors in survival outcomes for patients with renal cell carcinoma." American Urological Association (AUA) Annual Meeting. New Orleans, LA (May 2022)
PD18-12 *J Urol* 207(5 Suppl):e348, 2022.
4. Alam R, Cheaib J, Biles M, Winoker J, **Singla N**, Bivalacqua T, Pierorazio P, Kates M, Patel S. "Survival outcomes in solitary kidney patients diagnosed with upper tract urothelial carcinoma." American Urological Association (AUA) Annual Meeting. New Orleans, LA (May 2022)
PD58-08 *J Urol* 207(5 Suppl):e1014-e1015, 2022.
5. **Singla N**. "Best Papers in 2020 that Changed Your Practice: Upper Tract Urothelial Carcinoma." Mid-Atlantic American Urological Association (MA-AUA) Annual Meeting. National Harbor, MD (Oct. 2021)
Plenary Session
6. Cheaib J, Patel S, Alam R, Metcalf M, Enikeev D, Trock B, Jing Y, Ged Y, Allaf M, Pierorazio P, **Singla N**. "Racial differences in the natural history of small renal masses: A prospective registry study." American Urological Association (AUA) Annual Meeting. Las Vegas, NV (Sept. 2021)
PD52-09 *J Urol* 206(3 Suppl):e914, 2021.
7. Wang S, Cheaib JG, Patel S, Alam R, Metcalf M, Enikeev D, Jing Y, Trock B, Allaf M, Ged Y, Pierorazio P, **Singla N**. "Clinicopathologic and survival differences between African Americans and Caucasians with renal cell carcinoma." American Urological Association (AUA) Annual Meeting. Las Vegas, NV (Sept. 2021)
PD52-11 *J Urol* 206(3 Suppl):e915, 2021.
8. Srivastava A, Patel H, Cheaib J, **Singla N**, Woldu S, Quek M, Gupta G, Kim I, Singer E, Jang T, Pierorazio P, Bagrodia A, Patel H. "Risk stratification in advanced non-seminomatous germ cell tumors (NSGCT): Validation of age and metastatic disease site to improve the traditional IGCCCG risk groups." American Urological Association (AUA) Annual Meeting. Las Vegas, NV (Sept. 2021)
PD53-11 *J Urol* 206(3 Suppl):e920-e921, 2021.
9. **Singla N**, Hutchinson RC, Ghandour RA, Freifeld Y, Sagalowsky AI, Lotan Y, Bagrodia A, Margulis V, Hammers HJ, Woldu SL. "Improved survival after cytoreductive nephrectomy for metastatic renal cell

- carcinoma in the contemporary immunotherapy era: A national population-based analysis.” American Urological Association (AUA) Annual Meeting. (May 2020) [On-site meeting canceled due to COVID-19] PD39-11 *J Urol* 203(4 Suppl):e813, 2020.
10. Kenigsberg AP, Lafin JT, Meng X, Abe D, Savalyeva A, **Singla N**, Woldu SL, Lotan Y, Kapur P, Margulis V, Amatruda JF, Bagrodia A. “Predictive capacity of miRNA-375 in identifying teratoma in post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND).” American Urological Association (AUA) Annual Meeting. (May 2020) [On-site meeting canceled due to COVID-19] PD19-09 *J Urol* 203(4 Suppl):e385, 2020.
 11. **Singla N**, Lafin JT, Woldu S, Lotan Y, Lewis CM, Majmudar K, Zhou M, Kapur P, Margulis V, Murray MJ, Amatruda JF, Bagrodia A. “Serum microRNA-371a-3p levels predict viable germ cell tumor in chemotherapy-naïve patients undergoing retroperitoneal lymph node dissection.” Indian American Urological Association (IAUA) Annual Meeting. (May 2020) [On-site meeting canceled due to COVID-19]
 12. **Singla N**, Kenigsberg AP, Lafin JT, Meng X, Abe D, Savalyeva A, Woldu SL, Lotan Y, Kapur P, Margulis V, Amatruda JF, Bagrodia A. “Predictive capacity of miRNA-375 in identifying teratoma in post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND).” Indian American Urological Association (IAUA) Annual Meeting. (May 2020) [On-site meeting canceled due to COVID-19]
 13. Lafin JT, **Singla N**, Woldu S, Lotan Y, Lewis CM, Majmudar K, Zhou M, Kapur P, Margulis V, Murray MJ, Amatruda JF, Bagrodia A. “Serum microRNA-371a-3p levels predict viable germ cell tumor in chemotherapy-naïve patients undergoing retroperitoneal lymph node dissection.” 20th Annual Meeting of the Society of Urologic Oncology (SUO). Washington, D.C. (Dec. 2019)
 14. **Singla N**, Patel HD, Ghandour RA, Freifeld Y, Woldu SL, Pierorazio PM, Bagrodia A. “Site of extranodal metastasis impacts survival in patients with testicular germ cell tumors.” International Extracranial Germ Cell Tumour Conference. Cambridge, UK (Sept. 2019)
European Urology Supplements 18(4):9, 2019.
 15. Lafin JT, **Singla N**, Woldu S, Lotan Y, Lewis CM, Majmudar K, Zhou M, Kapur P, Margulis V, Murray MJ, Amatruda JF, Bagrodia A. “Serum microRNA-371a-3p levels predict viable germ cell tumor in chemotherapy-naïve patients undergoing retroperitoneal lymph node dissection.” International Extracranial Germ Cell Tumour Conference. Cambridge, UK (Sept. 2019)
European Urology Supplements 18(4):21-22, 2019.
 16. Singla S, Wong J, **Singla N**, Krailo M, Huang L, Shaikh F, Billmire D, Rescorla F, Ross J, Dicken B, Amatruda JF, Frazier AL, Bagrodia A. “Clinicopathologic predictors of outcomes in children with stage I germ cell tumors: A pooled *post hoc* analysis of trials from the Children’s Oncology Group.” International Extracranial Germ Cell Tumour Conference. Cambridge, UK (Sept. 2019)
European Urology Supplements 18(4):17-18, 2019.
 17. Chertack N, Ghandour RA, **Singla N**, Freifeld Y, Hutchinson R, Courtney K, Moore JA, Aydin AM, Margulis V, Lotan Y, Woldu S, Bagrodia A. “Overcoming patient factors in the care of under-served testicular cancer patients.” International Extracranial Germ Cell Tumour Conference. Cambridge, UK (Sept. 2019)
European Urology Supplements 18(4):10-11, 2019.
 18. **Singla N**, Bhanvadia RR, Kusin S, Ghandour RA, Freifeld Y, Woldu SL, Margulis V, Lotan Y, Bagrodia A. “A cost comparison of open versus robotic retroperitoneal lymph node dissection for germ cell tumors.” International Extracranial Germ Cell Tumour Conference. Cambridge, UK (Sept. 2019)
European Urology Supplements 18(4):24, 2019.
 19. Chertack N, Ghandour R, **Singla N**, Freifeld Y, Margulis V, Woldu S, Bagrodia A. “Overcoming patient factors in the care of underserved testicular cancer patients.” 98th Annual Meeting of South Central Section (SCS) American Urological Association (AUA). Colorado Springs, CO (Sept. 2019)
Finalist, Resident Essay Competition
 20. **Singla N**, Christie A, Clinton T, Freifeld Y, Ghandour R, Woldu S, Petros F, Qiao W, Robyak H, Bagrodia A, Lotan Y, Raman J, Matin S, Margulis V. “Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma.” American Urological Association (AUA) Annual Meeting. Chicago, IL (May 2019)
PD62-11 *J Urol* 201(4 Suppl):e1111, 2019.
 21. **Singla N**, Choi J, Onabolu O, Woolford L, Stevens C, Tcheuyap V, McKenzie T, Xie Z, Wang T, McKay R, Christie A, Kapur P, Rini B, Brugarolas J. “Comprehensive molecular and genomic characterization of

- pancreatic tropism in metastatic renal cell carcinoma.” American Urological Association (AUA) Annual Meeting. Chicago, IL (May 2019)
PD03-10 *J Urol* 201(4 Suppl):e71-e72, 2019.
22. **Singla N**, Elias R, Ghandour R, Freifeld Y, Bowman I, Woldu S, Gahan J, Bagrodia A, Brugarolas J, Hammers H, Margulis V. “Safety and feasibility of nephrectomy after receipt of immune checkpoint inhibitors for renal cell carcinoma.” American Urological Association (AUA) Annual Meeting. Chicago, IL (May 2019)
PD03-09 *J Urol* 201(4 Suppl):e71, 2019.
 23. Petros F, Qiao W, **Singla N**, Clinton T, Robyak H, Raman J, Margulis V, Matin S. “Preoperative multiplex nomogram for prediction of high risk non-organ confined upper-tract urothelial carcinoma.” 97th Annual Meeting of South Central Section (SCS) American Urological Association (AUA). Nashville, TN (Sept. 2018)
 24. **Singla N**. “Genomic and metabolomic markers of renal function decline following platinum exposure.” Bladder Cancer Advocacy Network (BCAN) Bladder Cancer Think Tank. Denver, CO (Aug. 2018)
 25. Shapiro DD, Master V, Raman JD, **Singla N**, Margulis V, Wang C, Roberts P, Chan W, Patil D, Allen GO, Abel EJ. “Predictors of recurrence and survival in patients with metastatic renal cell carcinoma undergoing complete surgical resection.” American Urological Association (AUA) Annual Meeting. San Francisco, CA (May 2018)
PD24-11 *J Urol* 199(4 Suppl):e490-e491, 2018.
 26. Woldu SL, Matulay JT, Clinton TN, **Singla N**, Freifeld YN, Sanli ON, Krabbe L, Hutchinson RC, Lotan Y, Hammers HJ, Hannan R, Brugarolas J, Bagrodia A, Margulis V. “Incidence and outcomes of delayed targeted therapy following cytoreductive nephrectomy for metastatic renal cell carcinoma: A nationwide cancer registry study.” American Urological Association (AUA) Annual Meeting. San Francisco, CA (May 2018)
PD24-04 *J Urol* 199(4 Suppl):e486-e487, 2018.
 27. Shakir N, Wang C, **Singla N**, Alhalabi F, Christie A, Lemack G, Zimmern P. “Global outcomes of suburethral synthetic midurethral sling removal.” Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) 2018 Winter Meeting. Austin, TX (Mar. 2018)
Neurourology and Urodynamics 37 Suppl 1:S559-S560, 2018.
 28. Woldu S, Matulay J, **Singla N**, Clinton T, Krabbe L, Hutchinson R, Freifeld Y, Sagalowsky A, Lotan Y, Margulis V, Bagrodia A. “Impact of hospital case volume on testicular cancer outcomes and practice patterns.” 18th Annual Meeting of the Society of Urologic Oncology (SUO). Washington, D.C. (Nov. 2017)
 29. Clinton T, Woldu S, Rao A, Hutchinson R, **Singla N**, Krabbe L, Aydin A, Amatruda J, Lotan Y, Sagalowsky A, Margulis V, Bagrodia A. “Impact of insurance status on testicular cancer survival – implications of economic disparities in the United States.” 96th Annual Meeting of South Central Section (SCS) American Urological Association (AUA). Naples, FL (Nov. 2017)
1st Place, Resident Essay Competition
 30. **Singla N**, Fang D, Su X, Bao Z, Cao Z, Robyak H, Xiong G, Zhang L, Woldu S, Hutchinson R, Sagalowsky A, Lotan Y, Li X, Zhou L, Raman J, Margulis V. “Preoperative predictors of non-organ-confined disease in upper tract urothelial carcinoma differ between China and the United States.” 96th Annual Meeting of South Central Section (SCS) American Urological Association (AUA). Naples, FL (Nov. 2017)
3rd Place, Resident Essay Competition
 31. **Singla N**, Woldu S, Walker J, de la Fuente K, Roehrborn C. “Use of MRI-guided targeted prostate biopsies does not impact infectious complications.” 96th Annual Meeting of South Central Section (SCS) American Urological Association (AUA). Naples, FL (Nov. 2017)
 32. Clinton T, Krabbe L, **Singla N**, Woldu S, Hutchinson R, Lotan Y, Sagalowsky A, Raj G, Cadeddu J, Bagrodia A, Margulis V. “Correlation of tumor grade obtained on ureteroscopic biopsy to the final pathologic grade of upper tract urothelial carcinoma at nephroureterectomy – implications for treatment decision-making.” 96th Annual Meeting of South Central Section (SCS) American Urological Association (AUA). Naples, FL (Nov. 2017)
 33. Woldu S, Hutchinson R, Krabbe L, Rao A, Clinton T, **Singla N**, Passoni N, Lotan Y, Sagalowsky A, Bagrodia A, Margulis V. “Impact of socioeconomic factors on management of testicular germ cell tumors

- in areas of controversy. 96th Annual Meeting of South Central Section (SCS) American Urological Association (AUA). Naples, FL (Nov. 2017)
34. **Singla N**, Aggarwal H, Foster J, Alhalabi F, Lemack G, Zimmern P. "Management of urinary incontinence following sub-urethral sling removal." American Urological Association (AUA) Annual Meeting. Boston, MA (May 2017)
PD50-11 *J Urol* 197(4 Suppl):e983, 2017.
 35. Hutchinson R, **Singla N**, Woldu S, Akhtar A, Haridas J, Bhat D, Roehrborn C, Lotan Y. "Impact of primary care physician factors on adherence to United States Preventative Services Task Force recommendation against PSA screening." American Urological Association (AUA) Annual Meeting. Boston, MA (May 2017)
PD40-11 *J Urol* 197(4 Suppl):e754, 2017.
 36. Woldu S, Hutchinson R, **Singla N**, Viers B, Krabbe L, Sagalowsky A, Lotan Y, Bagrodia A, Margulis V. "Adherence to guidelines: Surgical staging of inguinal lymph nodes in high-risk clinically localized penile cancer and survival implications." American Urological Association (AUA) Annual Meeting. Boston, MA (May 2017)
PD49-03 *J Urol* 197(4 Suppl):e974-e975, 2017.
 37. **Singla N**, Aggarwal H, Foster J, Alhalabi F, Lemack G, Zimmern P. "Management of urinary incontinence following sub-urethral sling removal." 95th Annual Meeting of South Central Section (SCS) American Urological Association (AUA). Colorado Springs, CO (Sept. 2016)
1st Place, Resident Essay Competition
 38. **Singla N**, Walker J, Passoni N, De La Fuente K, Roehrborn C. "Formalin disinfection of prostate biopsy needles reduces post-biopsy infectious complications." 95th Annual Meeting of South Central Section (SCS) American Urological Association (AUA). Colorado Springs, CO (Sept. 2016)
Finalist, Resident Essay Competition
 39. **Singla N**, Cadeddu J. "Refractory gross hematuria in a 63-year-old man." *T. Leon Howard Imaging Session*, 95th Annual Meeting of South Central Section (SCS) American Urological Association (AUA). Colorado Springs, CO (Sept. 2016)
 40. **Singla N**, Hutchinson R, Haddad A, Sagalowsky A, Lotan Y, Margulis V. "Preoperative hydronephrosis is associated with less decline in renal function after radical nephroureterectomy for upper tract urothelial carcinoma." 95th Annual Meeting of South Central Section (SCS) American Urological Association (AUA). Colorado Springs, CO (Sept. 2016)
 41. **Singla N**, Lay A, Tachibana I, Jacobs I, Canvasser N, Gahan J. "A comparison of oncologic and functional outcomes of Retzius-sparing versus conventional robotic radical prostatectomy." 95th Annual Meeting of South Central Section (SCS) American Urological Association (AUA). Colorado Springs, CO (Sept. 2016)
 42. Hutchinson R, **Singla N**, Haddad A, Shariat S, Lotan Y, Sagalowsky A, Raman J, Wood C, Weizer A, Roscigno M, Montorsi F, Bolenz C, Remzi M, Bensalah K, Margulis V. "Sessile tumor architecture predicts adverse oncologic outcomes in patients treated for low grade upper tract urothelial carcinoma." 95th Annual Meeting of South Central Section (SCS) American Urological Association (AUA). Colorado Springs, CO (Sept. 2016)
 43. Hofer M, **Singla N**, Cordon B, Scott J, Morey A. "Analysis of clinical and morphometric risk factors associated with urethral atrophy. 90th Annual Meeting of North Central Section (NCS) American Urological Association (AUA). Chicago, IL (Sept. 2016)
 44. **Singla N**, Hutchinson R, Fang D, Su X, Bao Z, Cao Z, Jafri S, Xiong G, Zhang L, Sagalowsky A, Lotan Y, Li X, Zhou L, Raman J, Margulis V. "A multi-institutional evaluation of clinical and tumor characteristics in upper tract urothelial carcinoma from China and the United States." American Urological Association (AUA) Annual Meeting. San Diego, CA (May 2016)
PD13-03 *J Urol* 195(4 Suppl):e298-e299, 2016.
 45. Hutchinson R, **Singla N**, Akhtar A, Haridas J, Bhat D, Roehrborn C, Lotan Y. "Practice time of primary care physicians is associated with change in PSA ordering habits in the years surrounding the United States Preventative Services Task Force Recommendation against PSA screening." American Urological Association (AUA) Annual Meeting. San Diego, CA (May 2016)
PD15-02 *J Urol* 195(4 Suppl):e389, 2016.
 46. Foster J, **Singla N**, Aggarwal H, Alhalabi F, Lemack G, Zimmern P. "Mid-term outcomes following sub-urethral synthetic sling removal in women." American Urological Association (AUA) Annual Meeting. San Diego, CA (May 2016)

- PD36-12 *J Urol* 195(4 Suppl):e853-e854, 2016.
47. Chen G, Rew C, Hutchinson R, **Singla N**, Sheth K, Meissner M, Haddad A, Mann M, Abel EJ, Margulis V, Thompson RH. "Presence of bland thrombus is a negative indicator for cancer specific survival in patients undergoing nephrectomy for kidney tumors with venous tumor thrombus." American Urological Association (AUA) Annual Meeting. San Diego, CA (May 2016)
PD29-02 *J Urol* 195(4 Suppl):e706, 2016.
48. Foster J, **Singla N**, Aggarwal H, Alhalabi F, Lemack GE, Zimmern PE. "Mid-term outcomes following sub-urethral synthetic sling removal in women" Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) 2016 Winter Meeting. New Orleans, LA (Feb. 2016)
Neurourology and Urodynamics 35 Suppl 1:S98, 2016.
49. **Singla N**, Haddad A, Meissner M, Passoni N, Lotan Y. "Anti-inflammatory use does not negatively impact oncologic outcomes following intravesical BCG for high grade non-muscle invasive bladder cancer." 94th Annual Meeting of South Central Section (SCS) American Urological Association (AUA). Scottsdale, AZ (Oct. 2015)
50. **Singla N**, Morey AF, Tausch TJ, Klein AK, Siegel JA, Carmel M. "The male stress incontinence grading scale: Pilot study of a new objective clinical tool for evaluation of men with post-prostatectomy urinary incontinence." 94th Annual Meeting of South Central Section (SCS) American Urological Association (AUA). Scottsdale, AZ (Oct. 2015)
51. Starke N, **Singla N**, Haddad A, Lotan Y. "Long-term outcomes of high risk bladder cancer screening cohort." American Urological Association (AUA) Annual Meeting. New Orleans, LA (May 2015)
PD23-02 *J Urol* 193(4 Suppl):e481, 2015.
52. **Singla N**, Simhan J, Siegel JA, Tausch TJ, Klein A, Thoreson GR, Morey AF. "Does Pressure Regulating Balloon Location Make a Difference in Functional Outcomes of Artificial Urinary Sphincter?" 93rd Annual Meeting of South Central Section (SCS) American Urological Association (AUA). Rancho Mirage, CA (Oct. 2014)
53. Haddad A, **Singla N**, Kapur P, Raman J, Then M, Nuhn P, Buchner A, Bastian P, Seitz C, Shariat S, Bensalah K, Rioux-Leclercq N, Sagalowsky A, Lotan Y, Margulis V. "Validation of mammalian target of rapamycin biomarker panel in patients with clear cell renal cell carcinoma." 93rd Annual Meeting of South Central Section (SCS) American Urological Association (AUA). Rancho Mirage, CA (Oct. 2014)
54. Simhan J, Morey AF, **Singla N**, Tausch TJ, Scott JF, Lemack GE, Roehrborn CG. "3.5 cm Artificial Urinary Sphincter Cuff Erosion Occurs Predominantly in Radiated Patients." 93rd Annual Meeting of South Central Section (SCS) American Urological Association (AUA). Rancho Mirage, CA (Oct. 2014)
55. **Singla N**, Singla AK. "Fate of Eroded Artificial Urinary Sphincter (AUS)." 87th Annual Meeting of North Central Section (NCS) American Urological Association (AUA). Naples, FL (Oct. 2013)
56. **Singla N**, Mehta M, Wolf JS, Kin J, Billi J. "Increasing the efficiency of operating room turnover for adult endourology cases." 87th Annual Meeting of North Central Section (NCS) American Urological Association (AUA). Naples, FL (Oct. 2013)
57. **Singla N**, Montie JE, Lee CT, Wolf JS, Faerber GJ. "Retrograde ureteroscopy in patients with orthotopic ileal neobladder reconstruction for bladder cancer: A 17-year experience." American Urological Association (AUA) Annual Meeting. San Diego, CA (May 2013)
J Urol 189(4 Suppl):e581, 2013.
58. **Singla N**. "A Novel, Non-Invasive Approach to Diagnosing Urinary Tract Obstruction Using CFD and Computer Simulation," Southeastern Michigan Regional Junior Science and Humanities Symposium (JSHS). Detroit, MI
The National Junior Science and Humanities Symposium Abstracts of the Research Finalists. 44: 45, 2006.
Third Place Award

C. Video Presentations

1. Mauck R, Zhao L, **Singla N**, Hatchette C. "Interdisciplinary approach to dermoid cyst of the spine: How can urologists help neurosurgeons?" American Urological Association (AUA) Annual Meeting. San Francisco, CA (May 2018)
V06-12 *J Urol* 199(4 Suppl):e664, 2018.

2. Mauck R, Zhao L, **Singla N**, Hatchette C. "Interdisciplinary approach to dermoid cyst of the spine: How can urologists help neurosurgeons?" 96th Annual Meeting of South Central Section (SCS) American Urological Association (AUA). Naples, FL (Nov. 2017)
3. Mauck R, Zhao L, **Singla N**, Hatchette C. "Interdisciplinary approach to dermoid cyst of the spine: How can urologists help neurosurgeons?" 35th World Congress Endourology and SWL. Vancouver, Canada (Sept. 2017)
V5-13 *J Endourol* 31(S2):A437, 2017.
4. Morey A, **Singla N**, Chung P, Klein A, Tausch T, Siegel J, Tachibana I, Scott J, Carmel M. "Male stress incontinence grading scale for evaluation of men with post-prostatectomy incontinence: A pilot study." American Urological Association (AUA) Annual Meeting. San Diego, CA (May 2016)
V3-03 *J Urol* 195(4 Suppl):e467, 2016.

D. Panels and Courses

1. *Speaker and Expert Panelist*, Urology Speaks: "Living with Genitourinary Cancer and Navigating Recovery." Johns Hopkins University, Baltimore, MD (Mar. 2023)
2. *Speaker and Expert Panelist*, Greenberg Bladder Cancer Institute (GBCI) Grand Rounds. "Is it OK to Get a 2nd Opinion and is it OK to Change My Care Team?" Johns Hopkins University. Baltimore, MD (Jan. 2023)
3. *Faculty*, Kidney Cancer Course. 23rd Annual Meeting of the Society of Urologic Oncology (SUO). San Diego, CA (Nov. 2022)
4. *CME Course Director/Host*, The Brady Urological Institute Visiting Professor (Robert G. Uzzo, MD, MBA, FACS), The Johns Hopkins University School of Medicine. Baltimore, MD (Nov. 2022)
5. *Debater - Pro*, Prostate Cancer: "Oligometastatic Disease on PSMA PET/CT in Setting of Negative Conventional Staging Studies Should Impact Treatment Decision." Indian American Urological Association (IAUA) Meeting at the AUA Annual Meeting. New Orleans, LA (May 2022)
6. *Speaker and Expert Panelist*, Bladder Cancer Advocacy Network (BCAN) Treatment Talk. "What You Need to Know About Treating Upper Tract Urothelial Carcinoma (UTUC)." (Mar. 2022)
7. *Expert Panelist*, Multidisciplinary Genitourinary Oncology Tumor Board Conference. Aliada Centro Oncologico. Lima, Peru [Presented Virtually] (Nov. 2021)
8. *Speaker and Expert Panelist*, Greenberg Bladder Cancer Institute (GBCI) Grand Rounds. "Upper Tract Urothelial Cancer: It's a Team Effort." Johns Hopkins University. Baltimore, MD (Oct. 2021)
9. *Moderator*, Indian American Urological Association (IAUA) Young Clinicians Forum. Bladder Cancer Session: "Optimal Management for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: Bladder Sparing vs. Radical Cystectomy" (May 2021)
10. *Moderator and Expert Panelist*, Virtual Testicular Cancer Conference, Testicular Cancer Awareness Foundation (Apr. 2021)
11. *Debater*, National Chief Resident Debate: Prostate Cancer. American Urological Association (AUA) Annual Meeting. San Francisco, CA (May 2018)

E. Grand Rounds, Visiting Professorships, and Educational Lectures

1. **Singla N**. "Guiding Multimodal Treatment in Kidney Cancer Through Precision Oncology: A New Era." Department of Urology, Rabin Medical Center. Petah Tikva, Israel [Presented Virtually] (June 2023)
Invited Visiting Professor
2. **Singla N**. "Guiding Multimodal Treatment in Kidney Cancer Through Precision Oncology: A New Era." Department of Urology, Medical University of Vienna. Vienna, Austria (May 2023)
Invited Visiting Professor, including case discussions
3. **Singla N**. "Creating an Identity: Launching an Academic Career from Training and Beyond." Department of Urology, Medical University of Vienna. Vienna, Austria (May 2023)
Invited Visiting Professor, including case discussions
4. **Singla N**. "Guiding Multimodal Treatment in Kidney Cancer Through Precision Oncology: A New Era." Department of Urology, Semmelweis University, Faculty of Medicine. Budapest, Hungary (May 2023)
Invited Visiting Professor – live surgery performed (robotic assisted partial nephrectomy)
5. **Singla N**. "Creating an Identity: Launching an Academic Career from Training and Beyond." Department of Urology, Semmelweis University, Faculty of Medicine. Budapest, Hungary (May 2023)
Invited Visiting Professor – live surgery performed (robotic assisted partial nephrectomy)

6. **Singla N**, Ged Y. "The Kidney Cancer Program: Annual Review (Year 2)." Kidney Cancer Program, Johns Hopkins University. Baltimore, MD (Oct. 2022)
7. **Singla N**. "Managing Testicular Cancer: A Stage-Based Approach." The James Buchanan Brady Urological Institute Grand Rounds, Johns Hopkins University School of Medicine. Baltimore, MD (Sept. 2022)
8. **Singla N**. "It's All Related: Kidney Health for Patients with Urothelial Cancer." Greenberg Bladder Cancer Institute (GBCI) Grand Rounds. Johns Hopkins University. Baltimore, MD (Feb. 2022)
9. **Singla N**. "Primer on Kidney Cancer." Genes to Society Pre-Clinical Medical Student Curriculum, The Johns Hopkins University School of Medicine. Baltimore, MD (Jan. 2022)
10. **Singla N**. "Fundamentals of Testicular Cancer: Origins and Management." Genes to Society Pre-Clinical Medical Student Curriculum, The Johns Hopkins University School of Medicine. Baltimore, MD (Jan. 2022)
11. **Singla N**. "Guiding Precision Oncology Through Tropic Evolution in Renal Cell Carcinoma." Department of Urology, Walter Reed National Military Medical Center. Bethesda, MD (Nov. 2021)

Invited Visiting Professor

12. Ged Y, **Singla N**. "The Kidney Cancer Program: 1-Year Review." Kidney Cancer Program, Johns Hopkins University. Baltimore, MD (Oct. 2021)
13. Tsou T, **Singla N**. "Evaluating a simplified nephrometry score for renal masses." Persky Summer Research Awards Seminar. The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine. Baltimore, MD (Sept. 2021)
14. **Singla N**. "Faculty Spotlight." The Brady Urological Institute Advisory Board Meeting, Johns Hopkins University School of Medicine. Baltimore, MD (May 2021)
15. **Singla N**. "Managing Testicular Cancer: A Stage-Based Approach." Urology Resident Teaching Conference, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine. Baltimore, MD (Apr. 2021)
16. **Singla N**. "Guiding Precision Oncology Through Tropic Evolution in Renal Cell Carcinoma." Institute for Urology and Reproductive Health, Sechenov University. Moscow, Russia [Presented Virtually] (Mar. 2021)

Invited Visiting Professor

17. **Singla N**. "Guiding Precision Oncology Through Tropic Evolution in Renal Cell Carcinoma." The James Buchanan Brady Urological Institute Grand Rounds, Johns Hopkins University School of Medicine. Baltimore, MD (Mar. 2021)
18. **Singla N**. "Unanswered Questions in Upper Tract Urothelial Carcinoma." Greenberg Bladder Cancer Institute Scientific Retreat, Johns Hopkins University. Baltimore, MD (Feb. 2021)
19. **Singla N**. "Stereotactic Radiation Program Introduction." Kidney Cancer Program, Johns Hopkins University. Baltimore, MD (Oct. 2020)
20. **Singla N**. "Who Am I?" The James Buchanan Brady Urological Institute Grand Rounds, Johns Hopkins University School of Medicine. Baltimore, MD (Aug. 2020)
21. **Singla N**. "The OLYMPUS Trial: Primary Chemoablation for Low-Grade Upper Tract Urothelial Carcinoma." Genitourinary Oncology Grand Rounds, Memorial Sloan Kettering Cancer Center. New York, NY (June 2020)
22. **Singla N**. "Growing Teratoma Syndrome." Genitourinary Oncology Grand Rounds, Memorial Sloan Kettering Cancer Center. New York, NY (May 2020)
23. **Singla N**. "Salvage Pelvic Lymphadenectomy for Nodally Recurrent Prostate Cancer: Indications, Techniques, and Outcomes." Genitourinary Oncology Grand Rounds, Memorial Sloan Kettering Cancer Center. New York, NY (Feb. 2020)
24. **Singla N**. "The Aggressive Small Renal Mass." Genitourinary Oncology Grand Rounds, Memorial Sloan Kettering Cancer Center. New York, NY (Jan. 2020)
25. **Singla N**. "Constrained Tumor Evolution of Pancreatic Tropism in Metastatic Renal Cell Carcinoma Underpins Angiogenesis Inhibitor Responsiveness." Department of Urology Grand Rounds, New York University (NYU) Langone Medical Center. New York, NY (Dec. 2019)
26. **Singla N**. "Are All UTUC Created Equal? Implications of Unique Risk Factors for Pathogenesis and Therapeutic Response." Genitourinary Oncology Grand Rounds, Memorial Sloan Kettering Cancer Center. New York, NY (Oct. 2019)

27. **Singla N.** "Surgical Quality Assurance: Management of the Post-Operative Fragile Patient." Quality and Safety Grand Rounds, Department of Surgery, Memorial Sloan Kettering Cancer Center. New York, NY (Oct. 2019)
28. **Singla N.** "Pathologic Stage as a Surrogate for Oncologic Outcomes after Receipt of Neoadjuvant Chemotherapy for High-Grade Upper Tract Urothelial Carcinoma." Bladder Cancer Working Group Meeting, Memorial Sloan Kettering Cancer Center. New York, NY (Oct. 2019)
29. **Singla N.** "Cytoreductive Nephrectomy Following Complete Pathological Response to Immune Checkpoint Inhibition for Renal Cell Carcinoma." Genitourinary Oncology Grand Rounds, Memorial Sloan Kettering Cancer Center. New York, NY (Sept. 2019)
30. **Singla N.** "Constrained Tumor Evolution of Pancreatic Tropism in Metastatic Renal Cell Carcinoma Underpins Angiogenesis Inhibitor Responsiveness." Genitourinary Oncology Grand Rounds, Memorial Sloan Kettering Cancer Center. New York, NY (Aug. 2019)
31. **Singla N.** "ASCO Update 2019: Renal Cell Carcinoma and Germ Cell Tumor." Urologic Oncology Fellows' Didactic Lecture Series, University of Texas Southwestern Medical Center (UTSW). Dallas, TX (June 2019)
32. **Singla N.** "Part I: Constrained Tumor Evolution of Pancreatic Tropism in Metastatic Renal Cell Carcinoma Underpins Angiogenesis Inhibitor Responsiveness." University of Texas Southwestern Medical Center (UTSW), Department of Urology Grand Rounds. Dallas, TX (May 2019)
33. **Singla N.** "Part II: The Value of Protecting Research Time During Training." University of Texas Southwestern Medical Center (UTSW), Department of Urology Grand Rounds. Dallas, TX (May 2019)
34. **Singla N.** "Constrained Tumor Evolution of Pancreatic Tropism in Metastatic Renal Cell Carcinoma Underpins Angiogenesis Inhibitor Responsiveness." RCC Research and SPORE Conference. Kidney Cancer Program, University of Texas Southwestern Medical Center (UTSW). Dallas, TX (May 2019)
35. **Singla N.** "Research Year Wrap-Up and Future Directions." Kidney Cancer Program (KCP) Didactics Conference, University of Texas Southwestern Medical Center (UTSW). Dallas, TX (May 2019)
36. **Singla N.** "Metastatic Tropism in Renal Cell Carcinoma: To the Pancreas and Beyond." Kidney Cancer Program Visiting Professor (Brian I. Rini, MD). University of Texas Southwestern Medical Center (UTSW). Dallas, TX (May 2019)
37. **Singla N.** "Tumorgrafts: A Robust Platform for Novel Biological Discovery." Simmons Comprehensive Cancer Center Kidney Cancer Program and Genentech Summit. University of Texas Southwestern Medical Center (UTSW). Dallas, TX (Apr. 2019)
38. **Singla N.** "Exploring Metastatic Tropism in Renal Cell Carcinoma: A Focus on the Pancreas." Simmons Comprehensive Cancer Center Kidney Cancer Program and Genentech Summit. University of Texas Southwestern Medical Center (UTSW). Dallas, TX (Apr. 2019)
39. **Singla N.** "Systemic Therapies for Metastatic Renal Cell Carcinoma: Current Treatment Paradigms." Urologic Oncology Fellows' Didactic Lecture Series, University of Texas Southwestern Medical Center (UTSW). Dallas, TX (Apr. 2019)
40. **Singla N.** "Comprehensive Characterization of Pancreatic Tropism in Metastatic Renal Cell Carcinoma." Physician Scientist Conference. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center (UTSW). Dallas, TX (Apr. 2019)
41. **Singla N.** "Evaluating the Prognostic Utility of ctDNA Profiling in Metastatic and Clinically Localized Clear Cell Renal Cell Carcinoma" CTM 5209: Practical Clinical & Translational Research Proposal Development. University of Texas Southwestern Medical Center (UTSW). Dallas, TX (Apr. 2019)
42. **Singla N.** "Exploring Metastatic Tropisms in Renal Cell Carcinoma: A Focus on the Pancreas." Frontiers in Medicine Lab Tour, University of Texas Southwestern Medical Center (UTSW). Dallas, TX (Feb. 2019)
43. **Singla N.** "Exploring Metastatic Tropisms in Renal Cell Carcinoma: A Focus on the Pancreas." Kidney Cancer Program (KCP) SPORE Grant External Advisory Board (EAB) Meeting, University of Texas Southwestern Medical Center (UTSW). Dallas, TX (Jan. 2019)
44. **Singla N.** "Unraveling the Molecular Profile Underpinning Pancreatic Tropisms in Metastatic Clear Cell Carcinoma." Kidney Cancer Program (KCP) Didactics Conference, University of Texas Southwestern Medical Center (UTSW). Dallas, TX (Jan. 2019)
45. **Singla N.** "Epidemiology, Genetics, and Familial Syndromes in Renal Cell Carcinoma." Urologic Oncology Fellows' Didactic Lecture Series, University of Texas Southwestern Medical Center (UTSW). Dallas, TX (Jan. 2019)

46. **Singla N.** "Leveraging a Robust Patient-Derived Xenograft Platform to Characterize Tumor Behavior in Patients with Renal Cell Carcinoma." Center for Translational Medicine (CTM) Translational Science Forum. University of Texas Southwestern Medical Center (UTSW). Dallas, TX (Dec. 2018)
47. **Singla N.** "Career Development through the Kidney Cancer Program." 2nd Annual Kidney Cancer Program (KCP) Trainee Retreat, University of Texas Southwestern Medical Center (UTSW). Dallas, TX (Dec. 2018)
48. **Singla N.** "Evaluating the Prognostic Utility of Circulating Tumor DNA Profiling in Metastatic and Clinically Localized Clear Cell Renal Cell Carcinoma." Urology Works in Progress, University of Texas Southwestern Medical Center (UTSW). Dallas, TX (Sept. 2018)
49. **Singla N.** "Non-Invasive Screening Test for RCC Using Urinary Biomarkers." Kidney Cancer Program (KCP) Didactics Conference, University of Texas Southwestern Medical Center (UTSW). Dallas, TX (Aug. 2018)
50. **Singla N, Wang T.** "Pancreatic Tropism in Metastatic RCC: Genomic Determinants and Implications." Kidney Cancer Program (KCP) Genomics Retreat, University of Texas Southwestern Medical Center (UTSW). Dallas, TX (May 2018)
51. **Singla N.** "Chief Resident Case Presentation: An Unexpected Finding from Nephroureterectomy." University of Texas Southwestern Medical Center (UTSW), Department of Urology Grand Rounds. Dallas, TX (Mar. 2018)
52. **Singla N.** "Chief Resident Case Presentation: Infiltrative Malignant Priapism." University of Texas Southwestern Medical Center (UTSW), Department of Urology Grand Rounds. Dallas, TX (Jan. 2018)
53. **Singla N.** "Evaluating the Prognostic Utility of Circulating Tumor DNA Profiling in Metastatic and Clinically Localized Clear Cell Renal Cell Carcinoma." 1st Annual Kidney Cancer Program (KCP) Trainee Retreat, University of Texas Southwestern Medical Center (UTSW). Dallas, TX (Dec. 2017)
54. **Singla N.** "Bladder Cancer in a Patient with Prune Belly Syndrome: Management Considerations." Pediatric Urology Rising Stars Visiting Professor, University of Texas Southwestern Medical Center (UTSW). Dallas, TX (Dec. 2017)
55. **Singla N.** "Chief Resident Case Presentation: Synchronous Bilateral Testicular Masses." University of Texas Southwestern Medical Center (UTSW), Department of Urology Grand Rounds. Dallas, TX (Dec. 2017)
56. **Singla N.** "AUA Update 2017: Bladder Cancer and Upper Tract Urothelial Carcinoma." University of Texas Southwestern Medical Center (UTSW), Department of Urology Grand Rounds. Dallas, TX (Aug. 2017)
57. **Singla N.** "Reducing Infectious Complications Following Transrectal Ultrasound-Guided Prostate Biopsies." 54th Harry M. Spence Visiting Professor Conference, University of Texas Southwestern Medical Center (UTSW). Dallas, TX (June 2017)
58. **Singla N.** "RCC with a Twist: Implications for Management." Vincent J. O'Connor, Jr. Visiting Professor Conference, Department of Urology, Northwestern University Feinberg School of Medicine. Chicago, IL (Mar. 2017)

Invited Visiting Professor

59. **Singla N.** "Unclassified RCC: Prognosis, Genomics, and Management." University of Texas Southwestern Medical Center (UTSW), Department of Urology Grand Rounds. Dallas, TX (Mar. 2017)
60. **Singla N.** "Urologic Considerations in Pediatric Renal Transplantation." University of Texas Southwestern Medical Center (UTSW), Pediatric Urology Grand Rounds. Dallas, TX (Sept. 2016)
61. **Singla N.** "Renal Fusion Anomalies: Variations, Associations, and Other Considerations." University of Texas Southwestern Medical Center (UTSW), Pediatric Urology Grand Rounds. Dallas, TX (June 2016)
62. **Singla N.** "Management of Peyronie's Disease and Priapism." University of Texas Southwestern Medical Center (UTSW), Department of Urology Campbell's Conference for Resident Education. Dallas, TX (June 2016)
63. **Singla N.** "AUA Update 2016: Bladder Cancer and Upper Tract Urothelial Carcinoma." University of Texas Southwestern Medical Center (UTSW), Department of Urology Grand Rounds. Dallas, TX (June 2016)
64. **Singla N.** "A multi-institutional evaluation of clinical and tumor characteristics in UTUC from China and the United States." 53rd Harry M. Spence Visiting Professor Conference, University of Texas Southwestern Medical Center (UTSW). Dallas, TX (Apr. 2016)

65. **Singla N.** "Genetic considerations in papillary RCC." University of Texas Southwestern Medical Center (UTSW), Department of Urology Grand Rounds. Dallas, TX (Mar. 2016)
66. **Singla N.** "Neurourology review." University of Texas Southwestern Medical Center (UTSW), Department of Urology Campbell's Conference for Resident Education. Dallas, TX (Jan. 2016)
67. **Singla N.** "Do anti-inflammatory agents impact oncologic outcomes in patients treated with intravesical BCG for HG NMIBC?" University of Texas Southwestern Medical Center (UTSW), Department of Urology Grand Rounds. Dallas, TX (Dec. 2015)
68. **Singla N.** "AUA Update 2015: Advanced Prostate Cancer." University of Texas Southwestern Medical Center (UTSW), Department of Urology Grand Rounds. Dallas, TX (July 2015)
69. **Singla N.** "Fistula formation after bladder neck closure." 52nd Harry M. Spence Visiting Professor Conference, University of Texas Southwestern Medical Center (UTSW). Dallas, TX (Apr. 2015)
70. **Singla N.** "Penile Ossification: A Reconstructive Challenge." University of Texas Southwestern Medical Center (UTSW), Department of Urology Grand Rounds. Dallas, TX (Feb. 2015)
71. **Singla N.** "Obstructive Uropathy Arising from a Benign Bladder Entity." University of Texas Southwestern Medical Center (UTSW), Department of Urology Grand Rounds. Dallas, TX (Aug. 2014)
72. **Singla N.** "Urinary Diversions: A Focus on Ileal Conduits." General Surgery Residents' Teaching Conference, University of Texas Southwestern Medical Center (UTSW). Dallas, TX (June 2014)
73. **Singla N.** "Retrograde Ureteroscopy in Patients with Orthotopic Neobladder." University of Texas Southwestern Medical Center (UTSW), Department of Urology Grand Rounds. Dallas, TX (Nov. 2013)
74. **Singla N.** "Ileal Conduits: Indications, Techniques, and Complications." General Surgery Residents' Teaching Conference, University of Texas Southwestern Medical Center (UTSW). Dallas, TX (Aug. 2013)
75. **Singla N.** "Post-Orchiectomy Management of Clinical Stage I Non-Seminomatous Germ Cell Tumors (NSGCTs)," Pathology Clerkship, University of Michigan Medical School. Ann Arbor, MI (Feb. 2013)
76. **Singla N, Mehta M.** "Increasing the Efficiency of Operating Room Turnover Using Lean Intervention: The Adult Endourology Experience at the University of Michigan," The University of Toledo Medical Center, Department of Urology Grand Rounds. Toledo, OH (Feb. 2013)
77. **Singla N.** "A Walk through Masses: Abdominal and Pelvic Teaching Cases," Abdominal Radiology Clerkship, University of Michigan Medical School. Ann Arbor, MI (Feb. 2013)
78. **Singla N.** "Enzalutamide: A new treatment for castration-resistant prostate cancer," Advanced Medical Therapeutics, University of Michigan Medical School. Ann Arbor, MI (Oct. 2012)
79. **Singla N, Mehta M.** "Increasing the efficiency of OR turnover for adult endourology cases," Presented to Dr. John Billi, Associate Dean for Clinical Affairs and Associate Vice President for Medical Affairs, Michigan Quality System, University of Michigan Health System (UMHS). Ann Arbor, MI (Sept. 2012)
80. **Singla N.** "Performing Retrograde Ureteroscopy in Patients with Orthotopic Ileal Neobladder," The James Buchanan Brady Urological Institute Grand Rounds, Johns Hopkins University School of Medicine. Baltimore, MD (Aug. 2012)
81. **Singla N.** "Approaching the Orthotopic Neobladder with Retrograde Ureteroscopy," University of California, San Francisco (UCSF), Department of Urology Grand Rounds. San Francisco, CA (July 2012)
82. **Singla N.** "Evolution of the Orthotopic Neobladder and the Michigan Experience with Retrograde Ureteroscopy," University of Michigan, Department of Urology Grand Rounds. Ann Arbor, MI (July 2012)
83. **Singla N.** "Open mesh versus laparoscopic mesh repair of inguinal hernia: Reviewing the evidence," General Surgery Clerkship, University of Michigan Medical School. Ann Arbor, MI (Dec. 2011)
84. **Singla N.** "Educational System in the USA," Urogenital Research Unit, Universidade do Estado do Rio de Janeiro (UERJ). Rio de Janeiro, Brazil (July 2009)
85. **Singla N, Hewes P, Hill D, Kim D, Kochanski R, Sweet J.** "A Device for the Identification of Pacemaker and Defibrillator Manufacturers," University of Michigan College of Engineering. Ann Arbor, MI (Apr. 2009)
86. **Singla N.** "Conventional Repair vs. Double Switch Operation for Congenitally Corrected Transposition of the Great Arteries (CCTGA)," Presented to Dr. Eric J. Devaney, Assistant Professor of Cardiac Surgery, Department of Surgery, University of Michigan Medical School. Ann Arbor, MI (Apr. 2009)
87. **Singla N, Raheja S, Dhar V.** "Muscle Structure and Theories of Contraction: Force Generation in Striated Muscle," University of Michigan College of Engineering. Ann Arbor, MI (Sept. 2008)
88. **Singla N.** "Assessment of tumorigenicity and invasiveness by overexpression of EZH2 in normal cells in vitro and in vivo," Michigan Center for Translational Pathology (MCTP). Ann Arbor, MI (Aug. 2008)

89. Gauvin A, **Singla N**. “Exercises in Human Physiology,” University of Michigan. Ann Arbor, MI (Oct. 2007)
90. **Singla N**. “Characterization of ERG overexpression in RWPE, a prostate cell line,” Michigan Center for Translational Pathology (MCTP). Ann Arbor, MI (Aug. 2007)
91. **Singla N**, Holscher C, LaPointe L, Mahmud M, Momont C. “Combined Genotypic and Phenotypic Lab-on-a-Chip Test for Primary Hypertension,” University of Michigan College of Engineering. Ann Arbor, MI (Nov. 2006)